<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>accelerateddia12312014.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Arial, Helvetica, Sans-Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>UNITED
STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>FORM
10-K</B></FONT></P>

<P STYLE="font: 10pt/140% Arial, Helvetica, Sans-Serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Wingdings">&thorn;</FONT> <FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>
ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt/140% Arial, Helvetica, Sans-Serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">For the fiscal year ended
December 31, 2014</P>

<P STYLE="font: 10pt/140% Arial, Helvetica, Sans-Serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Wingdings">o</FONT>
<B>TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt/140% Arial, Helvetica, Sans-Serif; margin: 0 0 6pt; text-align: center; text-indent: 0.5in"><B>Commission file number:
001-31822</B></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: center; text-indent: 0.5in"><FONT STYLE="font-size: 12pt"><B>ACCELERATE
DIAGNOSTICS, INC.</B></FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: center; text-indent: 0.5in">(Exact name of registrant
as specified in its charter)</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 0.8pt; text-align: center; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><b>Delaware</b></td>
    <TD STYLE="width: 50%; padding-right: 0.8pt; text-align: center; line-height: 115%; font-family: Arial,sans-serif"><b>84-1072256</b></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif">(State&nbsp;or&nbsp;other&nbsp;jurisdiction</td>
    <TD STYLE="padding-right: 0.8pt; text-align: center; line-height: 115%; font-family: Arial,sans-serif">&nbsp;&#9;(I.R.S.&nbsp;Employer Identification&nbsp;No.)</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif">of&nbsp;incorporation&nbsp;or&nbsp;organization)</td>
    <TD STYLE="padding-right: 0.8pt; text-align: center; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif">&nbsp;</td>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><b>3950 South Country Club, Suite 470</b></td>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><b>Tucson, Arizona</b></td>
    <TD STYLE="padding-right: 0.8pt; text-align: center; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><b>85714</b></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif">(Address&nbsp;of&nbsp;principal&nbsp;executive&nbsp;offices)</td>
    <TD STYLE="padding-right: 0.8pt; text-align: center; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif">(Zip&nbsp;Code)</td></tr>
</table>
<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: center; text-indent: 0.5in">Registrant&rsquo;s telephone
number, including area code:</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: center; text-indent: 0.5in"><B>(520) 365-3100</B></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">&nbsp;Securities registered
pursuant to Section 12(b) of the Act:</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 0.8pt; text-decoration: underline; text-align: center; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><u>Title of each class</u></td>
    <TD STYLE="width: 50%; padding-right: 0.8pt; text-decoration: underline; text-align: center; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><u>Name of each exchange on which registered</u></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif">Common Stock, $0.001 par value per share</td>
    <TD STYLE="padding-right: 0.8pt; text-align: center; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif">The NASDAQ Stock Market LLC<br>
(NASDAQ Capital Market)</td></tr>
</table>
<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: center; text-indent: 0.5in">&nbsp;Securities registered
pursuant to Section 12(g) of the Act: None</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial, Helvetica, Sans-Serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Indicate by check mark if
the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. <FONT STYLE="font-family: Wingdings">o</FONT>
Yes&nbsp; <FONT STYLE="font-family: Wingdings">&thorn;</FONT> &nbsp;No</P>

<P STYLE="font: 10pt/115% Arial, Helvetica, Sans-Serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;Indicate by check mark
if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.&nbsp;<FONT STYLE="font-family: Wingdings">o</FONT>
Yes&nbsp; <FONT STYLE="font-family: Wingdings">&thorn;</FONT> &nbsp;No</P>

<P STYLE="font: 10pt/115% Arial, Helvetica, Sans-Serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;Indicate by check mark
whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp; <FONT STYLE="font-family: Wingdings">&thorn;</FONT>
&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">o</FONT> &nbsp;No</P>

<P STYLE="font: 10pt/115% Arial, Helvetica, Sans-Serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;Indicate by check mark
whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required
to be submitted and posted pursuant to Rule 405 of Regulation S-T (&sect;229.405 of this chapter) during the preceding 12 months
(or for such shorter period that the registrant was required to submit and post such files). <FONT STYLE="font-family: Wingdings">&thorn;</FONT>
&nbsp;Yes&nbsp; <FONT STYLE="font-family: Wingdings">o</FONT> &nbsp;No</P>

<P STYLE="font: 10pt/115% Arial, Helvetica, Sans-Serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">&nbsp;Indicate by check mark
if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (&sect; 229.405) is not contained herein, and will not
be contained, to the best of registrant&rsquo;s knowledge, in definitive proxy or information statements incorporated by reference
in Part III of this Form 10-K or any amendment to this Form 10-K.&nbsp; <FONT STYLE="font-family: Wingdings">&thorn;</FONT></P>

<P STYLE="font: 10pt/140% Arial, Helvetica, Sans-Serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial, Helvetica, Sans-Serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See
the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo;
in Rule 12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Arial,sans-serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 65%; text-align: right; vertical-align: top">Large accelerated
filer</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 31%"> <FONT STYLE="font-family: Wingdings">o</FONT>&#9;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: right; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: right; vertical-align: top">Accelerated filer
<FONT STYLE="font-family: Wingdings"></font></TD>
    <TD>&nbsp;</TD>
    <TD>
<FONT STYLE="font-family: Wingdings">&thorn;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: right; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-align: right; vertical-align: top">Non-accelerated file &#9744; (Do not check if a smaller reporting company)&#9;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: right; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: right; vertical-align: top">Smaller reporting
company</TD>
    <TD>&nbsp;</TD>
    <TD> <FONT STYLE="font-family: Wingdings">o</FONT>&#9;</TD></TR>
</TABLE>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/140% Arial, Helvetica, Sans-Serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp;</P>

<P STYLE="font: 10pt/140% Arial, Helvetica, Sans-Serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Wingdings">o</FONT>
&nbsp;Yes&nbsp; <FONT STYLE="font-family: Wingdings">&thorn;</FONT> &nbsp;No</P>

<P STYLE="font: 10pt/115% Arial, Helvetica, Sans-Serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">The aggregate market value
of the shares of the registrant&rsquo;s common stock held by non-affiliates on June 30, 2014, the last day of the registrant&rsquo;s
most recently completed second fiscal quarter, was approximately $569.6 million based on the closing price quoted on the NASDAQ
Stock Market.</P>

<P STYLE="font: 10pt/140% Arial, Helvetica, Sans-Serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">There were 44,651,496 shares
of common stock of the registrant outstanding as of February 17, 2015.</P>

<P STYLE="font: 10pt/140% Arial, Helvetica, Sans-Serif; margin: 0 0 9pt; text-align: center; text-indent: 0.5in"><B>DOCUMENTS INCORPORATED
BY REFERENCE</B></P>

<P STYLE="font: 10pt/115% Arial, Helvetica, Sans-Serif; margin: 0 0 6pt; text-align: left; text-indent: 0.5in">Portions of the definitive proxy
statement relating to the registrant&rsquo;s 2015 Annual Meeting of Stockholders are incorporated by reference in Part III of this
Form 10-K.</P>

<P STYLE="font: 10pt/140% Arial, Helvetica, Sans-Serif; margin: 0 0 6pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 6pt; text-align: center">2</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: left; text-indent: 0.5in; border-bottom: Black 1pt solid">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: center; text-indent: 0.5in"><B>TABLE OF CONTENTS</B>&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Calibri">
    <TD STYLE="text-align: left; text-indent: 0.5in; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">Introductory Note</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">4</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Calibri">
    <TD STYLE="text-align: left; text-indent: 0.5in; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">Forward-Looking Statements</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">4</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Calibri">
    <TD STYLE="text-align: left; text-indent: 0.5in; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">Industry and other data</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">4</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Calibri">
    <TD STYLE="width: 90%; text-align: left; text-indent: 0.5in; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">PART I</TD>
    <TD STYLE="width: 10%; text-align: right; padding-top: 0in; padding-bottom: 5pt">5</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Calibri">
    <TD STYLE="text-align: left; text-indent: 0.5in; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">Item 1.&nbsp; Business</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">5</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Calibri">
    <TD STYLE="text-align: left; text-indent: 0.5in; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">Item 1A.&nbsp; Risk Factors</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">21</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Calibri">
    <TD STYLE="text-align: left; text-indent: 0.5in; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">Item 1B.&nbsp; Unresolved Staff Comments</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">43</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Calibri">
    <TD STYLE="text-align: left; text-indent: 0.5in; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">Item 2.&nbsp; Properties</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">43</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Calibri">
    <TD STYLE="text-align: left; text-indent: 0.5in; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">Item 3.&nbsp; Legal Proceedings</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">43</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Calibri">
    <TD STYLE="text-align: left; text-indent: 0.5in; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">Item 4.&nbsp; Mine Safety Disclosures</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">43</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Calibri">
    <TD STYLE="text-align: left; text-indent: 0.5in; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">PART II</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">43</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Calibri">
    <TD STYLE="text-align: left; text-indent: 0.5in; padding-top: 0in; padding-left: 0in">Item 5.&nbsp; Market for Registrant&rsquo;s Common Equity, Related Stockholder Matters and Issuer </TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt"></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Calibri">
    <TD STYLE="text-align: left; text-indent: 0.5in; padding-top: 0in; padding-bottom: 5pt; padding-left: 44pt">Purchases of
    Equity Securities</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">43</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Calibri">
    <TD STYLE="text-align: left; text-indent: 0.5in; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">Item 6.&nbsp; Selected Financial Data</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">44</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Calibri">
    <TD STYLE="text-align: left; text-indent: 0.5in; padding-top: 0in; padding-left: 0in">Item 7.&nbsp; Management&rsquo;s Discussion and Analysis of Financial Condition and Results of</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt"></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Calibri">
    <TD STYLE="text-align: left; text-indent: 0.5in; padding-top: 0in; padding-bottom: 5pt; padding-left: 44pt">Operations</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">45</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Calibri">
    <TD STYLE="text-align: left; text-indent: 0.5in; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">Item 7A.&nbsp; Quantitative and Qualitative Disclosures About Market Risk</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">51</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Calibri">
    <TD STYLE="text-align: left; text-indent: 0.5in; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">Item 8.&nbsp; Financial Statements and Supplementary Data</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">51</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Calibri">
    <TD STYLE="text-align: left; text-indent: 0.5in; padding-top: 0in; padding-left: 0in">Item 9.&nbsp; Changes in and Disagreements With Accountants on Accounting and Financial</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt"></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Calibri">
    <TD STYLE="text-align: left; text-indent: 44pt; padding-top: 0in; padding-bottom: 5pt; padding-left: 0.5in">Disclosure</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">79</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Calibri">
    <TD STYLE="text-align: left; text-indent: 0.5in; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">Item 9A.&nbsp; Controls and Procedures</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">79</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Calibri">
    <TD STYLE="text-align: left; text-indent: 0.5in; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">Item 9B.&nbsp; Other Information</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">80</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Calibri">
    <TD STYLE="text-align: left; text-indent: 0.5in; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">PART&nbsp;III</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">80</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Calibri">
    <TD STYLE="text-align: left; text-indent: 0.5in; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">Item 10.&nbsp; Directors, Executive Officers and Corporate Governance</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">80</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Calibri">
    <TD STYLE="text-align: left; text-indent: 0.5in; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">Item 11.&nbsp; Executive Compensation</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">80</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Calibri">
    <TD STYLE="text-align: left; text-indent: 0.5in; padding-top: 0in; padding-left: 0in">Item 12.&nbsp; Security Ownership of Certain Beneficial Owners and Management and Related</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt"></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Calibri">
    <TD STYLE="text-align: left; text-indent: 0.5in; padding-top: 0in; padding-bottom: 5pt; padding-left: 44pt">Stockholder Matters</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">80</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Calibri">
    <TD STYLE="text-align: left; text-indent: 0.5in; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">Item 13.&nbsp; Certain Relationships and Related Transactions, and Director Independence</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">80</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Calibri">
    <TD STYLE="text-align: left; text-indent: 0.5in; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">Item 14.&nbsp; Principal Accounting Fees and Services</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">80</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Calibri">
    <TD STYLE="text-align: left; text-indent: 0.5in; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">Item 15.&nbsp; Exhibits, Financial Statement Schedules</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">80</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Calibri">
    <TD STYLE="text-align: left; text-indent: 0.5in; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">SIGNATURES</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">81</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Calibri">
    <TD STYLE="text-align: left; text-indent: 0.5in; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">EXHIBIT INDEX</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">82</TD></TR>
</TABLE>



<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 10pt 0 6pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 10pt; margin-bottom: 6pt; text-align: center">3</P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin-top: 10pt; margin-bottom: 6pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 10pt 0 6pt; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 10pt 0 6pt; text-align: justify"></P>

<P STYLE="font: bold 10pt/150% Arial,sans-serif; margin: 10pt 0 9pt; text-align: justify">Introductory Note</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;Except as otherwise
indicated by the context, references in this Annual Report on Form 10-K (this &ldquo;Form 10-K&rdquo;) to the &ldquo;Company,&rdquo;
&ldquo;Accelerate,&rdquo; &ldquo;we,&rdquo; &ldquo;us&rdquo; or &ldquo;our&rdquo; are references to the combined business of Accelerate
Diagnostics, Inc.</P>

<P STYLE="font: bold 10pt/150% Arial,sans-serif; margin: 10pt 0 9pt; text-align: left">&nbsp;Forward-Looking
Statements</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;This Annual Report
on Form 10-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended
(the &ldquo;Securities Act&rdquo;) and Section 21E of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;),
and the Company, intends that such forward-looking statements be subject to the safe harbors created thereby. These forward-looking
statements, which can be identified by the use of words such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;expect,&rdquo; &ldquo;anticipate,&rdquo;
&ldquo;estimate,&rdquo; or &ldquo;continue,&rdquo; or variations thereon or comparable terminology, include the plans and objectives
of management for future operations, including plans and objectives relating to the products and future economic performance of
the Company. In addition, all statements other than statements of historical facts that address activities, events, or developments
the Company expects, believes, or anticipates will or may occur in the future, and other such matters, are forward-looking statements.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">The forward-looking statements
included herein are based on current expectations that involve a number of risks and uncertainties. These forward-looking statements
are based on assumptions that the Company will retain key management personnel, the Company will be successful in the development
of the Accelerate ID/AST system, the Company will obtain sufficient capital to complete the development and required clinical trials
of the Accelerate ID/AST system, the Company will be able to protect its intellectual property, the Company&rsquo;s ability to
respond to technological change, that the Company will accurately anticipate market demand for the Company&rsquo;s products and
that there will be no material adverse change in the Company&rsquo;s operations or business. Assumptions relating to the foregoing
involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions,
all of which are difficult or impossible to predict accurately and many of which are beyond the control of the Company. Although
the Company believes that the assumptions underlying the forward-looking statements are reasonable, any of the assumptions could
prove inaccurate and, therefore, there can be no assurance that the results contemplated in forward-looking statements will be
realized. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information,
future events or otherwise.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">The following discussion
should be read in conjunction with the Company&rsquo;s audited financial statements and related notes included elsewhere herein.
The Company&rsquo;s future operating results may be affected by various trends and factors which are beyond the Company's control.
These include, among other factors, general public perception of issues and solutions, and other uncertain business conditions
that may affect the Company&rsquo;s business. The Company cautions the reader that a number of important factors discussed herein,
and in other reports, filed with the Securities and Exchange Commission including but not limited to the risks in the section entitled
&ldquo;Risk Factors&rdquo; in this Form 10-K, could affect the Company&rsquo;s actual results and cause actual results to differ
materially from those discussed in forward-looking statements.</P>

<P STYLE="font: bold 10pt/150% Arial,sans-serif; margin: 10pt 0 9pt; text-align: justify">Industry and other data</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">We obtained the industry,
statistical and market data from our own internal estimates and research as well as from industry and general publications and
research, surveys and studies conducted by third parties. Industry publications, studies and surveys generally state that they
have been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information.
While we believe that each of these studies and publications is reliable, we have not independently verified statistical, market
and industry data from third-party sources. While we believe our internal company research is reliable and the market definitions
are appropriate, neither such research nor these definitions have been verified by any independent source.</P>



<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 10pt 0 6pt; text-align: justify"></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 6pt; text-align: center">4</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 6pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify"></P>

<P STYLE="font: bold 10pt/150% Arial,sans-serif; margin-right: 0; margin-bottom: 9pt; margin-left: 0; text-align: center">PART
I</P>

<P STYLE="font: bold 10pt/150% Arial,sans-serif; margin: 10pt 0 9pt; text-align: justify">Item 1. Business</P>

<P STYLE="font: bold 10pt/150% Arial,sans-serif; margin: 10pt 0 9pt; text-align: justify">Overview</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Accelerate Diagnostics, Inc.
(&ldquo;we&rdquo; or &ldquo;us&rdquo; or &ldquo;our&rdquo; or &ldquo;Accelerate&rdquo; or &ldquo;the Company&rdquo;) is an <I>in
vitro</I> diagnostics company dedicated to providing solutions which improve patient outcomes and lower healthcare costs through
the rapid diagnosis of serious infections. Microbiology laboratories are in need of new tools to address what the U.S. Centers
for Disease Control and Prevention (&ldquo;CDC&rdquo;) calls one of the most serious healthcare threats of our time, antibiotic
resistance. A significant contributor to the rise of resistance is the overuse and misuse of antibiotics, which is exacerbated
by a lack of timely diagnostic results. The delay of these results is often due to the reliance of microbiology laboratories on
traditional culture-based tests that often take two to three days to complete. Our technology platform is built to address these
challenges by delivering significantly faster and accurate testing of infectious pathogens in various patient sample types.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Since 2004, we have focused
our efforts on the development of an innovative rapid diagnostic platform, the Accelerate ID/AST System&trade; (the &ldquo;ID/AST
System&rdquo; or &ldquo;Accelerate ID/AST System&rdquo;), intended for the rapid diagnosis of infectious pathogens. Our goal is
to reduce the failure rate of initial antibiotic drug therapy by shortening lab turnaround time to approximately five hours, rather
than the two to three days now required to deliver identification and susceptibility results. The ID/AST System utilizes genotypic
technology to identify (&ldquo;ID&rdquo;) infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing
(&ldquo;AST&rdquo;), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic.
Development of this system and the first test kit for positive blood culture samples is substantially complete. Accordingly, we
plan to initiate a U.S. clinical trial to support U.S. Food and Drug Administration (&ldquo;FDA&rdquo;) marketing approval in the
first half of 2015, and following the successful completion of this trial, we plan to commercialize the FDA approved system. Achieving
each of these milestones will depend on our ability to achieve the goals specified in our detailed project plan according to the
deadlines included in such plan.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">In addition to the ID/AST
System, we have developed and licensed OptiChem&reg; surface coatings for use in microarraying components. However, in 2012, we
decided to discontinue our efforts to develop and actively market OptiChem&reg; and our other surface chemistry products.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">We plan to introduce additional
test kits for use on the Accelerate ID/AST System enabling the system&rsquo;s use with other sample types. In addition, we plan
to invest in the development of additional instruments, tests, and other solutions to realize our mission of establishing global
market leadership in clinical microbiology.</P>

<P STYLE="font: bold 10pt/150% Arial,sans-serif; margin: 10pt 0 9pt; text-align: justify">History and Strategy</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">We were incorporated in 1982
in Colorado under the name Sage Resources Corp., and through a series of subsequent transactions, we became Accelerate Diagnostics,
Inc., a Delaware corporation, in December 2012.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">From 2001 to 2012, we focused
primarily upon furthering the research and development of the OpTest portfolio of technologies (&ldquo;OpTest&rdquo;) that we
acquired from DDx, Inc. in 2001 and the development of revenue producing products related to that technology. The purchase of
OpTest provided us with a proprietary surface chemistry formulation, which led to our OptiChem&reg; and other surface chemistry
products, and quantitative bio-analytical measurement instruments. We have supplemented these assets to develop the ID/AST System.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/150% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center">5</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">In 2012, our Board of Directors
and management team established a new strategic direction for the Company, which was (1) to focus on the internal development,
manufacture, and commercialization of the ID/AST System and (2) to discontinue efforts to develop and actively market OptiChem
and our other surface chemistry products. Our Board of Directors and management team decided to pursue this new strategic direction
based on the belief that we could internally develop and commercialize the ID/AST System, formerly called the BacCel System.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Since the adoption of the
new strategic direction in 2012, we have made significant investments in research and development personnel, facilities, equipment,
and consumables to support the internal development of the ID/AST System. The Company has also invested in the hiring of regulatory,
manufacturing, quality, sales, and marketing personnel experienced in the manufacture and commercialization of medical devices.
In addition, the Company completed three successful prototypes of the ID/AST System. We anticipate initiating clinical trials for
the ID/AST System in the first half of 2015.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">The new strategic direction
has also required the Company to raise additional capital. In March 2013, the Company obtained additional capital through the exercise
of warrants issued to Abeja Ventures, LLC in the aggregate amount of $20,068,000. In August 2013, the Company completed a rights
offering that raised gross proceeds of $20,000,000, and in April 2014, the Company completed a rights offering that raised additional
gross proceeds of $45,000,000.</P>

<P STYLE="font: bold 10pt/150% Arial,sans-serif; margin: 10pt 0 9pt; text-align: justify">Clinical Need</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Sepsis is a leading cause
of death in the United States and the most expensive hospital-treated condition. Sepsis is a severe inflammatory response to a
bacterial or fungal infection, with a mortality rate of approximately 30%. According to data published by the U.S. Department
of Health and Human Services for 2011, the cost of sepsis is over $20&nbsp;billion in the United States, or approximately 5% of
the total aggregate costs associated with domestic hospital stays. Sepsis is typically caused by a relatively small number of
bacterial or fungal pathogens, and effective treatment of sepsis requires the early detection, identification, and determination
of antibiotic or anti-fungal treatment. Today, sepsis is typically diagnosed through traditional culture-based and culture-dependent
testing methods with substantial limitations that require up to several days. Due to this timing, antibiotics are typically prescribed
empirically and when the test results are available therapy is modified. Recent studies have shown that empiric antibiotic therapy
is over-prescribed in 50% of cases and inadequate in 25-30% of cases leading to potentially avoidable patient mortality, morbidity,
and hospital costs.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Sepsis is typically diagnosed
based on the testing of blood samples. However, sepsis does not typically originate in the blood stream but instead is introduced
to the blood stream through the progression of infections in other parts of the body. For example a progressive respiratory infection
can infect the blood stream and if treated ineffectively further progress to sepsis. When a serious infection of any origin is
suspected it is typical for both a blood and suspected origin sample (e.g., a respiratory sample) test to be ordered.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Respiratory infections are
particularly difficult to accurately diagnose and treat and can result in serious pneumonias, acute respiratory distress syndrome,
and sepsis. These infections are further complicated by the high occurrence of ventilator associated pneumonias which because
they originate in a hospital setting have a much higher likelihood of being drug resistant and have a 33-50% attributable mortality
rate. Patients suspected of a bacterial respiratory infection have sputum and/or <FONT STYLE="color: #1C1C1C">bronchoalveolar
</FONT>lavage samples taken and provided to the hospital microbiology laboratory for identification and susceptibility testing.
These samples are streaked onto petri dishes and incubated at least overnight. Then, the colonies are reviewed and picked for
further incubation, and upon isolation are tested for identification and antibiotic susceptibility. This process is complex, laborious,
and can take up to four days to complete.</P>

<P STYLE="font: 10pt/150% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center">6</P>

<P STYLE="font: 10pt/150% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">In addition to blood and
respiratory samples, the microbiology laboratory is responsible for delivering pathogen identification and susceptibility testing
of additional sample types including skin and soft tissue, urine, spinal fluid, and stool samples. These varied sample types present
unique analysis and workflow challenges in today&rsquo;s microbiology laboratories. Infections in all of these sample types can
be serious and costly to manage. Skin and soft tissue infections often occur after trauma including hospital procedures and can
necessitate costly follow-on procedures to revise infected tissue from surgical sites.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Microbiology labs are also
experiencing a labor shortage exacerbating the need for laboratory automation.</P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 10pt 0 9pt; text-align: justify">Products</P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">Accelerate
ID/AST System &amp; Positive Blood Culture Test Kit</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">The Accelerate ID/AST System
is the Company&rsquo;s first <I>in vitro</I> diagnostic system and is intended for the identification and antibiotic susceptibility
testing of pathogens most commonly associated with serious infections, including Gram-positive and Gram-negative organisms such
as Staphylococcus organisms as well as yeasts. The Accelerate ID/AST System uses long-accepted bacteriological testing principles,
but applies the Company&rsquo;s proprietary technology to adapt them to analyze live bacteria extracted directly from a patient
specimen. The Accelerate ID/AST System uses automated digital microscopy to simultaneously detect and identify multiple pathogens
directly from a single patient sample and then, following such identification, perform susceptibility tests based on the identification
results. This technology eliminates the need for time-consuming traditional bacterial culturing, thus eliminating the major source
of delay with current testing methods. The identification result is provided in approximately one hour of presenting the patient
sample to the system, and the susceptibility result is provided approximately four hours after the presentation of the identification
result. This combined turnaround time of five hours is a significant improvement over the 40-72 hours required to obtain these
results using conventional culture-based and culture-dependent testing methods.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Diagnostic speed is highly
impactful to patient outcomes and hospital costs. In a recent study, published in the journal <I>Antimicrobial Agents and Chemotherapy</I>,
it was reported that starting patients on effective therapy within 48 hours of admission leads to a 50% reduction in mortality.</P>



<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 6pt; text-align: center">&#9;7</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">The ID/AST System features
walk-away automation and consists of a fixed instrument and proprietary single-use test kit. The instrument consists of module(s)
connected to a single analysis computer, which allows hospitals to acquire various numbers of modules to address their particular
test volume. In order to run a patient sample on the Accelerate ID/AST System the technician would pipette the patient sample into
our system, insert the test kit, and initiate the run. In the case of our initial test a positive blood culture sample is introduced
to the system through pipetting directly from the blood culture bottle into our test kit. Blood culture is a routine laboratory
process which determines negative from positive samples through incubation and takes on average 8 hours to complete. After approximately
one hour from sample introduction, an ID result would be available, and after an additional four hours the AST would also be complete.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">The Accelerate ID/AST System
is the result of over a decade of technology development and three years of instrument design/engineering. Initially prototype
systems featured off-the-shelf pipetting robots, high-speed cameras, microscopes/illumination, and computers. The now final instrument
is comprised entirely of custom-engineered functional components, including a pipette robot for fluidic manipulation, an optical
system with both dark-field and fluorescent illumination, and an imaging system. These components, among others, are used in the
four processes that follow, each of which is a crucial component in delivering approximately one hour ID, and five hour AST. These
processes include:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif"><I>Automated specimen preparation</I>. The initial step
in the process is the automated purification of samples through an on-board and proprietary process to separate live organisms
from sample debris.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif"><I>Live-cell immobilization</I>. Following preparation,
the purified sample is moved to the imaging cassette where pathogens are immobilized onto the cassette surface such that they can
be imaged and analyzed in a stationary position during the identification and antibiotic susceptibility testing.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif"><I>Identification testing via fluorescent in situ hybridization
(FISH)</I>. The now immobilized cells are tested with our proprietary FISH probes to enable identification. Because the genetic
sequences of bacteria are distinctive, the binding of fluorescently labeled probes indicates the presence of a specific target
sequence of RNA associated with a single or group of bacterial species or yeasts. When the probe finds a targeted sequence, it
binds to it&mdash;generating a fluorescent signal&mdash;which is visible by the imaging system on the ID/AST System. Positive fluorescent
signals from more than one target probe indicate polymicrobial samples and a universal bacterial stain discriminates target from
non-target bacteria/fungi. The identification result is presented on the ID/AST System&rsquo;s graphic user interface in approximately
one hour from the introduction of the sample into the ID/AST System. That one-hour timeframe is inclusive of the sample preparation
and immobilization processes described previously.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif"><I>Susceptibility testing via live-cell optical analysis</I>.
With the identification of the pathogen known, the system&rsquo;s software determines the antibiotic panel to be used for susceptibility
testing. These antibiotics, growth media, and additional patient sample are introduced to additional channels on the optical cassette.
Finally, our proprietary imaging platform and algorithms determine the minimum inhibitory concentration (MIC) of the bacteria through
the observation of which antibiotics arrested live cell growth and lead to cell death and which antibiotics were ineffective in
ceasing live cell growth. The susceptibility test result is presented approximately four hours after the conclusion of the identification
test or a total of approximately five hours after the presentation of the patient sample.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">The Accelerate ID/AST System
in its various iterations has been the subject of 30 papers and scientific posters. Further, our internal laboratories have conducted
thousands of tests on the various prototype systems and the final instrument. Published study abstracts and links to full papers
are available on our website at http://acceleratediagnostics.com/our-science/publications/.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">During the fiscal year ended
July 31, 2008, the Company placed two identical development systems in collaborating research institutions: Denver Health, and
Barnes-Jewish Hospital at Washington University in St. Louis, Missouri. The two institutions have replicated and extended the
Company&rsquo;s own pre-clinical research using analytical methods developed by the Company. In 2008, both institutions have also
begun began a series of pilot clinical studies on clinical isolates and then specimens from intensive care unit (&ldquo;ICU&rdquo;)
patients using experimental protocols authorized by their respective Institutional Review Boards. We expect these pilot clinical
studies to continue until we enter our clinical trials in 2015. In 2013, an additional instrument was placed at Geisinger Health
System.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 6pt; text-align: center">8</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 6pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Our collaborations with each
of Denver Health, Barnes-Jewish Hospital and Geisinger Health System are ongoing with various studies either in progress or planned
with these institutions. Barnes-Jewish has been engaged to assist in pre-clinical studies utilizing ICU patient samples. Under
the Company&rsquo;s agreement with Barnes-Jewish, Barnes-Jewish conducted an evaluation of our FISH identification assay using
one of our prototype engineering units and leftover clinical positive blood culture specimens.&nbsp; Denver Health has similarly
partnered with the Company as a part of the Defense Medical Research and Development Program (&ldquo;DMRDP&rdquo;) to apply our
rapid diagnostic system to wound infections and other serious infections secondary to trauma. This research began in September
2012 and will conclude in September 2015. Geisinger Health Systems is conducting a study to evaluate the antimicrobial susceptibility
coagulase-negative staphylococci using an ID/AST System prototype and is expected to conclude in the first half of 2015.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">The Company will be seeking
a single FDA submission for the integrated Accelerate ID/AST System and positive blood culture test kit. This panel will cover
over 80% of the routine and significant pathogens causing blood stream infections and over 90% of the antibiotics useful in treating
those pathogens. While some molecular diagnostic companies have sought separate regulatory approval for each species of bacteria
tested by an identification system, the Company is pursuing approval via a single, consolidated submission, similar to approaches
taken since early 2013 by molecular diagnostic companies for their multiplexed identification tests. The difference in these approaches
has been driven by the technology utilized. Consequently, as Accelerate&rsquo;s technology tests for multiple types of pathogens,
simultaneously, we intend to file a single submission for our identification panel and susceptibility panel.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">As of December 31, 2014 we
have completed the following steps toward our goal of obtaining regulatory approvals for E.U. and U.S. launches of the ID/AST System
and positive blood culture test kit:</P>

<P STYLE="font: 12pt/115% Times New Roman,serif; margin: 0 0 6pt 0.75in; text-indent: -0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT><FONT STYLE="font: 7pt Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font: 10pt Arial,sans-serif">design of the final ID/AST System and positive blood culture test kit; </FONT></P>

<P STYLE="font: 12pt/115% Times New Roman,serif; margin: 0 0 6pt 0.75in; text-indent: -0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT><FONT STYLE="font: 7pt Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font: 10pt Arial,sans-serif">meeting with the FDA to discuss the regulatory approval path for the ID/AST System
and positive blood culture test kit; </FONT></P>

<P STYLE="font: 12pt/115% Times New Roman,serif; margin: 0 0 6pt 0.75in; text-indent: -0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT><FONT STYLE="font: 7pt Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font: 10pt Arial,sans-serif">design of the U.S. clinical study; </FONT></P>

<P STYLE="font: 12pt/115% Times New Roman,serif; margin: 0 0 6pt 0.75in; text-indent: -0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT><FONT STYLE="font: 7pt Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font: 10pt Arial,sans-serif">selection of clinical trial sites;</FONT></P>

<P STYLE="font: 12pt/115% Times New Roman,serif; margin: 0 0 6pt 0.75in; text-indent: -0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT><FONT STYLE="font: 7pt Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font: 10pt Arial,sans-serif">obtain ISO13485 certification based on the establishment and audit of a product
quality system; and</FONT></P>

<P STYLE="font: 12pt/115% Times New Roman,serif; margin: 0 0 6pt 0.75in; text-indent: -0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT><FONT STYLE="font: 7pt Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font: 10pt Arial,sans-serif">building good manufacturing practice (GMP) manufacturing and test facilities.
</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Key remaining steps toward
obtaining a CE-mark for commercialization in the E.U., anticipated for the first half of 2015, and upon obtaining FDA approval
commercializing the product in the U.S., include:</P>

<P STYLE="font: 12pt/115% Times New Roman,serif; margin: 0 0 6pt 0.75in; text-indent: -0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT><FONT STYLE="font: 7pt Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font: 10pt Arial,sans-serif">completing product technical files and providing a self-declaration of conformity
to our E.U. authorized representative after which CE mark will be obtained;</FONT></P>

<P STYLE="font: 12pt/115% Times New Roman,serif; margin: 0 0 6pt 0.75in; text-indent: -0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT><FONT STYLE="font: 7pt Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font: 10pt Arial,sans-serif">the execution of the U.S. clinical trials;</FONT></P>

<P STYLE="font: 12pt/115% Times New Roman,serif; margin: 0 0 6pt 0.75in; text-indent: -0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT><FONT STYLE="font: 7pt Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font: 10pt Arial,sans-serif">preparation of the FDA submission following the clinical trials; and </FONT></P>

<P STYLE="font: 12pt/115% Times New Roman,serif; margin: 0 0 6pt 0.75in; text-indent: -0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT><FONT STYLE="font: 7pt Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font: 10pt Arial,sans-serif">obtaining a positive review of this submission from the FDA.</FONT></P>



<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center">9</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify"></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Pilot studies with clinical
partners and internal studies demonstrate sensitivity and specificity rates in the high nineties across all on-target species and
specie drug combinations, which if replicated during the clinical trial should be more than sufficient to obtain market approval
from the FDA. The Company anticipates entering clinical trials for the ID/AST System and positive blood culture test kit in the
first half of 2015, and upon obtaining FDA market approval, the Company plans to commercialize the product. The ID/AST System and
positive blood culture test kit is not yet cleared by the FDA and not commercially available. Therefore, we have not yet generated
any sales revenues from the ID/AST System.</P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">OptiChem</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">In addition to developing
the Accelerate ID/AST System, we have developed and licensed OptiChem surface coatings for use in microarraying components. As
a coating for analytical devices, management believes that OptiChem offers superior noise rejection (non-specific binding by interfering
substances) and high capacity for target binding, compared with other bio-coatings. For example, in microarraying this results
in higher sensitivity and simplified sample preparation.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">We have licensed various
OptiChem microarraying coatings to Schott Jenaer Glas GmbH (&ldquo;SCHOTT&rdquo;) (Germany), NanoString Technologies, Inc. (&ldquo;NanoString&rdquo;)
(U.S., WA), and Nanosphere, Inc. (&ldquo;Nanosphere&rdquo;) (U.S., IL). See &ldquo;Sales, Licensing, and Alliances&rdquo; below.
For the period ended December 31, 2014 licensing revenues from OptiChem were the Company&rsquo;s only source of revenue.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">As discussed above, we are
discontinuing our efforts to develop and actively market OptiChem and our other surface chemistry products. Instead, we are focusing
our efforts on the successful development, manufacture and commercialization of the ID/AST System.</P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 10pt 0 9pt; text-align: justify">Market Opportunity</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Accelerate Diagnostics is
focused on the clinical microbiology industry, which is currently valued at $3.4 billion globally and is estimated to grow at a
rate in excess of 15% through 2019. Initially, we plan on targeting our system across three regions; North America, Europe, and
various countries in Asia Pacific. In these geographies, we estimate there are over 14 million high-acuity tests across various
sample types including: blood, respiratory, skin and soft tissue, and urine. We believe the available market opportunity for our
first <I>in vitro</I> diagnostic instrument, the Accelerate ID/AST System and first test kit for positive blood culture samples
is 5 million annual tests across our targeted geographies.</P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 10pt 0 9pt; text-align: justify">Sales, Marketing, and Distribution</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">The target customer for our
products is hospital microbiology laboratories that perform identification and antibiotic susceptibility testing.&nbsp; Globally,
the vast majority of hospitals with an intensive care unit have such a laboratory. In general, we plan to build our own sales force
to market the ID/AST System directly to our targeted customers.&nbsp; However, in select geographies, we plan to use third-party
distributors to market the product.</P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 10pt 0 9pt; text-align: justify">Research and Development</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">The Company plans to continue
making significant investments in the research and development of new applications for existing technologies and in the research
and development of new complementary technologies.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center">10</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify"></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">With the development of the
Accelerate ID/AST System and positive blood culture test kit substantially complete, the Company will immediately focus on the
development of additional test kits to address opportunities in sample types including but not limited to respiratory, skin and
soft tissue, and urine. Similar to the positive blood culture kit, the objective is to develop test kits which work seamlessly
on the Accelerate ID/AST System and deliver substantial benefits to the microbiology laboratory and to physicians in the treatment
of serious infections. Proof of concept research has already been completed on some of these sample types aided in part by DMRDP
grant which aims to apply the Accelerate ID/AST System to respiratory and skin and soft tissue samples.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">We anticipate seeking separate
regulatory approval for each additional test kit. If and when we determine that we will pursue regulatory approvals for those applications,
we would likely include the identification of the most prevalent infectious pathogens found in each specimen type and the applicable
antimicrobial agents for treatment.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Our research activity is
also focused on shortening the time required to distinguish between positive and negative whole blood and potentially urine samples
prior to using the ID/AST System.</P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 10pt 0 9pt; text-align: justify">Intellectual Property</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">We rely on a combination
of patent, copyright, trademark and trade secret laws, employee and third-party non-disclosure agreements, license agreements,
and other intellectual property protection methods to protect our proprietary rights. We intend to continue developing intellectual
property, and we intend to aggressively protect our position in key technologies. Our patented technology covers key components
of the ID/AST System and is, thus, very important to the Company.&nbsp; Our patents are focused on several key technologies, including
our automated process for sample preparation, automated immobilization process, and methods for imaging and analysis of individual
pathogen cells. The Company&rsquo;s first patent on the ID/AST System technology, U.S. Patent No. 7,341,841 titled &quot;Rapid
Microbial Detection and Antimicrobial Susceptibility Testing&quot; was issued on March 11, 2008. The patent specification covers
methods used to derive identification and antibiotic susceptibility from tests on individual immobilized bacterial cells. As of
December 31, 2014, we had 18 issued patents worldwide, including 12 patents issued in the United States and six issued outside
the United States.&nbsp; One of our patents expires in 2017, and the remaining 17 will expire on various dates in 2022 through
2033.&nbsp; Additionally, as of December 31, 2014, we had 12 patent applications pending worldwide, including six U.S. applications
and six applications outside the United States. The Company believes that its patent suite would make it difficult for any other
company to conduct rapid antibiotic susceptibility testing of individual pathogens.</P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 10pt 0 9pt; text-align: justify">Government Regulation</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Our products under development
and our operations are subject to significant government regulation. In the United States, our products are regulated as medical
devices by the FDA and other federal, state, and local regulatory authorities.</P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">FDA
Regulation of Medical Devices</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">The FDA and other U.S. and
foreign governmental agencies regulate, with respect to medical devices:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37.8pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif">design, development, manufacturing, and storage;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37.8pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif">testing, content, and language of instructions for use
and storage;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37.8pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif">labeling;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37.8pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif">pre-clinical testing and clinical trials;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37.8pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif">product safety;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37.8pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif">advertising, promotion, marketing, sales, and distribution;</FONT></TD></TR></TABLE>



<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center">11</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37.8pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif">pre-market clearance and approval;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37.8pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif">record-keeping procedures;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37.8pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif">advertising and promotion;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37.8pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif">recalls and corrective field actions;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37.8pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif">post-market reporting, including reporting of deaths,
serious injuries, and malfunctions that, if they were to recur, could lead to death or serious injury;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37.8pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif">post-market studies and surveillance; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37.8pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif">product import and export.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">In the United States, numerous
laws and regulations govern all the processes by which medical devices are brought to market and marketed. These include the Federal
Food, Drug and Cosmetic Act (the &ldquo;FDCA&rdquo;) and the FDA's implementing regulations.</P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">FDA
Pre-market Clearance and Approval Requirements</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Each medical device we seek
to commercially distribute in the United States must first receive 510(k) clearance, approval of a reclassification petition or
de novo classification request, or pre-market approval from the FDA, unless specifically exempted by the FDA. The FDA classifies
all medical devices into one of three classes. Devices deemed to pose the lowest risk are categorized as either Class&nbsp;I or
II, which generally requires the manufacturer to submit to the FDA a 510(k) pre-market notification submission requesting clearance
of the device for commercial distribution in the United States. Some low risk devices are exempted from this requirement. Devices
deemed by the FDA to pose the greatest risk, such as life sustaining, life-supporting, or implantable devices, or devices deemed
not substantially equivalent to a previously 510(k)-cleared device are categorized as Class&nbsp;III. These devices generally require
submission and approval of a pre-market approval application, or PMA.</P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">510(k)
Clearance Process</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">To obtain 510(k) clearance,
we must submit a pre-market notification to the FDA demonstrating that the proposed device is substantially equivalent to a device
that has previously obtained 510(k) clearance, a device that has been classified into Class&nbsp;I or II, or a device that was
legally marketed before May&nbsp;28, 1976 and that is not yet subject to an FDA order requiring pre-market approval. In rare cases,
Class&nbsp;III devices may be cleared through the 510(k) process. The FDA has committed to review most 510(k) decisions within
90 days, but the review clock may be stopped due to requests for additional information. A decision may take significantly longer,
and clearance is never assured. Although many 510(k) pre-market notifications are cleared without clinical data, in some cases,
the FDA requires significant clinical data to support substantial equivalence. In reviewing a pre-market notification submission,
the FDA may request additional information, including clinical data, which may significantly prolong the review process.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">After a device receives
510(k) clearance, any subsequent modification of the device that could significantly affect its safety or effectiveness, or that
would constitute a major change in its intended use, requires a new 510(k) clearance or, in some cases, approval of a PMA. The
FDA requires each manufacturer to make this determination initially, but the FDA may review any such decision and may disagree
with a manufacturer's determination. If the FDA disagrees with a manufacturer's determination, the FDA may require the manufacturer
to cease marketing and/or recall the modified device until 510(k) clearance or approval of a PMA is obtained. Under these circumstances,
the FDA may also subject a manufacturer to enforcement action and sanctions, including those described below. In addition, the
FDA is currently evaluating the 510(k) process and may make substantial changes to regulatory requirements, including changes
that could affect which devices are eligible for 510(k) clearance, the FDA&rsquo;s ability to rescind 510(k) clearances, and additional
requirements that may significantly impact the 510(k) review process.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center">12</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify"></P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">Pre-market
Approval Process</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">A PMA generally must be submitted
if the medical device is in Class&nbsp;III or cannot be cleared through the 510(k) process. A PMA must be supported by extensive
technical, preclinical, clinical, manufacturing, and labeling data to demonstrate to the FDA's satisfaction the safety and effectiveness
of the device.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">After a PMA is submitted
and filed, the FDA begins an in-depth review of the submitted information. During this review, the FDA may request additional
information or clarification of information already provided. Also during the review period, an advisory panel of experts from
outside the FDA may be convened to review and evaluate the application and provide recommendations to the FDA as to the approvability
of the device. In addition, the FDA will conduct a pre-approval inspection of the manufacturing facility to ensure compliance
with Quality System Regulation (&ldquo;QSR&rdquo;), which imposes elaborate development, testing, control, documentation and other
quality assurance requirements on the design and manufacturing process. The FDA has committed to review most PMAs within 180 days
where an advisory panel is not required and within 320 days where an advisory panel is required, but the review clock may be stopped
due to requests for additional information. A decision may take significantly longer, and approval is never assured. The FDA may
approve a PMA with post-approval conditions intended to ensure the safety and effectiveness of the device including restrictions
on labeling, promotion, sale, and distribution and collection of safety data. Failure to comply with the conditions of approval
can result in enforcement action and sanctions, including those described below. New PMAs or PMA supplements are required for
significant modifications to the manufacturing process, labeling of the product, or design of a device that is approved through
the PMA process. PMA supplements often require submission of the same type of information as an original PMA, except that the
supplement is limited to information needed to support any changes from the device covered by the original PMA and may not require
as extensive clinical data or the convening of an advisory panel.&nbsp;</P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">De
novo Classification Process</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Medical device types that
the FDA has not previously classified as Class&nbsp;I, II, or III are automatically classified into Class&nbsp;III regardless of
the level of risk they pose. The Food and Drug Administration Modernization Act of 1997 established a new route to market for low-to-moderate
risk medical devices that are automatically placed into Class&nbsp;III due to the absence of a predicate device, called the &quot;Request
for Evaluation of Automatic Class&nbsp;III Designation,&quot; or the de novo classification procedure. This procedure allows a
manufacturer whose novel device is automatically classified into Class&nbsp;III to request down-classification of its medical device
into Class&nbsp;I or Class&nbsp;II on the basis that the device presents low or moderate risk, rather than requiring the submission
and approval of a PMA. Prior to the enactment of the Food and Drug Administration Safety and Innovation Act (&ldquo;FDASIA&rdquo;)
in July 2012, a medical device could only be eligible for de novo classification if the manufacturer first submitted a 510(k) pre-market
notification and received a determination from the FDA that the device was not substantially equivalent. FDASIA streamlined the
de novo classification pathway by permitting manufacturers to also request de novo classification directly without first submitting
a 510(k) pre-market notification to the FDA and receiving a not substantially equivalent determination. Under FDASIA, the FDA is
required to classify the device within 120&nbsp;days following receipt of such a direct de novo request. If the manufacturer seeks
classification into Class&nbsp;II, the manufacturer should include a draft proposal for special controls that are necessary to
provide a reasonable assurance of the safety and effectiveness of the medical device. In addition, the FDA may reject a de novo
request if the FDA identifies a legally marketed predicate device that would be appropriate for a 510(k), determines that the device
is not low-to-moderate risk, or determines that general controls would be inadequate to control the risks and special controls
cannot be developed. We plan to utilize the de novo classification process to obtain marketing authorization for the ID/AST System,
which we believe will be placed within Class II.</P>



<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0"></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center">13</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">Clinical
Trials</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Clinical trial data is typically
required to support a PMA and is sometimes required for a 510(k) pre-market notification. Initiation of a clinical trial generally
requires submission of an application for an Investigational Device Exemption (an &ldquo;IDE&rdquo;) to the FDA. The IDE application
must be supported by appropriate data, such as animal and laboratory testing results, showing that it is safe to test the device
in humans and that the investigational protocol is scientifically sound. The IDE application must be approved in advance by the
FDA for a specified number of patients, unless the product is deemed a non-significant risk device and eligible for abbreviated
IDE requirements. Clinical trials for a significant risk device may begin once the IDE application is approved by the FDA as well
as the appropriate institutional review boards at the clinical trial sites and the informed consent of the patients participating
in the clinical trial is obtained. After a trial begins, the FDA may place it on hold or terminate if it concludes that the clinical
subjects are exposed to unacceptable risks. Any trials we conduct must be conducted in accordance with FDA regulations as well
as other federal regulations and state laws concerning human subject protection and privacy. Moreover, the results of a clinical
trial may not be sufficient to obtain clearance or approval of the product.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Clinical trial sponsors may
also be subject to the Medicare Secondary Payer laws, which prohibit Medicare from making a payment if payment has been made or
can reasonably be expected to be made by other plans, such as liability insurance plans (including self-insurance). Section 111
of the Medicare, Medicaid, and SCHIP Extension Act of 2007 (&ldquo;MMSEA&rdquo;) established mandatory reporting requirements with
respect to Medicare beneficiaries who receive settlements, judgments, awards, or other payment from liability insurance (including
self-insurance) plans. When payments are made by sponsors of clinical trials for complications or injuries arising out of the trials,
such payments are considered to be payments by liability insurance (including self-insurance) and must be reported. Section III
of the MMSEA includes authority for CMS to impose civil monetary penalties against liability insurance (including self-insurance)
plans that are determined to be non-compliant with the applicable reporting requirements.</P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">Pervasive
and Continuing Regulation</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">After a medical device is
placed on the market, numerous FDA regulatory requirements apply, including the following:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 38.15pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif">the QSR, which imposes elaborate development, testing,
control, documentation, and other quality assurance requirements on the design and manufacturing process;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 38.15pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif">establishment registration, which requires establishments
involved in the production and distribution of medical devices, intended for commercial distribution in the United States, to register
with the FDA;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 38.15pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif">medical device listing, which requires manufacturers
to list the devices they have in commercial distribution with the FDA;</FONT></TD></TR></TABLE>



<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify"></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center">14</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 38.15pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif">labeling regulations and various statutory provisions,
which prohibit false or misleading labeling, as well as the promotion of products for unapproved or &quot;off-label&quot; uses,
and impose other restrictions on labeling; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 38.15pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif">post-market reporting requirements, which require that
manufacturers report to the FDA deaths, serious injuries, and malfunctions that, if they were to recur, could lead to death or
serious injury, recalls, and corrective field actions.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">In certain cases, advertising
is also subject to scrutiny by the Federal Trade Commission. The FDA and other agencies actively enforce these and other applicable
laws and regulations. Failure to comply with applicable requirements may result in enforcement action by the FDA and/or the U.S.
Department of Justice, which may include one or more of the following administrative or judicial sanctions:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37.8pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif">untitled letters or warning letters;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37.8pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif">fines, injunctions, and civil penalties;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37.8pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif">mandatory recall or seizure of our products;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37.8pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif">administrative detention or banning of our products;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37.8pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif">operating restrictions, partial suspension, or total
shutdown of production;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37.8pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif">import holds;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37.8pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif">refusing to approve pending 510(k) notifications or PMAs;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37.8pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif">revocation of 510(k) clearance or pre-market approvals
previously granted; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37.8pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif">criminal prosecution and penalties.</FONT></TD></TR></TABLE>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0"></P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">International
Regulation</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Sales of medical devices
outside the United States are subject to foreign government regulations, which vary substantially from country to country. In order
to market our products in other countries, we must obtain regulatory approvals and comply with extensive safety and quality regulations
in other countries. The time required to obtain approval by a foreign country may be longer or shorter than that required for FDA
clearance or approval, and the requirements may differ significantly.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">In the European Economic
Area, or EEA, which comprises the 28&nbsp;Member States of the EU plus Liechtenstein, Norway and Iceland, in vitro medical devices
are required to conform with the essential requirements of the EU Directive on in vitro diagnostic medical devices (Directive
98/79/EC, as amended). To demonstrate compliance with the essential requirements, the manufacturer must undergo a conformity assessment
procedure. The conformity assessment varies according to the type of medical device and its classification. For low-risk devices,
the conformity assessment can be carried out internally, but for higher risk devices (self-test devices and those included in
List A and B of Annex&nbsp;II of Directive 98/79/EC) it requires the intervention of an accredited EEA Notified Body. If successful,
the conformity assessment concludes with the drawing up by the manufacturer of an EC Declaration of Conformity entitling the manufacturer
to affix the CE mark to its products and to sell them throughout the EEA.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center">15</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">Other
Healthcare Laws</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Although we currently do
not have any products on the market, we anticipate that the ID/AST System will receive FDA approval in calendar year 2015. Once
commercialized, our business activities, including the activities of any third-party distributors that we retain, will likely be
subject to additional healthcare laws and regulations and related enforcement by the federal government as well as the governments
of states and foreign jurisdictions where we conduct our business. These laws and regulations include, without limitation, state
and federal anti-kickback, fraud and abuse, false claims, privacy and security, and physician payment transparency laws and regulations.
Violations of these laws or regulations can result in criminal or civil sanctions, including substantial fines and, in some cases,
exclusion from participation in federal healthcare programs, such as Medicare and Medicaid. The following discussion describes
certain federal and state healthcare laws and regulations that may impact our operations and the operations of our customers, but
is not intended to be an exhaustive discussion of all potentially applicable federal and state health laws and regulations.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">The federal Anti-Kickback
Statute prohibits any person from knowingly and willfully offering, soliciting, receiving, or providing remuneration, directly
or indirectly, overtly or covertly, in cash or in kind, in exchange for or to induce either the referral of an individual for an
item or service, or the purchasing, leasing, ordering, or arranging for or recommending the purchase, lease, or order of any good,
facility, item, or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the
Medicare and Medicaid programs. A person need not have actual knowledge of the Anti-Kickback Statute or specific intent in order
to commit a violation, and several courts have interpreted the intent requirement of the Anti-Kickback Statute to mean that if
any one purpose of an arrangement is to induce referrals or purchases of federal healthcare program business, the Anti-Kickback
Statute has been violated. In addition to criminal fines and penalties set forth under the Anti-Kickback Statute, violations of
the Anti-Kickback Statute can result in exclusion or debarment from participation in the federal healthcare programs, as well as
substantial penalties under the Civil Monetary Penalties Statute, which imposes penalties against any person or entity that is
determined to have presented or caused to be presented a claim to a federal healthcare program that the person knows or should
know is for an item or service that was not provided as claimed or is false or fraudulent. A violation of the federal Anti-Kickback
Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act, which, as discussed below, imposes
liability on any person or entity that knowingly presents, or causes to be presented, a false or fraudulent claim for payment by
a federal healthcare program. Several states also have anti-kickback laws which establish similar prohibitions and, in some cases,
may apply to items or services reimbursed by any third-party payor, including commercial insurers.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">The federal False Claims
Act imposes liability on any person or entity that knowingly presents or causes to be presented a false or fraudulent claim for
payment to, or approval by, the U.S. government. Liability under the False Claims Act can give rise to treble damages and civil
penalties of up to $11,000 per claim. In addition to actions initiated by the government itself, the qui<I> </I>tam provisions
of the False Claims Act authorize private individuals to bring False Claims Act actions on behalf of the federal government alleging
that the defendant has submitted a false claim to the federal government, and to share in a percentage of the recovery. In recent
years, the government and qui tam relators have initiated suits resulting in multi-million and multi-billion dollar settlements
under the False Claims Act in addition to criminal convictions under applicable criminal statutes. Given the significant size of
actual and potential settlements, it is expected that the government and qui tam relators will continue to devote substantial resources
and use the False Claims Act to investigate and prosecute healthcare companies&rsquo; compliance with applicable fraud and abuse
laws.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">The federal Health Insurance
Portability and Accountability Act of 1996 (&ldquo;HIPAA&rdquo;) created federal criminal statutes that prohibit knowingly and
willfully executing, or attempting to execute, a scheme or artifice to defraud any healthcare benefit program, including private
third-party payors or to obtain&mdash;by means of false or fraudulent pretenses, representations, or promises&mdash;any of the
money or property owned by or under the custody or control of any healthcare benefit program; and knowingly and willfully falsifying,
concealing, or covering up a material fact or making any materially false, fictitious, or fraudulent statement in connection with
the delivery of or payment for healthcare benefits, items or services. The Affordable Care Act amended certain sections of the
HIPAA criminal statutes such that a person need not have actual knowledge of the applicable statute or specific intent in order
to have committed a healthcare fraud violation.</P>



<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center">16</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">As stated above, many states
and foreign countries have adopted similar fraud and abuse laws that may be broader in scope and may apply regardless of payor.
Violations of any of these laws can lead to additional risk such as risk of plaintiff class actions, state attorney general actions,
and investigation by agencies such as the Department of Justice (&ldquo;DOJ&rdquo;) or the Federal Trade Commission (&ldquo;FTC&rdquo;).</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">The Physician Payment Sunshine
Act, implemented by Section&nbsp;6002 of the Affordable Care Act, imposes transparency requirements on certain manufacturers, referred
to as &ldquo;applicable manufacturers,&rdquo; of drugs, devices, biological, or medical supplies for which payment is available
under Medicare, Medicaid, the Children&rsquo;s Health Insurance Program (&ldquo;CHIP&rdquo;), or a waiver of a plan offered under
CHIP. Applicable manufacturers must track and report to the Centers for Medicare &amp; Medicaid Services (&ldquo;CMS&rdquo;) certain
payments or &quot;transfers of value&quot; provided to U.S. licensed physicians and teaching hospitals during the preceding calendar
year, as well as certain ownership and investment interests held by U.S. licensed physicians and their immediate family members.
CMS releases the reported data on a public website on an annual basis. Failure to report as required under the Physician Payment
Sunshine Act could subject applicable manufacturers to significant financial penalties, while tracking and reporting the required
payments and transfers of value may result in considerable administrative expense. Several states currently have similar laws,
and more states may enact similar legislation, some of which may be broader in scope. For example, certain states require the implementation
of compliance programs, compliance with industry ethics codes, implementation of gift bans, and spending limits, and/or reporting
of gifts, compensation, and other remuneration to healthcare professionals.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">We also may be subject to
data privacy and security regulation by both the federal government and the states in which we conduct our business. HIPAA, as
amended by the Health Information Technology for Economic and Clinical Health Act (&ldquo;HITECH&rdquo;), and their respective
implementing regulations, including the final omnibus rule published by the Department of Health and Human Services Office for
Civil Rights (&ldquo;OCR&rdquo;) in January&nbsp;2013, restrict the use and disclosure of patient-identifiable health information,
mandate the adoption of standards relating to the privacy and security of patient-identifiable health information, and require
us to report certain security breaches to healthcare provider customers with respect to such information where we are acting as
a HIPAA business associate, as that term is defined, to that customer. In addition to HIPAA criminal penalties, HITECH created
four new tiers of civil and monetary penalties and gave state attorneys general new authority to file civil actions for damages
or injunctions in federal courts to enforce the federal HIPAA privacy and security laws and seek attorneys' fees and costs associated
with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in certain circumstances
and impose reporting requirements for data breaches, many of which differ from each other and HIPAA in significant ways and may
not have the same effect, thus complicating compliance efforts.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">The use of certain diagnostic
products by our potential customers is affected by the Clinical Laboratory Improvement Amendments (&ldquo;CLIA&rdquo;) and related
federal and state regulations that provide for regulation of laboratory testing. CLIA is intended to ensure the quality and reliability
of clinical laboratories in the United States by mandating specific standards in the areas of personnel qualifications, administration,
and participation in proficiency testing, patient test management, quality assurance, quality control, and inspections. Current
or future CLIA requirements or the promulgation of additional regulations affecting laboratory testing may prevent some laboratories,
hospitals, providers, or other customers with laboratories from using some or all of our diagnostic products.&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center">17</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">Healthcare
Reform</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">In the United States and
several foreign jurisdictions, there have been, and we expect there may continue to be, a number of legislative and regulatory
changes to the healthcare system seeking to reduce healthcare costs that could affect our future results of operations as we begin
to commercialize our products.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">In the United States, the
Affordable Care Act (&ldquo;ACA&rdquo;), enacted in March 2010, made changes that are expected to have a continued and significant
impact on the medical device industry and clinical laboratories, including the way healthcare is delivered and financed by governmental
and private insurers. For example, the legislation provided for reductions in the Medicare clinical laboratory fee schedule and,
since 2013, has required that certain medical device manufacturers pay an excise tax in an amount equal to 2.3% of the price for
which such manufacturer sells its medical devices. We will be subject to this tax once we begin selling the ID/AST System.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">In addition, frequently in
recent years, other legislative, regulatory, and political changes aimed at regulating healthcare delivery in general and clinical
laboratories in particular have been proposed and adopted in the United States. Payment and reimbursement for the laboratory industry
and hospital and other healthcare provider services have been under significant pressure. Most recently, in January 2015, the Department
of Health and Human Services (&ldquo;HHS&rdquo;) announced a plan to shift the Medicare program and the healthcare system at large
toward paying providers based on quality, rather than the quantity of care provided to patients, and the President&rsquo;s budget
for fiscal year 2016 proposed reductions in Medicare spending.</P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">Reimbursement</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">We do not believe that hospitals
will specifically seek reimbursement from the government or private insurance companies for their purchase of the ID/AST System
or the positive blood culture test kits. Instead, we believe that hospitals will recoup such costs by obtaining reimbursement from
the government or private insurance companies for in-bed occupancies, which traditionally includes all testing required for admitted
patients.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Hospitals, clinical laboratories,
and other healthcare provider customers that may purchase our products, if approved, generally bill various third-party payors
to cover all or a portion of the costs and fees associated with diagnostic tests, including the cost of the purchase of our products.
We currently expect that all of our diagnostic tests will be performed in a hospital inpatient setting, where governmental payors,
such as Medicare, generally reimburse hospitals a single bundled payment that is based on the patient&rsquo;s diagnosis under a
classification system known as the Medicare severity diagnosis-related groups (&ldquo;MS-DRGs&rdquo;) classification for all items
and services provided to the patient during a single hospitalization, regardless of whether our diagnostic tests are performed
during such hospitalization.</P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 10pt 0 9pt; text-align: justify">Competition</P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">Leading
Competitors</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">To the best of our knowledge,
no other company has a product with capabilities matching those of the ID/AST System. The leading companies with automated microbiological
testing products include Becton, Dickinson and Company (&ldquo;BD&rdquo;), bioMerieux, Danaher Corporation, and Thermo Fisher
Scientific&rsquo;s subsidiary TREK Diagnostics Systems, Inc. (&ldquo;TREK&rdquo;). These companies provide products for the broad-based
culturing and analysis of a wide variety of bacteria. However, none of our competitor&rsquo;s products is able to provide results
as quickly as the ID/AST System.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center">18</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify"></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt 1.4pt; text-align: justify; text-indent: 34.6pt">Our competitor&rsquo;s
products require purified bacterial strains or &ldquo;isolates&rdquo; for analysis, which require at least overnight culturing
of a sample to produce enough organisms to test. These standard culturing methods, including enrichment growth and colony isolation,
cannot achieve the speed provided by the ID/AST System. The ID/AST System eliminates the need to produce an isolated culture and
corresponding inoculums of a sample. Instead, once a sample is introduced into the ID/AST System by an operator, it automatically
processes the sample using our proprietary sample preparation method. Once this sample preparation process is complete, our system
uses a proprietary high speed imaging system to analyze the bacteria in real time. An identification result is available within
approximately one hour of introducing the sample into the ID/AST System, and its susceptibility profile is generally available
within four hours later. This greatly decreases the time of analysis and eliminates the need for a standardized, cultured inoculum,
resulting in a process that takes approximately five hours in total instead of the much longer time period required under standard
culturing methods.</P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">Industry
Developments</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">The clinical microbiology
industry is subject to rapid technological changes, and new products are frequently introduced for rapid bacterial identification
using genes or other molecular markers (&ldquo;molecular diagnostics&rdquo;). Numerous acquisitions, licenses, and distribution
arrangements have been announced over the last few years for such products. However, we do not believe that any of these technologies
offers the advantages offered by the ID/AST System. For example, gene detection can be highly sensitive and specific for the identification
of pathogens, but very few antibiotic resistance mechanisms are simple enough to allow accurate guidance for drug selection. Even
in those rare instances that have a direct relationship between a gene and effective resistance, such as particular <I>Methicillin-Resistant
Staphylococcus Aureus</I> (MRSA) strains, leading literature has reported novel mutations that escape detection by recently commercialized
tests.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&#9;Fundamental biological
limitations arise from the complexity of the majority of drug resistance expression mechanisms. This complexity precludes direct
interpretation of molecular marker presence or absence and extrapolating to prescription guidance. Many new diagnostic technologies
also require prior isolation of cultured colonies in order to assure accuracy. The time required to obtain such isolates, with
a minimum of overnight turnaround, prevents these technologies from serving as rapid diagnostics for treatment decision support.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&#9;Another new technology
receiving wide attention is mass spectrometry, and particularly the matrix-assisted laser desorption ionization time of flight
version (&ldquo;MALDI-TOF&rdquo;), such as the Biotyper&reg; system from Bruker Corporation, which has not yet received FDA clearance.
Bruker Corporation has agreements with a number of companies for distribution, including BD, TREK, and Siemens. bioMerieux has
a similar system for distribution with Shimadzu Corporation. These systems build an empiric database from protein spectra acquired
from many thousands of purified bacterial and fungal strains. They require a pure strain isolate for analysis and enrichment culturing
to produce enough material to analyze. Some research papers on these systems report attempts to directly analyze isolate or blood
culture smears, but results are not as reliable as those from samples prepared using a cleanup process to produce crude protein
extracts.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center">19</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">MALDI-TOF systems have a
major advantage over other molecular methods in identifying a very broad range of organisms. Cost of ownership is also substantially
below that of older molecular methods. But the requirement for extensive organism enrichment and purification, as well as the inability
to quantify live organisms or distinguish samples derived from viable organisms, substantially limits this technology from time-critical
decision support. In this respect, the ID/AST System provides a substantial advantage for more rapid test results. Finally, as
with the older molecular methods, MALDI-TOF systems cannot identify major drug resistance expression and faces the same fundamental
biological barriers as gene detection.</P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 10pt 0 9pt; text-align: justify">Operations</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">In January 2013, we relocated
our headquarters from Denver, Colorado to Tucson, Arizona, where we currently lease approximately 27,404 square feet of office
and laboratory space and have plans to significantly expand our facilities in 2015. Further information regarding our Tucson facility
is included in Part I, Item 2, &ldquo;Properties,&rdquo; included elsewhere in this report, and details regarding our lease arrangement
are included in Note 14, &ldquo;Commitments,&rdquo; to the audited consolidated financial statements included elsewhere in this
report.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">We plan to assemble the ID/AST
System instrument and consumable test kits in our facilities in Tucson, Arizona. The ID/AST System requires certain components
that are custom-fabricated to our specifications. Such components include injection-molded plastic components, die-cut laminates,
and machined mechanical components. We own the necessary production tooling and believe that we will be able to qualify secondary
sources as needed to support future demand for the ID/AST System.</P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 10pt 0 9pt; text-align: justify">Raw Materials</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 10pt 0 9pt 2.1pt; text-align: justify; text-indent: 33.9pt"><FONT STYLE="font-weight: normal">We
purchase many different types of raw materials, including plastics, glass, metals, electronic and mechanical sub-assemblies and
various biological and chemical products. We seek to ensure continuity of raw material supply by securing multiple options for
sourcing. However, our components are custom-made by only a few outside suppliers. In certain instances, we have a sole source
supply for key product components of the ID/AST System. We have entered into supply agreements with most of our suppliers to help
ensure component availability and flexible purchasing terms with respect to the purchase of such components. </FONT></P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 10pt 0 9pt; text-align: justify">Employees</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">We have 73 employees as of
December 31, 2014. We have not entered into any collective bargaining agreements and consider our labor practices and employee
relations to be good.</P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 10pt 0 9pt; text-align: justify">Available Information</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">We regularly file reports
with the SEC, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and any other
filings required by the SEC. We make these reports available free of charge in the investor relations section of our corporate
website (http://ir.axdx.com/) as soon as reasonably practicable after such material is electronically filed with or furnished to
the SEC. References to our corporate website address in this report are intended to be inactive textual references only, and none
of the information contained on our website is part of this report or incorporated in this report by reference.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">The public may inspect and
copy materials we file with the SEC at the SEC&rsquo;s Public Reference Room at 100 F Street, NE, Room 1580, Washington, DC 20549.
You may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. You may also access
these materials, and other information regarding issuers like us that file information electronically with the SEC, from the SEC&rsquo;s
internet website at http://www.sec.gov/.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center">20</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 12pt/normal Arial,sans-serif; margin: 0 0 9pt; text-align: justify">Item 1A. Risk Factors</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Investing in our securities
involves a high degree of risk. You should carefully consider the risks described below, in addition to the other information included
or incorporated by reference in this Annual Report on Form 10-K, including our financial statements and the related notes. If any
of the following risks materializes, our business, financial condition, results of operations or growth prospects could be materially
adversely affected, and the value of an investment in our common stock may decline significantly.</P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 10pt 0 9pt; text-align: justify">Risks Related to Our Business and Strategy</P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">Our
future profitability and continued existence is dependent in large part upon the successful final development and the successful
commercialization of the Accelerate ID/AST System&trade;.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Our principle business
strategy involves the successful development and commercialization of the Accelerate ID/AST System, associated test kits and complimentary
products. Our development of the ID/AST System is substantially complete, although various clinical trials and regulatory authorizations
are still in process. We have dedicated a significant amount of resources to finalize the development of and prepare to market
and sell the ID/AST System, and we plan to continue our investment in finalizing the development and commercialization of the ID/AST
System in the United States and other jurisdictions in which we intend to pursue marketing authorization. There can be no assurance
that we will successfully finalize the development of and commercialize the ID/AST System, associated test kits and complimentary
products. We may be required to expend significantly more resources than planned in this process, and as a result we may have to
cease investing in the ID/AST System or developing other products.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">If we are not successful
in the development of the ID/AST System, such failure could lead to impairment of certain of our intellectual property and may
result in our ceasing operations.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Further, if we are
not successful in conveying to hospitals that the ID/AST System provides equivalent or superior diagnostic information in a shorter
period of time compared to existing technologies, or that the ID/AST System improves patient outcomes or decreases healthcare costs,
we may experience reluctance from hospitals to order our product. If we fail to successfully commercialize the ID/AST System, we
may never receive a return on the significant investments in product development, sales and marketing, regulatory compliance, manufacturing
and quality assurance we have made and further investments we intend to make, and may fail to generate revenue and gain economies
of scale from such investments.</P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">Our
product candidates have not obtained marketing authorization from the FDA or regulatory clearance in any jurisdiction, and they
may never obtain such marketing authorization or regulatory clearance<FONT STYLE="font: 12pt Times New Roman,serif">.</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Our success depends on our
ability to obtain marketing authorization from the FDA or regulatory clearance of the ID/AST System and other product candidates
in our pipeline. If our attempts to obtain marketing authorization are unsuccessful, we may be unable to generate sufficient revenue
to sustain and grow our business. Our future product candidates may not be sufficiently sensitive or specific to obtain, or may
prove to have other characteristics that preclude our obtaining, marketing authorization from the FDA or regulatory clearance.
The process of obtaining regulatory clearance is expensive and time-consuming and can vary substantially based upon, among other
things, the type, complexity and novelty of our product candidates. Changes in regulatory policy, changes in or the enactment
of additional statutes or regulations or changes in regulatory review for each submitted product application may cause delays
in the clearance of, or receipt of marketing authorization from the FDA for, a product candidate or rejection of a regulatory
application altogether. The FDA has substantial discretion in the <I>de novo</I> review and clearance processes and may refuse
to accept any application or may decide that our data are insufficient for clearance and require additional pre-clinical, clinical
or other studies. In addition, varying interpretations of the data obtained from pre-clinical and clinical testing could delay,
limit or prevent marketing authorization from the FDA or regulatory clearance of a product candidate. Any marketing authorization
from the FDA or regulatory clearance we ultimately obtain may be limited or subject to restrictions or post-market commitments
that render the product candidate not commercially viable.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center">21</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">We
may not be able to enhance the capabilities of our current and new products to keep pace with our industry&rsquo;s rapidly changing
technology and customer requirements<FONT STYLE="font: 12pt Times New Roman,serif">.</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Our industry is characterized
by rapid technological changes, frequent new product introductions and enhancements and evolving industry standards. Our future
success will depend significantly on our ability to enhance our current products and develop or acquire and market new products
that keep pace with technological developments and evolving industry standards as well as respond to changes in customer needs.
New technologies, techniques or products could emerge that might offer better combinations of price and performance than the products
and systems that we plan to sell. It is critical to our success that we anticipate changes in technology and customer requirements
and physician, hospital and healthcare provider practices and successfully introduce new, enhanced and competitive technologies
to meet our prospective customers&rsquo; needs on a timely and cost-effective basis. At the same time, however, we must carefully
manage our introduction of new products. If potential customers believe that such products will offer enhanced features or be sold
for a more attractive price, they may delay purchases until such products are available.</P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">We
are developing additional uses for the ID/AST System. Any failure or delay in launching new applications may compromise our ability
to achieve our growth objectives.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">We are developing additional
uses for the ID/AST System, including the ability to test on additional specimen types (<I>e.g.</I>, respiratory samples, skin
and soft tissue). We may have problems applying our technologies to additional specimen types, and our new applications may not
be as effective in detection as our initial applications. We may also encounter difficulties obtaining regulatory approval for
additional uses of the ID/AST System. Any failure or delay in launching new applications may compromise our ability to achieve
our growth objectives.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">There can be no assurance
that we will be successful in developing or acquiring product enhancements or new products to address changing technologies and
customer requirements adequately, that we can introduce such products on a timely basis or that any such products or enhancements
will be successful in the marketplace. If we are unable to successfully develop or acquire new products or if the market does not
accept our products, or if we experience difficulties or delays in the development of our products, including the ID/AST System,
we may be unable to attract additional customers for our products or license our products to other strategic partners.</P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">The
failure of the ID/AST System or any future diagnostic products to perform as expected could significantly impair our reputation
and the public image of our products, and we may be subject to legal claims arising from any defects or errors.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Our success will depend
on the market&rsquo;s confidence that our technologies can provide reliable, high-quality diagnostic results. We believe that
our customers are likely to be particularly sensitive to any defects or errors in the ID/AST System. If we experience disruptions
or other performance problems with the ID/AST System or any future diagnostic product, we could face warranty and liability claims
against us or our reputation could suffer as a result of such failures. We cannot assure you that our product liability insurance
would adequately protect our assets from the financial impact of defending a product liability claim. Any product liability claim
brought against us, with or without merit, could increase our product liability insurance rates or prevent us from securing insurance
coverage in the future. In addition, the FDA and similar foreign governmental authorities have the authority to require the recall
of commercialized products in the event of material deficiencies or defects in design or manufacture of a product or in the event
that a product poses an unacceptable risk to health. A recall, material liability claim or other occurrence that harms our reputation
or decreases market acceptance of our products could cause us to incur significant costs, divert the attention of our key personnel
or cause other significant customer relations problems.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center">22</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">Limited
revenues from our products and no assurance of future revenues.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">We have received limited
revenue from sales based on products using our OptiChem technology, and we are in the process of discontinuing our efforts to develop
and actively market OptiChem and our other surface chemistry products. During the years ended December 31, 2014 and 2013 and the
five-month transition period ended December 31, 2012 and the fiscal year ended July 31, 2012, we experienced losses from operations.
Our future revenues are dependent on the successful development and commercialization of the ID/AST System, and there can be no
assurance that we will be successful. If we are unsuccessful in completing the development of the ID/AST System and generating
revenues from such product, we will likely continue to experience losses from operations and negative cash flow as we have in the
past.</P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">We
are a development-stage company that has incurred significant losses in recent years, and we expect to incur losses in the future.
We cannot be certain that we will achieve or sustain profitability.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">We
have incurred significant costs in connection with the </FONT>development and commercialization of our technology,<FONT STYLE="background-color: white">
and there is no assurance that we will achieve sufficient revenues to offset anticipated operating costs. </FONT>We have incurred
significant losses in recent years and expect to incur losses in the future. We expect that our losses will continue for at least
the next several years as we will be required to invest significant additional funds toward development and commercialization of
our technology. We also expect that our selling, general and administrative expenses will continue to increase due to the additional
costs associated with establishing a dedicated sales force and other marketing efforts for the ID/AST System. Our ability to achieve
or sustain profitability depends on numerous factors, many of which are beyond our control, including our ability to achieve marketing
authorization from the FDA or regulatory clearance for the Accelerate ID/AST System, the market acceptance of our product, future
product development and our market penetration and margins. If we are unsuccessful in completing the development of the ID/AST
System and generating revenues from ID/AST System sales, we will likely continue to experience losses from operations and negative
cash flow. <FONT STYLE="background-color: white">Although we anticipate deriving revenues from the sale of our products, no assurance
can be given that these products can be sold on a net profit basis. If we achieve profitability, we cannot give any assurance that
we will be able to sustain or increase profitability on a quarterly or annual basis in the future.</FONT></P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">We
have no experience in marketing and selling the ID/AST System.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">We have no experience marketing
and selling the ID/AST System. In anticipation of the receipt of marketing authorization from the FDA for the ID/AST System, we
have begun to build our own sales force to market the ID/AST System directly to our target customers, and we plan to continue
to build this sales force. In select geographies outside of the United States and Europe, we may also use third-party distributors
to market our product.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center">23</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Our future sales will depend
in large part on our ability to successfully establish an effective sales force. Because we have no experience in marketing and
selling the ID/AST System, our ability to forecast demand, the infrastructure required tosupport such demand and the sales cycle
of our potential customers is unproven.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Moreover, we may use third-party
distribution partners for certain geographic areas outside of the United States and Europe, and there is no guarantee that we will
be able to enter into such arrangements on favorable terms. Distributors may not commit the necessary resources to market and sell
the ID/AST System effectively or may choose to favor marketing the products of our competitors. If distributors do not perform
adequately, or if we are unable to enter into effective arrangements with distributors in particular geographic areas, we may not
realize our full potential for sales and growth in these areas.</P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">If
treatment guidelines for bacterial infection change, or the standard of care evolves, we may need to redesign and seek new marketing
authorization from the FDA for our product candidates.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">If treatment guidelines for
bacterial infections change, or the standard of care evolves, we may need to redesign and seek new marketing authorization from
the FDA for our product candidates. If treatment guidelines change so that different treatments become desirable, the ID/AST System
may no longer provide the information sought by physicians, and we could be required to seek marketing authorization from the FDA
for a revised product.</P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">We
may not be able to correctly estimate or control our future operating expenses, which could lead to cash shortfalls.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Our operating expenses may
fluctuate significantly in the future as a result of a variety of factors, many of which may be outside of our control. These factors
include, but are not limited to:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 9pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif">the time and resources required to develop, and conduct
clinical studies and obtain regulatory clearances for, the ID/AST System;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 9pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif">the expenses we incur for research and development required
to maintain and improve our technology, including developing the ID/AST System;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 9pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif">the expenses we incur in connection with the development
and regulatory approval of the use of the ID/AST System to test on additional specimen types;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 9pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif">the costs of preparing, filing, prosecuting, defending
and enforcing patent claims and other patent related costs, including litigation costs and the results of such litigation;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 9pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif">the expenses we incur in connection with commercialization
activities, including product marketing, sales and distribution expenses;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 9pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif">the costs incurred to build manufacturing capabilities;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 9pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif">our sales strategy;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 9pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif">the costs to attract and retain personnel with the skills
required for effective operations; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 9pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt/115% Arial,sans-serif">the costs associated with being a public company.</FONT></TD></TR></TABLE>



<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center">24</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Our budgeted expense levels
are based in part on our expectations concerning future revenues from sales of the ID/AST System, as well as our assessment of
the future investments needed to expand our commercial organization and support research and development activities in connection
with the ID/AST System. We may be unable to reduce our expenditures in a timely manner to compensate for any unexpected events
or a shortfall in revenue. Accordingly, a shortfall in demand for our products or other unexpected events could have an immediate
and material impact on our cash levels.</P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">Breaches
of our information technology systems could have a material adverse effect on our operations.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">We rely on information technology
systems to process, transmit and store electronic information in our day-to-day operations. In addition, our research and development
operations are highly dependent on our information technology and storage. Our information technology systems have been subjected
to computer viruses or other malicious codes and phishing attacks, and we expect to be subject to similar viruses and codes in
the future. These attacks could result in our intellectual property and other confidential information being lost or stolen, including
the disclosure of our trade secrets, disruption of our operations, loss of valuable research and development data, increased costs
for security measures or remediation costs and diversion of management attention and other negative consequences. While we will
continue to implement protective measures to reduce the risk of and detect future cyber incidents, cyber-attacks are becoming more
sophisticated and frequent, and the techniques used in such attacks change rapidly. There can be no assurance that our protective
measures will prevent future attacks that could have a significant impact on our business.</P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">We
are dependent on our key employees. If we are unable to recruit, train and retain qualified personnel, we may not achieve our goals.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Because of the complex and
technical nature of our products and the dynamic market in which we compete, our future success depends on our ability to recruit,
train and retain key personnel, including our senior management, research and development, science and engineering, manufacturing
and sales and marketing personnel. In particular, we are highly dependent on the management and business expertise of Lawrence
Mehren, our President and Chief Executive Officer. We do not maintain key man life insurance for Mr. Mehren or any of our employees.
Our industry is very competitive for qualified personnel. To the extent that the services of Mr. Mehren would be unavailable to
us, we may be unable to employ another qualified person with the appropriate background and expertise to replace Mr. Mehren on
terms suitable to us. Our growth depends, in particular, on attracting, retaining and motivating highly trained sales personnel
with the necessary scientific background and ability to understand our systems and pathogens at a technical level. In addition,
we may need additional employees at our manufacturing facilities to meet demand for our products as we scale up our sales and marketing
operations.</P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">We
face competition from industry participants who may have greater resources than we do.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">The industry in which we
compete is subject to rapid technological changes, and we face and expect to continue to face competition for our products. We
may also face competition from non-medical device companies. The ID/AST System also faces competition from laboratory developed
tests, or LDTs, developed by national and regional reference laboratories and hospitals. LDTs may not be subject to the same regulatory
requirements, including those requiring clinical trials and FDA review and clearance or approval that apply to the ID/AST System.</P>



<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center">25</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify"></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">Many
of our competitors and potential competitors may have substantially greater research and development, financial, manufacturing,
customer support, sales and marketing resources, larger customer bases, longer operating histories, greater name recognition and
more established relationships in the industry than we do. </FONT>In addition, some of our competitors may, individually or together
with companies affiliated with them, have greater human and scientific resources than we do. Our competitors could develop technologies
and methods that are more effective than our current and proposed technologies, including but not limited to the ID/AST System.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">We cannot assure you that
we will effectively compete or that we will be successful in the face of increasing competition from new products and technologies
introduced by existing or new competitors. In addition, we cannot assure you that our future competitors do not have or will not
develop products or technologies that enable them to produce competitive products with greater capabilities or at lower costs than
our products. Any failure to compete effectively could materially and adversely affect our business, financial condition and operating
results.</P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">We
expect to generate a portion of our future revenue internationally and are subject to various risks relating to our international
activities which could adversely affect our operating results.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Assuming we receive the applicable
regulatory approvals, we plan to market and sell the ID/AST System in Europe and other countries outside of the United States in
the future. In order to market our products in the European Union and many other foreign jurisdictions, we, or our distributors
or partners, must obtain separate regulatory approvals and comply with numerous and varying regulatory requirements regarding safety
and efficacy and governing, among other things, clinical studies and commercial sales and distribution of our products. The approval
procedure varies among countries and can involve additional testing. In addition, in many countries outside the United States,
a product must be approved for reimbursement before the product can be approved for sale in that country. We may not obtain approvals
from regulatory authorities outside the United States on a timely basis, if at all, which could harm our ability to expand into
markets outside the United States. In addition, engaging in international business involves a number of other difficulties and
risks, including:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 6pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial,sans-serif">required compliance with existing and changing foreign healthcare
and other regulatory requirements and laws, such as those relating to patient privacy or handling of bio-hazardous waste; </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial,sans-serif">required compliance with anti-bribery laws, such as the
U.S. Foreign Corrupt Practices Act and the U.K. Bribery Act, data privacy requirements, labor laws and anti-competition regulations;
</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial,sans-serif">export and import restrictions; </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial,sans-serif">various reimbursement and insurance regimes; </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial,sans-serif">laws and business practices favoring local companies; </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial,sans-serif">longer payment cycles and difficulties in enforcing agreements
and collecting receivables through certain foreign legal systems; </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial,sans-serif">political and economic instability; </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial,sans-serif">potentially adverse tax consequences, tariffs, customs charges,
bureaucratic requirements and other trade barriers; </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial,sans-serif">foreign exchange controls; </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial,sans-serif">fluctuations due to changes in foreign currency exchange
rates;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial,sans-serif">difficulties and costs of staffing and managing foreign
operations; and </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial,sans-serif">difficulties protecting or procuring intellectual property
rights.</FONT></TD></TR></TABLE>



<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center">26</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">Our
employees, independent contractors, principal investigators, consultants, commercial partners and vendors may engage in misconduct
or other improper activities, including non-compliance with regulatory standards and requirements.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">We are exposed to the risk
of fraud or other misconduct by our employees, independent contractors, principal investigators, consultants, commercial partners
and vendors. Misconduct by these parties could include intentional, reckless or negligent failures to: (i) comply with the regulations
of the FDA, the Centers for Medicare and Medicaid Services (&ldquo;CMS&rdquo;), the Department of Health and Human Services Office
of Inspector General (&ldquo;OIG&rdquo;), and other similar foreign regulatory bodies; (ii) provide true, complete and accurate
information to the FDA and other similar regulatory bodies; (iii) comply with manufacturing standards we have established; (iv)
comply with healthcare fraud and abuse laws and regulations in the United States and similar foreign fraudulent misconduct laws;
or (v) report financial information or data accurately, or disclose unauthorized activities to us. These laws may impact, among
other things, our activities with principal investigators and research subjects, as well as our sales, marketing and education
programs. In particular, the promotion, sales, marketing and business arrangements in the healthcare industry are subject to extensive
laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws may
restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs
and other business arrangements. Such misconduct could also involve the improper use of information obtained in the course of clinical
studies, which could result in regulatory sanctions and cause serious harm to our reputation. We currently have a code of conduct
applicable to all of our employees, but it is not always possible to identify and deter employee misconduct, and our code of conduct
and the other precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged
risks or losses, or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply
with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves
or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal
and administrative penalties, damages, monetary fines, disgorgement, individual imprisonment, possible exclusion from participation
in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future
earnings, and curtailment of our operations. Any of these actions or investigations could result in substantial costs to us, including
legal fees, and divert the attention of management from operating our business.</P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">We
may be unable to successfully manage our growth.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">We expect to expand our
operations following market authorization from the FDA and regulatory clearance and the commercial launch of the ID/AST System.
We intend to develop a targeted sales force in connection with our commercialization efforts. Our growth has placed and will continue
to place a significant strain on our management, operating and financial systems and our sales, marketing and administrative resources.
As a result of our growth, operating costs may escalate faster than planned, and some of our internal systems and processes, including
those relating to manufacturing our products, may need to be enhanced, updated or replaced. If we cannot effectively manage our
expanding operations, manufacturing capacity and costs, including scaling to meet increased demand, we may not be able to continue
to grow or we may grow at a slower pace than expected.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center">27</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify"></P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">Current
macroeconomic conditions and the uncertain economic outlook may remain challenging for the foreseeable future.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Global economic conditions
may remain challenging and uncertain for the foreseeable future. These conditions not only limit our access to capital but also
make it difficult for our customers, our vendors and us to accurately forecast and plan future business activities, and they could
cause U.S. and foreign hospitals and other customers to slow spending on our products, which would delay and lengthen sales cycles.
Some of our customers rely on government research grants to fund technology purchases. If negative trends in the economy affect
the government&rsquo;s allocation of funds to research, there may be less grant funding available for certain of our customers
to purchase technologies from us. Certain of our customers may face challenges gaining timely access to sufficient credit or may
otherwise be faced with budget constraints, which could result in decreased purchases of our products or in an impairment of their
ability to make timely payments to us. If our customers do not make timely payments to us, we may be required to assume greater
credit risk relating to those customers and increase our allowance for doubtful accounts, and our days sales outstanding would
be negatively impacted. Although we maintain allowances for doubtful accounts for estimated losses resulting from the inability
of our customers to make required payments, we may not continue to experience the same loss rates that we have in the past. Additionally,
challenging macroeconomic conditions and market turbulence may also impact our suppliers, causing them to be unable to supply in
a timely manner sufficient quantities of customized components, thereby impairing our ability to manufacture on schedule and at
commercially reasonable costs.</P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">Compliance
with public company corporate governance and reporting is complex and expensive.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">We are subject to laws and
regulations affecting our domestic and international operations in a number of areas. Many laws and regulations, notably those
adopted in connection with the Sarbanes-Oxley Act of 2002 by the Securities and Exchange Commission (the &ldquo;SEC&rdquo;), the
Dodd-Frank Wall Street Reform and Consumer Protection Act and The NASDAQ Stock Market, impose obligations on public companies,
such as ours, which have increased the scope, complexity and cost of corporate governance, reporting and disclosure practices.
Compliance with these laws, regulations and similar requirements may be onerous, requires substantial management time and oversight
and requires us to incur significant additional accounting, legal and compliance costs. Any such costs, which may rise in the future
as a result of changes in these laws and regulations or in their interpretation could individually or in the aggregate make our
products and services more expensive, delay the introduction of new products in one or more regions, or cause us to change or limit
our business practices. In addition, our larger competitors may be in a better position to absorb the costs of being a public company.
We have implemented policies and procedures designed to ensure compliance with applicable laws and regulations, but there can be
no assurance that our employees, contractors or agents will not violate such laws and regulations or our policies and procedures.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Additionally, changes to
existing accounting rules and standards and the implementation of new accounting rules or standards, such as tax accounting or
revenue recognition rules, may adversely impact our reported financial results and business, and may further require us to incur
greater accounting fees.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center">28</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify"></P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 10pt 0 9pt; text-align: justify">Risks Related to Our Intellectual Property</P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">If
we are unable to effectively protect our non-patented intellectual property, our business would be harmed.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">In addition to patent protection,
we rely on trademark, copyright, trade secret protection and confidentiality agreements to protect the intellectual property rights
related to our proprietary technologies, both in the United States and in other countries. If we fail to protect our intellectual
property, third parties may be able to compete more effectively against us and we may incur substantial litigation costs in our
attempts to recover or restrict use of our intellectual property. We own or exclusively license 12 issued U.S. patents and 6 pending
U.S. patent applications, including provisional and non-provisional filings. We also own or exclusively license 12 pending or granted
counterpart applications worldwide. In addition to our patents, we possess an array of unpatented proprietary technology and know-how,
and we license intellectual property rights to and from third parties. The strength of patents in our field involves complex legal
and scientific questions. Uncertainty created by these questions means that our patents may provide only limited protection and
may not adequately protect our rights or permit us to gain or keep any competitive advantage. In addition, competitors could purchase
our products and attempt to replicate some or all of the competitive advantages we derive from our development efforts, willfully
infringe our intellectual property rights, design around our protected technology or develop their own competitive technologies
that fall outside of the protections provided by our intellectual property rights. If our intellectual property, including licensed
intellectual property, does not adequately protect our market position against competitors&rsquo; products and methods, our competitive
position could be adversely affected, as could our business.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Further, if we are unable
to prevent unauthorized disclosure of our non-patented intellectual property, and there is no guarantee that we will have any such
enforceable trade secret protection, we may not be able to establish or maintain a competitive advantage. In addition, the laws
of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United
States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United
States and abroad.</P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">We
may not be successful in our currently pending or future patent applications, and even if such applications are successful, we
cannot guarantee that the resulting patents will sufficiently protect our products and proprietary technology.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">We cannot assure you that
any of our currently pending or future patent applications will result in issued patents with claims that cover our products and
technologies in the United States or in other foreign countries, and we cannot predict how long it will take for such patents to
be issued. Further, issuance of a patent is not conclusive as to its inventorship or scope, and there is no guarantee that our
issued patents will include claims that are sufficiently broad to cover our technologies or to provide meaningful protection from
our competitors. Further, we cannot be certain that all relevant prior art relating to our patents and patent applications has
been found. Accordingly, there may be prior art that can invalidate our issued patents or prevent a patent from issuing from a
pending patent application, at all or with claims that have a scope broad enough to provide meaningful protection from our competitors.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Even if patents do successfully
issue and even if such patents cover our products and technologies, we cannot assure you that other parties will not challenge
the validity, enforceability or scope of such issued patents in the United States and in foreign countries, including by proceedings
such as reexamination, <I>inter-partes</I> review, interference, opposition, or other patent office or court proceedings. The strength
of patents in our field involves complex legal and scientific questions. Moreover, we cannot assure you that if such patents were
challenged in court or before a regulatory agency that the patent claims will be held valid, enforceable, to be sufficiently broad
to cover our technologies or to provide meaningful protection from our competitors. Nor can we assure you that the court or agency
will uphold our ownership rights in such patents. Accordingly, we cannot guarantee that we will be successful in defending challenges
made against our patents and patent applications. Any successful third-party challenge to our patents could result in the unenforceability
or invalidity of such patents, or narrowing of claim scope, such that we could be deprived of patent protection necessary for the
successful commercialization of our products and technologies, which could adversely affect our business.</P>



<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center">29</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Furthermore, even if they
are unchallenged, our patents and patent applications may not adequately protect our intellectual property, provide exclusivity
for our products and technologies or prevent others from designing around our claims. Others may independently develop similar
or alternative products and technologies or duplicate any of our products and technologies. These products and technologies may
not be covered by claims of issued patents we hold. Any of these outcomes could impair our ability to prevent competition from
third parties, which may have an adverse impact on our business.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Further, if we encounter
delays in regulatory approvals, the period of time during which we could market a product under patent protection could be reduced.
Since patent applications in the United States and most other countries are confidential for a period of time after filing, and
some remain so until issued, we cannot be certain that we were the first to make the inventions covered by our pending patent applications,
or that we were the first to file any patent application related to a product candidate. Furthermore, if third parties have filed
such patent applications, an interference proceeding in the United States can be initiated by a third party to determine who was
the first to invent any of the subject matter covered by the patent claims of our applications. In addition, patents have a limited
lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. Various extensions
may be available; however the life of a patent, and the protection it affords, is limited.</P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">We
could face claims that our proprietary technologies infringe on the intellectual property rights of others.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Due to the significant number
of U.S. and foreign patents issued to, and other intellectual property rights owned by, entities operating in the industry in which
we operate, we believe that there is a risk of litigation arising from infringement of these patents and other rights. Third parties
may assert infringement or other intellectual property claims against us or our licensees.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">In addition, patent applications
in the United States and many foreign jurisdictions are typically not published until 18 months after the earliest filing date
for which a benefit is claimed. For this reason, and because publications in the scientific literature often lag behind actual
discoveries, we cannot be certain that others have not filed patent applications for technology covered by our issued patents or
our pending applications or that we were the first to invent the technology. Another party may have filed or may in the future
file patent applications covering our products or technology similar to ours. Under the &ldquo;first to invent&rdquo; rules applicable
to patents filed before March 2013, any such patent application may have priority over our patent applications or patents, which
could further require us to obtain rights to issued patents covering such technologies. If another party has filed a U.S. patent
application on inventions similar to ours, we may have to participate in an interference proceeding declared by the U.S. Patent
and Trademark Office to determine priority of invention in the United States. The costs of these proceedings could be substantial,
and it is possible that such efforts would be unsuccessful if the other party had independently arrived at the same or similar
invention prior to our own invention, resulting in a loss of our U.S. patent position with respect to such inventions.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">We may have to pay substantial
damages, including treble damages, for past infringement if it is ultimately determined that our products infringe on a third
party&rsquo;s proprietary rights. In addition, even if such claims are without merit, defending a lawsuit may result in substantial
expense to us and divert the efforts of our technical and management personnel. We may also be subject to significant damages
or injunctions against development and sale of some of our products. Furthermore, claims of intellectual property infringement
may require us to enter into royalty or license agreements with third parties, and we may be unable to obtain royalty or license
agreements on commercially acceptable terms, if at all.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center">30</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 10pt 0 9pt; text-align: justify">Risks Related to Our Research and Development
Activities</P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">We
have a single research and development facility and we may be unable to continue to conduct our research and development activities
if we lose this facility. If our facility or our equipment were damaged or destroyed, or if we experience a significant disruption
in our operations for any reason, our ability to continue to operate our business could be materially harmed.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">We currently conduct all
of our research and development and product development activities in our existing facility in Tucson, Arizona. If this facility
were to be damaged, destroyed or otherwise unable to operate, whether due to fire, floods, storms, tornadoes, other natural disasters,
employee malfeasance, terrorist acts, power outages or otherwise, or if our business is disrupted for any other reason, we may
not be able to develop the ID/AST System or any future products or test our products as promptly as our potential customers expect,
or possibly not at all, and we would have no other means of conducting such activities until we were able to restore such capabilities
at the current facility or develop an alternative facility. Further, in such an event, we may lose revenue and significant time
during which we might otherwise have conducted research and development and product development activities. Further, we may not
be able to maintain our relationships with our licensees or customers.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">The manufacture of components
of the ID/AST System involves complex processes, sophisticated equipment and strict adherence to specifications and quality systems
procedures. Any unforeseen manufacturing problems, such as contamination of our facility, equipment malfunction or failure to strictly
follow procedures or meet specifications, could result in delays or shortfalls in production of our products. Identifying and resolving
the cause of any manufacturing issues could require substantial time and resources. If we are unable to keep up with future demand
for our products by successfully manufacturing and shipping our products in a timely manner, our revenue growth could be impaired
and market acceptance of our product candidates could be adversely affected.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">While we carry a nominal
amount of business interruption insurance to cover lost revenue and profits, this insurance does not cover all possible situations.
If we have underestimated our insurance needs with respect to an interruption, or if an interruption is not subject to coverage
under our insurance policies, we may not be able to cover our losses. In addition, our business interruption insurance would not
compensate us for the loss of opportunity and potential adverse impact on relations with our licensees or customers.</P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">We
use hazardous materials in some of our research, development and manufacturing processes and face the accompanying risks and regulations
governing environmental safety.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Our operations are subject
to complex and stringent environmental, health, safety and other governmental laws and regulations that both public officials
and private individuals may seek to enforce. In particular, our research activities sometimes involve the controlled use of various
hazardous materials. Although we believe that our safety procedures for handling and disposing of such materials comply with the
standards prescribed by state and federal regulations, the risk of accidental contamination or injury from these materials cannot
be completely eliminated, and we may not be in compliance with these regulations. In addition, existing laws and regulations may
also be revised or reinterpreted, or new laws and regulations may become applicable to us, whether retroactively or prospectively,
causing us to incur additional compliance costs and/or change the manner in which we operate. We could be held liable for any
damages that might result from any accident or release involving hazardous materials.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center">31</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; text-align: justify; text-indent: 0in; margin-right: 0; margin-bottom: 6pt; margin-left: 0"></P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; text-align: justify; text-indent: 0in; margin-right: 0; margin-bottom: 6pt; margin-left: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 6pt; margin-left: 0"></P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; text-align: justify; text-indent: 0in; margin-right: 0; margin-bottom: 9pt; margin-left: 0"></P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">Disruptions
in the supply of raw materials, consumable goods or other key product components, or issues associated with their quality from
our single source suppliers, could result in a significant disruption in sales and profitability.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">We must manufacture or engage
third parties to manufacture components of our products in sufficient quantities and on a timely basis, while maintaining product
quality, acceptable manufacturing costs and complying with regulatory requirements. Our components are custom-made by only a few
outside suppliers. In certain instances, we have a sole source supply for key product components of the ID/AST System. We may be
unable to satisfy our forecasted demand from existing suppliers for our products, or we may be unable to find alternative suppliers
for key product components or ancillary items at reasonably comparable prices. If this occurs, we may be unable to manufacture
our products and/or meet our customer&rsquo;s needs.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Additionally, we have entered
into supply agreements with most of our suppliers to help ensure component availability and flexible purchasing terms with respect
to the purchase of such components. If our suppliers discontinue production of a key component for one or more of our products,
we may be unable to identify or secure a viable alternative on reasonable terms, or at all, which could limit our ability to manufacture
our products. While we may be able to modify our product candidates to utilize a new source of components, we may need to secure
marketing authorization from the FDA for the modified product, and it could take considerable time and expense to perform the requisite
tasks prior to seeking such authorization.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">In determining the required
quantities of our products and our manufacturing schedule, we will need to make significant judgments and estimates regarding factors
such as market trends and any seasonality with respect to our sales. Because of the inherent nature of estimates and our lack of
experience marketing the ID/AST System, there could be significant differences between our estimates and the actual amounts of
products we require. This can result in shortages if we fail to anticipate demand, or excess inventory and write-offs if we order
more than we need.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Reliance on third-party manufacturers
entails risk to which we would not be subject if we manufactured these components ourselves, including:<FONT STYLE="font: 12pt/115% Times New Roman,serif">
&#9;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 9pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial,sans-serif">reliance on third parties for regulatory compliance and
quality assurance;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 9pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial,sans-serif">possible breaches of manufacturing agreements by the third
parties because of factors beyond our control;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 9pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial,sans-serif">possible regulatory violations or manufacturing problems
experienced by our suppliers;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 9pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial,sans-serif">possible termination or non-renewal of agreements by third
parties, based on their own business priorities, at times that are costly or inconvenient for us;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 9pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial,sans-serif">the potential obsolescence and/or inability of our suppliers
to obtain required components;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 9pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial,sans-serif">the potential delays and expenses of seeking alternate sources
of supply or manufacturing services;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 9pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial,sans-serif">the inability to qualify alternate sources without impacting
performance claims of our products;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 9pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial,sans-serif">reduced control over pricing, quality and timely delivery
due to the difficulties in switching to alternate suppliers or assemblers; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 9pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial,sans-serif">increases in prices of raw materials and key components.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">The manufacturing operations
for the ID/AST System use highly technical processes involving unique, proprietary techniques. In addition, the manufacturing equipment
we use would be costly to repair or replace and could require substantial lead time to repair or replace. Any interruption in our
operations or decrease in the production capacity of our manufacturing facility or the facilities of any of our suppliers because
of equipment failure, natural disasters such as earthquakes, tornadoes and fires, or otherwise, would limit our ability to meet
customer demand for our products. In the event of a disruption, we may lose customers and we may be unable to regain those customers
thereafter. Our insurance may not be sufficient to cover all of our potential losses and may not continue to be available to us
on acceptable terms, or at all.</P>



<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; text-align: justify; text-indent: 0in; margin-right: 0; margin-bottom: 9pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center">32</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; text-align: justify; text-indent: 0in; margin-right: 0; margin-bottom: 6pt; margin-left: 0"></P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 6pt; margin-left: 0"></P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; text-align: justify; text-indent: 0in; margin-right: 0; margin-bottom: 6pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">We
have made and intend to make significant additional investments in research and development, but there is no guarantee that any
of these investments will ultimately result in a commercial product that will generate revenues.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">The ID/AST System integrates
several of our component products, systems and processes. We have dedicated significant resources on research and development activities,
and we intend to spend significantly more on research and development activities during the fiscal year ending December 31, 2015
and thereafter. Notwithstanding these investments, we anticipate that we will have to spend additional funds in the research and
development of the ID/AST System, particularly with respect to its use for additional specimen types. There can be no assurance
that we will be able to complete the development of the ID/AST System or that we will be able to expand its use for additional
specimen types. Further, we might also encounter substantial delays in getting products to market.</P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 10pt 0 9pt; text-align: justify">Risks Related to Government Regulation</P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">We
and our suppliers, contract manufacturers and customers are subject to various governmental laws and regulations, and we may incur
significant expenses to comply with, and experience delays in our product commercialization as a result of, these laws and regulations.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Our operations are affected
by various state, federal, and international healthcare, environmental, anti-corruption, fraud and abuse (including anti-kickback
and false claims laws) and employment laws. Violations of these laws can result in criminal or civil sanctions, including substantial
fines and, in some cases, exclusion from participation in health care programs such as Medicare and Medicaid.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">We are also subject to extensive
regulation by the FDA pursuant to the Federal Food, Drug, and Cosmetic Act, by comparable agencies in foreign countries and by
other regulatory agencies and governing bodies. Following the introduction of a product, these and other U.S. government agencies
such as CMS and OIG will periodically review our manufacturing processes, product performance and compliance with applicable requirements.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Once commercialized, we will
likely be subject to various U.S. healthcare related laws regulating sales, contracting and marketing practices and the use and
disclosure of individually identifiable health information. These include:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 9pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial,sans-serif">The federal Anti-Kickback Statute, which prohibits persons
from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in exchange for
or to induce either the referral of an individual, or the purchasing, ordering, recommending, furnishing or arranging for a good
or service, for which payment may be made under a federal health care program, such as Medicare or Medicaid.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 9pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial,sans-serif">The Health Insurance Portability and Accountability Act
of 1996 (&ldquo;HIPAA&rdquo;), which prohibits knowingly and willfully (i) executing a scheme to defraud any health care benefit
program, including private payors, or (ii) falsifying, concealing or covering up a material fact or making any materially false,
fictitious or fraudulent statement in connection with the delivery of or payment for health care benefits, items or services. </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 9pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial,sans-serif">HIPAA, as amended by the Health Information Technology for
Economic and Clinical Health Act of 2009, which also restricts the use and disclosure of patient-identifiable health information,
mandates the adoption of standards relating to the privacy and security of patient-identifiable health information and requires
us to report certain security breaches to health care provider customers with respect to such information where we are acting as
a HIPAA business associate to that customer.</FONT></TD></TR></TABLE>



<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center">33</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid"></P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; text-align: justify; text-indent: 0in; margin-right: 0; margin-bottom: 9pt; margin-left: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0"></P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; text-align: justify; text-indent: 0in; margin-right: 0; margin-bottom: 9pt; margin-left: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 9pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial,sans-serif">The federal Physician Payment Sunshine Act, which requires
manufacturers of certain medical devices to track payments or other transfers of value given to U.S. licensed physicians or teaching
hospitals and to report this data to the CMS annually for subsequent public disclosure. </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 9pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial,sans-serif">The federal False Claims Act, which imposes liability on
any person or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment
by a federal health care program. The <I>qui tam</I> provisions of the False Claims Act allow a private individual to bring actions
on behalf of the federal government alleging that the defendant has submitted a false claim to the federal government and to share
in any monetary recovery.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Similar requirements have
been adopted many states and foreign countries. Violations of any of these laws can lead to additional legal risk such as risk
of plaintiff class actions, state Attorney General actions, and investigations by the Federal Trade Commission, among others.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Failure to comply with applicable
requirements, or later discovery of previously unknown problems with our products or manufacturing processes, including our failure
or the failure of one of our contract manufacturers to take satisfactory corrective action in response to an adverse inspection,
can result in, among other things:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 9pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial,sans-serif">administrative or judicially imposed sanctions;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 9pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial,sans-serif">injunctions or the imposition of civil penalties;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 9pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial,sans-serif">recall or seizure of our products;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 9pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial,sans-serif">total or partial suspension of production or distribution;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 9pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial,sans-serif">withdrawal or suspension of marketing clearances or approvals;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 9pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial,sans-serif">clinical holds;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 9pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial,sans-serif">warning letters;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 9pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial,sans-serif">refusal to permit the import or export of our products;
</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 9pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial,sans-serif">criminal prosecution; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 9pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 12pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial,sans-serif">exclusion or debarment from participation in federal health
care programs such as Medicare and Medicaid.</FONT><FONT STYLE="font: 12pt Times New Roman,serif"> </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Any of these actions, in
combination or alone, could prevent us from marketing, distributing and selling our products.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">In addition, we have developed,
configured and we intend to market our products to meet customer needs created by these various regulations. Any significant change
in these regulations could reduce demand for our products. Governmental agencies may also impose new requirements regarding registration,
labeling or prohibited materials that may require us to modify or re-register products already on the market or otherwise adversely
impact our ability to market our products.</P>



<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; text-align: justify; text-indent: 0in; margin-right: 0; margin-bottom: 9pt; margin-left: 0"></P>

<P STYLE="font: 10pt/normal Arial,sans-serif; text-align: center; margin-bottom: 9pt">34</P>

<P STYLE="font: 10pt/normal Arial,sans-serif; text-align: center; margin-bottom: 9pt; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; text-align: justify; text-indent: 0in; margin-right: 0; margin-bottom: 9pt; margin-left: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0"></P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; text-align: justify; text-indent: 0in; margin-right: 0; margin-bottom: 9pt; margin-left: 0"></P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; text-align: justify; text-indent: 0in; margin-right: 0; margin-bottom: 9pt; margin-left: 0"></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">In addition, a product defect
or regulatory violation could lead to a government-mandated or voluntary recall by us. We believe that the FDA would request that
we initiate a voluntary recall if a product was defective or presented a risk of injury or gross deception. Regulatory agencies
in other countries have similar authority to recall devices because of material deficiencies or defects in design or manufacture
that could endanger health. Any recall would divert management attention and financial resources, could cause the price of our
shares of common stock to decline and expose us to product liability or other claims, including contractual claims from parties
to whom we sold products, and harm our reputation with customers.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">The use of our diagnostic
products by our customers is also affected by the Clinical Laboratory Improvement Amendments (&ldquo;CLIA&rdquo;) and related federal
and state regulations that provide for regulation of laboratory testing. CLIA is intended to ensure the quality and reliability
of clinical laboratories in the United States by mandating specific standards in the areas of personnel qualifications, administration,
participation in proficiency testing, patient test management, quality assurance, quality control and inspections. Current or future
CLIA requirements or the promulgation of additional regulations affecting laboratory testing may prevent some laboratories, hospitals,
providers or other customers with laboratories from using some or all of our diagnostic products.</P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">Maintaining
adequate sales of our product may depend on the availability of adequate reimbursement to our customers from third-party payors,
including government programs such as Medicare and Medicaid, private insurance plans, and managed care programs.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Maintaining and growing sales
of our product, if approved, may depend in part on the availability of adequate reimbursement to our customers from third-party
payors, including government programs such as Medicare and Medicaid, private insurance plans and managed care programs. Hospitals,
clinical laboratories and other healthcare provider customers that may purchase our products generally bill various third-party
payors to cover all or a portion of the costs and fees associated with diagnostic tests, including the cost of the purchase of
our products. We currently expect that all of our diagnostic tests will be performed in a hospital inpatient setting, where governmental
payors, such as Medicare, generally reimburse hospitals a single bundled payment that is based on the patient&rsquo;s diagnosis
under a classification system known as the Medicare severity diagnosis-related groups (MS-DRGs) classification for all items and
services provided to the patient during a single hospitalization, regardless of whether our diagnostic tests are performed during
such hospitalization. As a result, our customers&rsquo; access to adequate payment by government and private insurance plans is
central to the acceptance of our products. We may be unable to sell our products, if approved, on a profitable basis if third-party
payors reduce their current levels of payment or if our costs of production increase faster than increases in reimbursement levels.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Additionally, third-party
payors are increasingly reducing reimbursement for medical products and services. In addition, the U.S. government, state legislatures,
and foreign governments have and may continue to implement cost-containment measures and more restrictive policies, including price
controls and restrictions on reimbursement.&nbsp; While we cannot predict whether third-party reimbursement to our customers will
be adequate, cost-containment measures and similar efforts by third-party payors, including government programs such as Medicare
and Medicaid, could substantially impact the sales of our products and potentially limit our net revenue and results.</P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">We
may be adversely affected by healthcare policy changes, including additional healthcare reform and changes in managed healthcare.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Healthcare reform and the
growth of managed care organizations have been considerable forces in the medical diagnostics industry and in recent political
discussions. These forces have placed, and are expected to continue to place, constraints on the levels of overall pricing for
healthcare products and services as well as the coverage available by public and private insurance and thus, could have a material
adverse effect on the future profit margins of our products or the amounts that we are able to receive from third parties for the
licensing of our products. Changes in the United States healthcare market could also force us to alter our approach to selling,
marketing, distributing and servicing our products and customer base. In and outside the United States, changes to government reimbursement
policies could reduce the funding that healthcare service providers have available for diagnostic product expenditures, which could
have a material adverse impact on the use of the products we are developing and our future sales, license and royalty fees and
profit margin.</P>



<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; text-align: justify; text-indent: 0in; margin-right: 0; margin-bottom: 9pt; margin-left: 0"></P>

<P STYLE="font: 10pt/normal Arial,sans-serif; text-align: center; margin-bottom: 9pt">35</P>

<P STYLE="font: 10pt/normal Arial,sans-serif; text-align: center; margin-bottom: 9pt; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; text-align: justify; text-indent: 0in; margin-right: 0; margin-bottom: 9pt; margin-left: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0"></P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; text-align: justify; text-indent: 0in; margin-right: 0; margin-bottom: 9pt; margin-left: 0"></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="line-height: 115%">The
</FONT>Affordable Care Act (the &ldquo;ACA&rdquo;), enacted in March 2010, <FONT STYLE="line-height: 115%">made</FONT> changes
that are expected to <FONT STYLE="line-height: 115%">have a continued and significant</FONT> impact <FONT STYLE="line-height: 115%">on
</FONT>the pharmaceutical and medical device industries and clinical laboratories.<FONT STYLE="line-height: 115%"> For example,
the legislation provided for reductions in the Medicare clinical laboratory fee schedule, and since </FONT>2013, <FONT STYLE="line-height: 115%">has
required that </FONT>certain medical device manufacturers<FONT STYLE="line-height: 115%"> </FONT>pay an excise tax in an amount
equal to 2.3% of the price for which such manufacturer sells its medical devices.<FONT STYLE="line-height: 115%"> We will be subject
to this tax once we begin selling the ID/AST System. These and other applicable requirements set forth under the </FONT>ACA <FONT STYLE="line-height: 115%">and
its current and future implementing regulations </FONT>may significantly increase our <FONT STYLE="line-height: 115%">costs, and
/ or reduce our customer&rsquo;s ability to obtain adequate reimbursement for tests performed with our products</FONT>, which could
adversely affect our business and financial condition.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">In recent years, other legislative,
regulatory, and political changes aimed at regulating healthcare delivery in general and clinical laboratories in particular have
been proposed and adopted in the United States. Reimbursement for the laboratory industry is under significant pressure. Most recently,
in January 2015, the Department of Health and Human Services (&ldquo;HHS&rdquo;) announced a plan to shift the Medicare program
and the healthcare system at large, toward paying providers based on quality, rather than the quantity of care provided to patients,
and, in February 2016, the President&rsquo;s budget for fiscal year 2016 proposed reductions in Medicare spending. These measures
can result in reduced prices, added costs, and decreased test utilization for our customers.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">The full impact on our business
of the ACA and the other laws, regulations, and policies described above is uncertain. It is also unclear whether other legislative
changes will be adopted or how such changes would affect our industry generally or our ability to successfully commercialize the
ID/AST System. Changes in healthcare policy, such as the creation of broad test utilization limits for diagnostic products in general
or requirements that Medicare patients pay for portions of clinical laboratory tests or services received, could substantially
impact the sales of our tests, increase costs and divert management&rsquo;s attention from our business. Such co-payments by Medicare
beneficiaries for laboratory services were discussed as possible cost savings for the Medicare program as part of the debt ceiling
budget discussions in mid-2011 and may be enacted in the future. In addition, sales of our tests outside of the United States will
subject us to foreign regulatory requirements, which may also change over time.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">We cannot predict whether
future healthcare initiatives will be implemented at the federal or state level or in countries outside of the United States in
which we may do business, or the effect any future legislation or regulation will have on us. The expansion in the government&rsquo;s
regulation of the United States healthcare system may result in decreased profits to us, lower reimbursements to our customers
for laboratory testing or reduced medical procedure volumes.</P>



<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; text-align: justify; text-indent: 0in; margin-right: 0; margin-bottom: 9pt; margin-left: 0"></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center">36</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">The
regulatory processes applicable to our products and operations are expensive, time-consuming, and uncertain and may prevent us
from obtaining required approvals for the commercialization of our products.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Our products, including the
ID/AST System, are regulated as medical device products by the FDA and comparable agencies of other countries. In particular, FDA
regulations govern activities such as product development, product testing, product labeling, product storage, premarket clearance
or approval, manufacturing, advertising, promotion, product sales, reporting of certain product failures and distribution. Some
of our products, depending on their intended use, will require premarket approval (&ldquo;PMA&rdquo;) or 510(k) clearance from
the FDA prior to marketing. The 510(k) clearance process usually takes from three to four months from submission but can take longer.
The PMA process is much more costly, lengthy and uncertain and generally takes from six months to one year or longer from submission.
In the 510(k) clearance process, the FDA must determine that a proposed device is &ldquo;substantially equivalent&rdquo; to a device
legally on the market, known as a &ldquo;predicate&rdquo; device, with respect to intended use, technology and safety and effectiveness,
in order to clear the proposed device for marketing. Clinical data is sometimes required to support substantial equivalence. The
PMA pathway requires an applicant to demonstrate the safety and effectiveness of the device based, in part, on extensive data,
including technical, preclinical, clinical trial, manufacturing and labeling data. The PMA process is typically required for devices
that are deemed to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices. However, some devices
are automatically subject to the PMA pathway regardless of the level of risk they pose, because they have not previously been classified
into a lower risk class by the FDA. Manufacturers of these devices may request that the FDA review such devices in accordance with
the <I>de novo </I>classification procedure, which allows a manufacturer whose novel device would otherwise require the submission
and approval of a PMA prior to marketing to request down-classification of the device on the basis that the device presents low
or moderate risk. If the FDA agrees with the down-classification, the applicant will then receive approval to market the device.
This device type can then be used as a predicate device for future 510(k) submissions.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">The FDA can delay, limit
or deny clearance or approval of a device for many reasons, including:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 9pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial,sans-serif">we may not be able to demonstrate to the FDA's satisfaction
that our product candidates are safe and effective, sensitive and specific diagnostic tests, for their intended users;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 9pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial,sans-serif">the data from our pre-clinical studies and clinical trials
may be insufficient to support clearance or approval, where required; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 9pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial,sans-serif">the manufacturing process or facilities we or our contract
manufacturers use may not meet applicable requirements.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">We intend to utilize the
<I>de novo</I> classification procedures to seek marketing authorization for the ID/AST System. If the FDA requires us to go through
a lengthier, more rigorous examination for our product candidates than we had expected, our product introductions or modifications
could be delayed or canceled, which could cause our launch to be delayed or, in the future, our sales to decline. In addition,
the FDA may determine that our product candidates require the more costly, lengthy and uncertain PMA process. For example, if the
FDA disagrees with our determination that the <I>de novo</I> classification procedures are the appropriate path to obtain marketing
authorizations for the ID/AST System product candidates, the FDA may require us to submit a PMA application, which is generally
more costly and uncertain and can take from one to three years, or longer, from the time the application is submitted to the FDA
until an approval is obtained.</P>



<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify"></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center">37</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Further, even with respect
to those future products where a PMA is not required, we cannot assure you that we will be able to obtain 510(k) clearances with
respect to those products. The process of obtaining regulatory clearances or approvals, or completing the <I>de novo</I> classification
process, to market a medical device can be costly and time consuming, and we may not be able to successfully obtain pre-market
reviews on a timely basis, if at all. Further, even if we were to obtain regulatory clearance, it may not be for the uses we believe
are important or commercially attractive, in which case we would not be permitted to market our product for those uses.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Clinical trials are generally
required to support both PMA and 510(k) submissions. We are planning clinical trials for the ID/AST System. Clinical trials are
expensive and time-consuming. In addition, the commencement or completion of any clinical trials may be delayed or halted for any
number of reasons, including product performance, changes in intended use, changes in medical practice and the opinion of evaluator
Institutional Review Boards.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Additionally, since 2009,
the FDA has significantly increased the scrutiny applied to its oversight of companies subject to its regulations by hiring new
investigators and increasing inspections of manufacturing facilities. The FDA has also undertaken initiatives related to enhancement
of the 510(k) review process and has proposed significant changes to the regulation of laboratory developed tests (&ldquo;LDTs&rdquo;).
We continue to monitor these developments and analyze how they will impact the approval of our products. These and other actions
proposed by the FDA&rsquo;s Center for Devices and Radiological Health could result in significant changes to the 510(k) process,
which could complicate the product approval process, although we cannot predict the effect of such changes and cannot ascertain
if such changes will have a substantive impact on the approval of our products. If we fail to adequately respond to the increased
scrutiny and streamlined 510(k) submission process, our business may be adversely impacted.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Failure to comply with the
applicable requirements can result in, among other things, warning letters, administrative or judicially imposed sanctions such
as injunctions, civil penalties, recall or seizure of products, total or partial suspension of production, refusal to grant premarket
clearance or PMA for devices, withdrawal of marketing clearances or approvals, or criminal prosecution. With regard to products
for which we seek 510(k) clearance or PMA from the FDA, any failure or material delay to obtain such clearance or approval could
harm our business. If the FDA were to disagree with our regulatory assessment and conclude that approval or clearance is necessary
to market the products, we could be forced to cease marketing the products and seek approval or clearance. Once clearance or approval
has been obtained for a product, there is an obligation to ensure that all applicable FDA and other regulatory requirements continue
to be met.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">In addition, it is possible
that the current regulatory framework could change or additional regulations could arise at any stage during our product development
or marketing, which may adversely affect our ability to obtain or maintain approval of our products. For example, in response to
industry and healthcare provider concerns regarding the predictability, consistency and rigor of the 510(k) regulatory pathway,
the FDA initiated an evaluation of the program, and in January 2011, announced several proposed actions intended to reform the
review process governing the clearance of medical devices. The FDA intends for these reform actions to improve the efficiency and
transparency of the clearance process, as well as bolster patient safety. In addition, as part of the Food and Drug Administration
Safety and Innovation Act, Congress reauthorized the Medical Device User Fee Amendments with various FDA performance goal commitments
and enacted several &ldquo;Medical Device Regulatory Improvements&rdquo; and miscellaneous reforms that are further intended to
clarify and improve medical device regulation both pre- and post-approval. Any delay in, or failure to receive or maintain, clearance
or approval for our product candidates could prevent us from generating revenue from these product candidates. Additionally, the
FDA and other regulatory authorities have broad enforcement powers. Regulatory enforcement or inquiries, or other increased scrutiny
on us, could affect the perceived safety and efficacy of our product candidates and dissuade our customers from using our product
candidates, if and when they are authorized for marketing.</P>



<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify"></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center">38</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Our manufacturing facility
located in Tucson, Arizona, where we assemble and produce the IT/AST System, is subject to periodic regulatory inspections by the
FDA and other federal and state and foreign regulatory agencies. For example, this facility is subject to Quality System Regulations
(&ldquo;QSR&rdquo;) of the FDA and is subject to annual inspection and licensing by the State of Arizona. If we fail to maintain
this facility in accordance with the QSR requirements, international quality standards or other regulatory requirements, our manufacturing
process could be suspended or terminated, which would prevent us from being able to provide products to our customers in a timely
fashion.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Sales of our diagnostic product
candidates outside the United States are subject to foreign regulatory requirements governing clinical studies, vigilance reporting,
marketing approval, manufacturing, product licensing, pricing and reimbursement. These regulatory requirements vary greatly from
country to country. As a result, the time required to obtain approvals outside the United States may differ from that required
to obtain FDA clearance, and we may not be able to obtain foreign regulatory approvals on a timely basis or at all. Clearance by
the FDA does not ensure approval by regulatory authorities in other countries, and approval by one foreign regulatory authority
does not ensure clearance or approval by regulatory authorities in other countries or by the FDA. Foreign regulatory authorities
could require additional testing. Failure to comply with these regulatory requirements, or to obtain required clearances or approvals,
could impair our ability to commercialize our diagnostic product candidates outside of the United States.</P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">Modifications
to our products, if cleared or approved, may require new 510(k) clearances or pre-market approvals, or may require us to cease
marketing or recall the modified products until clearances are obtained.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Any modification to a device
authorized for marketing that could significantly affect its safety or effectiveness, or that would constitute a major change in
its intended use, design or manufacture, requires a new 510(k) clearance or, possibly, approval of a PMA. The FDA requires every
manufacturer to make this determination in the first instance, but the FDA may review any manufacturer&rsquo;s decision. The FDA
may not agree with our decisions regarding whether new clearances or approvals are necessary. If the FDA disagrees with our determination
and requires us to submit new 510(k) notifications or PMAs for modifications to previously cleared products for which we conclude
that new clearances or approvals are unnecessary, we may be required to cease marketing or to recall the modified product until
we obtain clearance or approval, and we may be subject to significant regulatory fines or penalties.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Furthermore, the FDA&rsquo;s
ongoing review of the 510(k) program may make it more difficult for us to make modifications to any products for which we obtain
clearance, either by imposing more strict requirements on when a manufacturer must submit a new 510(k) for a modification to a
previously cleared product, or by applying more onerous review criteria to such submissions. The practical impact of the FDA&rsquo;s
continuing scrutiny of the 510(k) program remains unclear.</P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">We
rely on third parties to conduct studies of our products that may be required by the FDA or other regulatory authorities, and those
third parties may not perform satisfactorily.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">We rely on third parties,
including medical investigators, to conduct studies on our products. Our reliance on these third parties for clinical development
activities will reduce our control over these activities. These third parties may not complete activities on schedule or conduct
studies in accordance with regulatory requirements or our study design. If applicable, our reliance on third parties that we do
not control will not relieve us of any applicable requirement to prepare, and ensure compliance with, various procedures required
under good clinical practices. If these third parties do not successfully carry out their contractual duties or regulatory obligations
or meet expected deadlines, if the third parties need to be replaced or if the quality or accuracy of the data they obtain is
compromised due to their failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our studies
may be extended, delayed, suspended or terminated, and we may not be able to obtain marketing authorization from the FDA or regulatory
clearance for our products.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center">39</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center">&nbsp;</P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">If
we obtain marketing authorization from the FDA, a recall of our products, either voluntarily or at the direction of the FDA, or
the discovery of serious safety issues with our products that leads to corrective actions, could have a significant adverse impact
on us.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">The FDA and similar foreign
governmental authorities have the authority to require the recall of commercialized products. Manufacturers may, under their own
initiative, recall a product if any material deficiency in a device is found. A government-mandated or voluntary recall by us or
one of our distributors could occur as a result of an unacceptable risk to health, component failures, manufacturing errors, design
or labeling defects or other deficiencies and issues. Under the FDA's medical device reporting regulations, we are required to
report to the FDA any incident in which our product may have caused or contributed to a death or serious injury or in which our
product malfunctioned and, if the malfunction were to recur, would likely cause or contribute to death or serious injury. Repeated
product malfunctions may result in a voluntary or involuntary product recall. Recalls of any of our products would divert managerial
and financial resources, have an adverse effect on our reputation, and may impair our ability to produce our products in a cost-effective
and timely manner in order to meet our customers' demands. Depending on the corrective action we take to redress a product's deficiencies
or defects, the FDA may require, or we may decide that we will need to obtain, new approvals or clearances for the device before
we may market or distribute the corrected device. Seeking such approvals or clearances may delay our ability to replace the recalled
devices in a timely manner. Moreover, if we do not adequately address problems associated with our devices, we may face additional
regulatory enforcement action, including FDA warning letters, product seizure, injunctions, administrative penalties, or civil
or criminal fines. We may also be required to bear other costs or take other actions that may have a negative impact on our sales
as well as face significant adverse publicity or regulatory consequences, which could harm our ability to market our products in
the future.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Any adverse event involving
our products could result in future voluntary corrective actions, such as recalls or customer notifications, or agency action,
such as inspection, mandatory recall or other enforcement action. Any corrective action, whether voluntary or involuntary, as well
as defending ourselves in a lawsuit, would require the dedication of our time and capital, distract management from operating our
business and may harm our reputation.</P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 10pt 0 9pt; text-align: justify">Risks Related to Our Common Stock</P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">Our
stock price has been volatile and may continue to be volatile and traded on low volumes.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">The trading price of our
common stock has been, and is likely to continue to be, highly volatile. One factor contributing to volatility in the price of
our common stock is the low trading volume currently prevailing in the market for our shares. The market value of your investment
in our common stock may rise or fall sharply at any time because of this volatility and also because of significant short positions
that may be taken by investors from time to time in our common stock. During the year ended December 31, 2014, the closing sale
price for our common stock ranged from $11.29 to $30.56 per share. The market prices for securities of medical technology companies
historically have been highly volatile, and the market has experienced significant price and volume fluctuations that are unrelated
to the operating performance of particular companies.</P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">We
do not anticipate paying any cash dividends on our capital stock in the foreseeable future.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">We have never declared or
paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth
and development of our business. Any future debt agreements may also preclude us from paying dividends. As a result, capital appreciation,
if any, of our common stock will be your sole source of gain for the foreseeable future.</P>



<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center"></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center">40</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">We
may require additional capital in the future, and you may incur dilution to your stock holdings.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">We have historically relied
upon our existing cash balance, revenues and capital from the sale of our securities to fund our operating losses, and we expect
that we will continue to incur operating losses until we are able to complete the development of the ID/AST System and sell it
into the marketplace or license it to a third party. If capital requirements vary materially from those currently forecast by management,
we may require additional capital sooner than expected. We may also require additional capital in the future to expand our product
offerings, expand our sales and marketing infrastructure, increase our manufacturing capacity, fund our operations, and continue
our research and development activities. Our future funding requirements will depend on many factors, including:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 9pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial,sans-serif">our ability to obtain marketing authorization from the FDA
or clearance from the FDA to market our product candidates;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 9pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial,sans-serif">market acceptance of our product candidates, if cleared;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 9pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial,sans-serif">the cost and timing of establishing sales, marketing and
distribution capabilities;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 9pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial,sans-serif">the cost of our research and development activities;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 9pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial,sans-serif">the ability of healthcare providers to obtain coverage and
adequate reimbursement by third-party payors for procedures using our products;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 9pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial,sans-serif">the cost and timing of marketing authorization or regulatory
clearances;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 9pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial,sans-serif">the cost of goods associated with our product candidates;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 9pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial,sans-serif">the effect of competing technological and market developments;
and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 9pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial,sans-serif">the extent to which we acquire or invest in businesses,
products and technologies, including entering into licensing or collaboration arrangements for product candidates, although we
currently have no commitments or agreements to complete any such transactions.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">If we require additional
capital, we may attempt to raise it through a variety of strategies, including the issuance and sale of additional shares of our
common stock. We have the authority to issue up to 55,000,000 shares of common stock (of which 44,651,496 shares were outstanding
as of February 17, 2015) and 5,000,000 shares of preferred stock (of which no shares were issued or outstanding as of the same
date). Issuances of additional shares of our common stock or preferred stock in the future, whether in connection with a rights
offering, follow-on offering or otherwise, would dilute existing stockholders and may adversely affect the market price of our
common stock.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">We cannot assure you that
we will be able to obtain additional funds on acceptable terms, or at all. Debt financing, if available, may involve covenants
restricting our operations or our ability to incur additional debt. Any debt or additional equity financing that we raise may contain
terms that are not favorable to us or our stockholders. If we raise additional funds through collaboration and licensing arrangements
with third parties, it may be necessary to relinquish some rights to our technologies or our products, or grant licenses on terms
that are not favorable to us. If we are unable to raise adequate funds, we may have to liquidate some or all of our assets or delay,
reduce the scope of or eliminate some or all of our product development.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">If we do not have, or are
not able to obtain, sufficient funds, we may be required to delay development or commercialization of the ID/AST System or license
to third parties the rights to commercialize our products or technologies that we would otherwise seek to commercialize ourselves.
We also may have to reduce marketing, customer support or other resources devoted to our product candidates or cease operations.
Any of these factors could harm our operating results.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center">41</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">The
ownership of our common stock is highly concentrated.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Our directors have beneficial
ownership of approximately 49% of our outstanding common stock as of February 17, 2015, as determined based on a review of each
director&rsquo;s filings under Section 16 of the Securities Exchange Act of 1934. As a result, these stockholders will be able
to affect the outcome of, or exert significant influence over, all matters requiring stockholder approval, including the election
and removal of directors and any change in control. In particular, this concentration of ownership of our common stock could have
the effect of delaying or preventing a change in control of us or otherwise discouraging or preventing a potential acquirer from
attempting to obtain control of us. This, in turn, could have a negative effect on the market price of our common stock. It could
also prevent our stockholders from realizing a premium over the market prices for their shares of common stock. Moreover, the interests
of this concentration of ownership may not always coincide with our interests or the interests of other stockholders. The concentration
of ownership also contributes to the low trading volume and volatility of our common stock.</P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">Provisions
in our certificate of incorporation and bylaws and Delaware law may delay or prevent acquisition of our Company, which could adversely
affect the value of our common stock.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Provisions contained in
our certificate of incorporation and bylaws, as well as provisions of the Delaware General Corporation Law, could delay or make
it more difficult to remove incumbent directors or for a third party to acquire us, even if a takeover would benefit our stockholders.
For example, our board of directors may fill any vacancy on the board of directors, whether such vacancy occurs as a result of
an increase in the number of directors or otherwise. Stockholders may not take action by written consent. Special meetings of
the stockholders may be called only by the President, a Vice President, our board of directors or the holders of not less than
one-tenth of all the shares entitled to vote at the meeting. Additionally, our board of directors has the authority to cause us
to issue, without any further vote or action by the stockholders, up to 5,000,000 shares of preferred stock, par value $0.001
per share, in one or more series, to designate the number of shares constituting any series, and to fix the rights, preferences,
privileges and restrictions thereof, including dividend rights, voting rights, rights and terms of redemption, redemption price
or prices and liquidation preferences of such series. The issuance of shares of preferred stock may have the effect of delaying,
deferring or preventing a change in control of our company without further action by the stockholders, even where stockholders
are offered a premium for their shares. Moreover, we are subject the provisions of Section 203 of the General Corporation Law
of the State of Delaware, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining
with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding
voting stock, unless the merger or combination is approved in a prescribed manner.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center">42</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 10pt 0 6pt; text-align: justify; text-indent: 0in">Item 1B. Unresolved
Staff Comments</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 10pt 0 6pt; text-align: justify; text-indent: 0in">Item 2. Properties</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">Until January 2013, we leased
approximately 6,400 square feet of office and laboratory space in Denver, Colorado. The monthly rent and utilities averaged approximately
$6,000 per month. In January 2013, we relocated our headquarters and currently lease approximately 27,404 square feet of office
and laboratory space in Tucson, Arizona. The lease provides for a term of three years, which may be extended by the Company for
up to three additional one-year periods. The monthly rent and utilities average approximately $24,000 per month. The Company exercised
a lease option to lease additional space totaling approximately 18,481 square feet with an anticipated occupancy date during 2015.
The monthly rent and utilities will increase to approximately $60,000 per month upon occupancy of the new space. See Item 8, Note
13, Commitments for additional details regarding the lease.</P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 10pt 0 6pt; text-align: justify; text-indent: 0in">Item 3. Legal Proceedings</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">We are not currently a party
to any material legal proceedings.</P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 10pt 0 6pt; text-align: justify; text-indent: 0in">Item 4. Mine Safety
Disclosures</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">&#9;Not applicable.</P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 24pt 0 6pt; text-align: center; text-indent: 0.5in">PART II</P>

<P STYLE="font: bold 10pt/normal Arial,sans-serif; margin: 0; text-align: justify; text-indent: 0in">Item 5. Market for Registrant&rsquo;s
Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 10pt 0 6pt; text-align: justify; text-indent: 0in">Market Information</P>

<P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;Since December 26, 2012,
the Company&rsquo;s Common Stock has been traded on the NASDAQ Capital Market under the trading symbol AXDX. Previously, our Common
Stock was traded on the NYSE Amex Stock Market under the trading symbol AXK. The information in the following table sets forth
the quarterly high and low sales price per share of our Common Stock, as reported by the NASDAQ Capital market, for the period
from January 1, 2013 through December 31, 2014.</P>

<P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font-weight: bold; text-align: center">Common Stock Closing Price</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt">Quarter Ended</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">High</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Low</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: justify; text-indent: 0in">March 31, 2013</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">8.52</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">4.06</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: 0in">June 30, 2013</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.22</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.87</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: 0in">September 30, 2013</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13.41</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.17</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: 0in">December 31, 2013</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15.69</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12.10</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: 0in">March 31, 2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21.81</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11.29</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: 0in">June 30, 2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30.56</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16.87</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: 0in">September 30, 2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26.48</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15.94</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: 0in">December 31, 2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29.22</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17.25</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 10pt 0 6pt; text-align: justify; text-indent: 0in">Performance Graph</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">The following Performance
Graph compares the cumulative 5-year total stockholder return on our common stock relative to the cumulative total returns of the
NASDAQ Composite index (XCMP) and the NASDAQ Biotechnology index (XNBI). An investment of $100 (with reinvestment of all dividends)
is assumed to have been made in our common stock and in each of the indexes on December 31, 2009 and its relative performance is
tracked through December 31, 2014. The Performance Graph and related information shall not be deemed to be &ldquo;soliciting material&rdquo;
or to be &ldquo;filed&rdquo; with the Securities and Exchange Commission, nor shall such information be incorporated by reference
into any filing under the Securities Act of 1933 or Securities Exchange Act of 1934, each as amended, except to the extent that
we specifically incorporate it by reference into such filing.</P>

<P STYLE="font: 9pt/115% Sans-Serif; margin: 0 0 6pt; text-align: justify; text-indent: 0in; color: Red"><B></B></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: left; "><IMG SRC="image_002.jpg" ALT=""></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 8pt; line-height: 115%">*
$100 invested on 12/31/2009 in stock or index, including reinvestment of dividends</FONT>.</P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in">Holders</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">As of February 17, 2015,
we had approximately 155 record owners of our Common Stock.</P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in">Dividends Paid and
Dividend Policy</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">Holders of Common Stock are
entitled to receive dividends as may be declared by the Board of Directors out of funds legally available. To date, no dividends
have been declared by the Board of Directors. We currently intend to retain all available funds and any future earnings for use
in the operation of our business and do not anticipate paying any cash dividends on our Common Stock for the foreseeable future.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">Future cash dividends, if
any, will be at the discretion of our Board of Directors and will depend upon our future operations and earnings, capital requirements
and surplus, general financial condition, contractual restrictions and other factors as our Board of Directors may deem relevant.
We do not intend to pay any cash dividends on our Common Stock in the foreseeable future.</P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in">Purchases of Equity
Securities by the Issuer and Affiliated Purchasers</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">None.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0pt; margin-bottom: 9pt; text-align: center">43</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0pt; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 50 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify"></P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in">Equity Compensation
Plan Information</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">The table set forth below
presents the securities authorized for issuance with respect to compensation plans under which equity securities are authorized
for issuance as of December 31, 2014:</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="13" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Equity Compensation Plan</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; text-indent: 0in; padding-left: 5.4pt; border-bottom: Black 1pt solid">Plan category</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">Number of securities to be issued upon exercise of outstanding options,</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">warrants and rights</P></TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid">Weighted average exercise price of
                                                                 available outstanding options, warrants and rights</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: top; border-bottom: Black 1pt solid">Number of securities remaining for future issuance under equity compensation plans (excluding securities reflected in the 1st column)</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 42%; text-align: left; text-indent: 0in; padding-left: 5.4pt">Equity compensation plans approved by security holders</TD><TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">5,603,726</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">5.21</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">3,649,037</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0in; padding-left: 5.4pt">Equity compensation plans not approved by security holders</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify; text-indent: 0in; padding-left: 5.4pt">Total</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">5,603,726</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">5.21</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">3,649,037</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in">Item 6. Selected Financial
Data</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">The following selected
consolidated financial data have been derived from our audited consolidated financial statements. The information below is not
necessarily indicative of the results of future operations, and should be read in conjunction with Item 7, Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations and the consolidated financial statements and related
notes thereto included in Item 8, Financial Statements and Supplementary Data in order to fully understand factors that may affect
the comparability of the information presented below.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 9pt Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="25" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Selected Consolidated Financial Data <BR>(in thousands except per share data)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 8pt; text-align: center"><P STYLE="font: 8pt/normal Arial,sans-serif; margin: 0; text-align: center; text-indent: 0in">12 months</P> <P STYLE="font: 8pt/normal Arial,sans-serif; margin: 0; text-align: center; text-indent: 0in"><u>12/31/2014</u></P></TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 8pt; text-align: center"><P STYLE="font: 8pt/normal Arial,sans-serif; margin: 0; text-align: center; text-indent: 0in">12 months</P> <P STYLE="font: 8pt/normal Arial,sans-serif; margin: 0; text-align: center; text-indent: 0in"><u>12/31/2013</u></P></TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 8pt; text-align: center"><P STYLE="font: 8pt/normal Arial,sans-serif; margin: 0; text-align: center; text-indent: 0in">12 months</P> <P STYLE="font: 8pt/normal Arial,sans-serif; margin: 0; text-align: center; text-indent: 0in">12/31/2012</P> <P STYLE="font: 8pt/normal Arial,sans-serif; margin: 0; text-align: center; text-indent: 0in"><u>(unaudited)</u></P></TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 8pt; text-align: center"><font style="font-size: 8pt">5 months<BR><u>12/31/2012</u></font></TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 8pt; text-align: center">12<font style="font-size: 8pt"> months<BR><u>7/31/2012</u></font></TD><TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 8pt; text-align: center"><FONT STYLE="font-size: 8pt">12
    months<BR><u>7/31/2011</U></font></TD>
</TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; font-size: 10pt; text-align: left; text-indent: 0in; padding-left: 5.4pt">Operating revenues</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 6%; text-align: right">122</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 6%; text-align: right">48</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 6%; text-align: right">52</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 6%; text-align: right">18</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 6%; text-align: right">236</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 6%; text-align: right">1,121</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0in; padding-left: 5.4pt">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(30,933</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(15,282</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,124</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,400</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,311</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(379</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0in; padding-left: 5.4pt">Basic and diluted loss per share (1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.71</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.41</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.44</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.13</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.43</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.04</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0in; padding-left: 5.4pt">Cash dividends</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0in; padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 9pt Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0in; padding-left: 5.4pt; padding-bottom: 1pt; width: 40%">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid; width: 6%">12/31/2014</TD><TD STYLE="text-align: left; padding-bottom: 1pt; width: 1%">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid; width: 6%">12/31/2013</TD><TD STYLE="text-align: left; padding-bottom: 1pt; width: 1%">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid; width: 6%">12/31/2012</TD><TD STYLE="text-align: left; padding-bottom: 1pt; width: 1%">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid; width: 6%">12/31/2012</TD><TD STYLE="text-align: left; padding-bottom: 1pt; width: 1%">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid; width: 6%">7/31/2012</TD><TD STYLE="text-align: left; padding-bottom: 1pt; width: 1%">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid; width: 6%">7/31/2011</TD><TD STYLE="text-align: left; padding-bottom: 1pt; width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0in; padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0in; padding-left: 5.4pt">Total assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">69,801</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">43,431</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">13,316</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">13,616</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">17,214</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6,264</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0in; padding-left: 5.4pt">Long-term obligations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">986</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,380</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify"><FONT STYLE="font-size: 9pt">(1)&nbsp;&nbsp;Loss per share has been adjusted for the effects of the rights offering (see Item 8, Note 9, Rights Offering).</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center"><FONT STYLE="font-size: 9pt">44</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 10pt 0 6pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 51 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 10pt 0 6pt; text-align: justify"></P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in">Item 7. Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">The following Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations (&ldquo;MD&amp;A&rdquo;) summarizes our change in fiscal
year, recent developments, the significant factors affecting our results of operations, capital resources and liquidity, off-balance
sheet arrangements, as well as discusses recent accounting pronouncements and our critical accounting policies and estimates. You
should read the following discussion and analysis together with our financial statements, including the related notes, which are
included in this Annual Report on Form 10-K. Certain information contained in the discussion and analysis set forth below and elsewhere
in this report, including information with respect to our plans and strategy for our business and related financing, includes forward-looking
statements that involve risks and uncertainties. See &ldquo;Risk Factors&rdquo; in Item 1A of this Annual Report on Form 10-K for
a discussion of important factors that could cause actual results to differ materially from the results described in or implied
by the forward-looking statements in this report.</P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in">Change in Fiscal Year</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">Effective December 31, 2012,
we changed our fiscal year end from July 31 to December 31. This MD&amp;A focuses on the fiscal year ended on December 31, 2014.
Comparative financial information is also provided with respect to the fiscal years that ended on December 31, 2013 (audited) and
December 31, 2012 (unaudited).</P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-style: normal"><B>Recent
Developments</B></FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">On August 22, 2012, the Company
entered into a Grant Agreement (the &ldquo;Grant Agreement&rdquo;) with the Arizona Commerce Authority, an agency of the State
of Arizona (the &ldquo;Authority&rdquo;), pursuant to which the Authority will provide certain state and county sponsored incentives
for the Company to relocate its corporate headquarters to, and expand its business within, the State of Arizona (the &ldquo;Project&rdquo;).
Details of this Grant Agreement are included in Item 8, Note 6, License Agreements and Grants.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">On July 12, 2013, the Company
publicly announced the final terms of a rights offering which resulted in gross proceeds of $20.0 million before costs associated
with the transactions, which totaled $88,000. Further details regarding this rights offering are included in Item 8, Note 9, Rights
Offering.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">On April 7, 2014, the Company
commenced a rights offering which resulted in gross proceeds of $45.0 million before costs associated with the transactions, which
totaled $125,000. The proceeds will be used to fund continued operations, clinical trials, and product commercialization efforts.
Further details regarding this rights offering are included in Item 8, Note 9, Rights Offering.</P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in">Changes in Results
of Operations: Fiscal year ended December 31, 2014 compared to fiscal year ended December 31, 2013</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2014, total revenues were $122,000 as compared to $48,000 during the year ended December 31, 2013, an increase of $74,000 or
154%. The increase was due to deferred royalties recognized in 2014. Further information is included in Item 8, Note 7, Deferred
Revenue and Income.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">Research and development
expenses for the year ended December 31, 2014 were $20,053,000 as compared to $10,673,000 during the year ended December 31, 2013,
an increase of $9,380,000 or 88%. The increase was primarily the result of increasing employee headcount, increased non-cash equity-based
compensation expenses of $2,679,000 and increased purchases of laboratory and instrument engineering supplies to support research
and development as well as pre-launch efforts.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2014, sales, general and administrative expenses were $10,695,000 as compared to $4,312,000 during the year ended December
31, 2013, an increase of $6,383,000 or 148%. The increase is primarily driven by salaries and related expenses as we ramp up our
operations and includes an increase in non-cash equity-based compensation expenses of $3,117,000.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0pt; margin-bottom: 9pt; text-align: center">45</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0pt; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 52 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2014, amortization was $71,000 as compared to $77,000 during the year ended December 31, 2013, a decrease of $6,000 or 8%.
This decrease is the result of patents that became fully amortized during the year.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">Depreciation for the year
ended December 31, 2014 was $817,000 as compared to $286,000 during the year ended December 31, 2013, an increase of $531,000 or
186%. The increased depreciation was the result of purchases of equipment to up-fit the Company&rsquo;s new Tucson facility laboratory,
manufacturing and administrative space.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">Impairment of intangibles
for the year ended December 31, 2014 was $3,000 compared to $11,000 for the year ended December 31, 2013, a decrease of $8,000
or 73%. Management routinely reviews intangible assets. As a result, certain capitalized intellectual property amounts carried
on our balance sheet were determined to be no longer recoverable and we abandoned our plan to pursue marketability resulting in
the impairment charge.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">As a result of the above
factors, loss from operations for the year ended December 31, 2014 was $31,517,000 as compared to the loss of $15,311,000 during
the year ended December 31, 2013, an increase in loss from operations of $16,206,000 or 106% which includes an increase of $5,796,000
in non-cash equity-based compensation expenses. This loss and further losses are anticipated and was the result of our continued
investments in research and development, expanded laboratory and operational space, increased employee headcount and other factors
as we develop and prepare to commercialize the Company&rsquo;s products.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">Other non-operating income
during the year ended December 31, 2014 was $57,000 as compared to $29,000 during the year ended December 31, 2013, an increase
of $28,000 or 97%. This change was due to increased interest and dividend income on our cash balances and investments, which increased
year-over-year.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">Income tax benefit during
the year ended December 31, 2014 was $527,000 as compared to $0 during the year ended December 31, 2013. This is due to becoming
eligible for and electing a partial refund of research and development tax credits.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">As a result of these factors,
net loss for the year ended December 31, 2014 was $30,933,000 as compared to a net loss of $15,282,000 during the year ended December
31, 2013, an increase in net loss of $15,651,000 or 102%.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">Unrealized loss on available-for-sale
investments for the year ended December 31, 2014 was $15,000 as compared to a gain of $22,000 during the year ended December 31,
2013. The resulting comprehensive losses were $30,948,000 and $15,260,000 for the years ended December 31, 2014 and December 31,
2013, respectively.</P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in">Changes in Results
of Operations: Year ended December 31, 2013 (audited) compared to year ended December 31, 2012 (unaudited)</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2013, total revenues were $48,000 as compared to $52,000 during the year ended December 31, 2012, a decrease of $4,000 or 8%.
The decrease was due to fluctuations in partner sales volumes on which royalties were due the Company.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">Research and development
expenses for the year ended December 31, 2013 were $10,673,000 as compared to $2,032,000 during the year ended December 31, 2012,
an increase of $8,641,000 or 425%. The increase is primarily the result of increasing employee headcount and increased purchases
of laboratory and instrument engineering supplies to support research and development efforts.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0pt; margin-bottom: 9pt; text-align: center">46</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0pt; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 53 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2013, sales, general and administrative expenses were $4,312,000 as compared to $3,673,000 during the year ended December 31,
2012, an increase of $639,000 or 17%. The increase is primarily driven by salaries and related expenses as we ramp up our operations.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2013, amortization was $77,000 as compared to $177,000 during the year ended December 31, 2012, a decrease of $100,000 or 56%.
This decrease is the result of impairment of patents and intellectual assets in the prior year as discussed below.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">Depreciation for the year
ended December 31, 2013 was $286,000 as compared to $6,000 during the year ended December 31, 2012, an increase of $280,000 or
4467%. The increased depreciation was the result of purchases of equipment to up-fit the new Tucson facility laboratory and administrative
space.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">Impairment of intangibles
for the year ended December 31, 2013 was $11,000 compared to $2,330,000 for the year ended December 31, 2012, a decrease of $2,319,000
or 100%. Management determined certain capitalized intellectual property amounts carried on our balance sheet were no longer recoverable
and abandoned its plan to pursue marketability resulting in the impairment charge.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">As a result of the above
factors, loss from operations for the year ended December 31, 2013 was $15,311,000 as compared to the loss of $8,166,000 during
the year ended December 31, 2012, an increase in loss from operations of $7,145,000 or 87%. This loss was anticipated and is the
result of planned growth.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;Other non-operating
income during the year ended December 31, 2013 was $29,000 as compared to $42,000 during the year ended December 31, 2012, a decrease
of $13,000 or 31%. This change is due to investment activity.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;As a result of
these factors, net loss for the year ended December 31, 2013 was $15,282,000 as compared to a net loss of $8,124,000 during the
year ended December 31, 2012, an increase in net loss of $7,158,000 or 88%.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">Unrealized gain on available-for-sale
investments for the year ended December 31, 2013 was $22,000 as compared to $0 during the year ended December 31, 2012. The resulting
comprehensive losses were $15,260,000 and $8,124,000 for the years ended December 31, 2013 and December 31, 2012, respectively.</P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in">Capital Resources and
Liquidity</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">Our primary source of liquidity
has been from sales of shares of common stock. As of December 31, 2014, the Company had $66.7 million in cash and cash equivalents
and available-for-sale securities, an increase of $24.7 million from $42.0 million at December 31, 2013. The primary reason for
the change in these assets was the Company&rsquo;s successful completion of the rights offering described in Item 8, Note 9, Rights
Offering.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">As discussed in Item 8, Note
9, Rights Offering, on April 7, 2014, the Company commenced a rights offering to raise $45.0 million which resulted in gross proceeds
of $45.0 million before expenses upon completion in May 2014. The purpose of the rights offering was to raise equity capital in
a cost-effective manner that gives all of the Company&rsquo;s existing stockholders the opportunity to participate on a pro rata
basis. The net proceeds of the offering will be used for working capital and specifically to fund continued operations, clinical
trials, and product commercialization efforts.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0pt; margin-bottom: 9pt; text-align: center">47</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0pt; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 54 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">The Company is subject to
a Lease Agreement with Pima County of Arizona. The future minimum lease payments under the Lease Agreement are included in Item
8, Note 13, Commitments.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">As of December 31, 2014,
management believes that current cash balances will be more than sufficient to fund our capital and liquidity needs for the next
twelve months.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">The following summarizes
selected items in the Company&rsquo;s condensed consolidated statements of cash flows for years ended December 31, 2014 and December
31, 2013 (in thousands):</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 72%; font: 10pt Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="text-align: center"><B>Cash Flow Summary</B> <BR>(in thousands)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 5.4pt; padding-bottom: 1pt; width: 40%">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; width: 5%">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt; width: 1%">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: top; border-bottom: Black 1pt solid; width: 10%"><B>12/31/2014</B></TD><TD STYLE="text-align: left; padding-bottom: 1pt; width: 1%"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1pt; width: 3%"><B>&nbsp;</B></TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt; width: 1%"><B>&nbsp;</B></TD><TD STYLE="text-align: center; vertical-align: top; border-bottom: Black 1pt solid; width: 10%"><B>12/31/2013</B></TD><TD STYLE="text-align: left; padding-bottom: 1pt; width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 5.4pt">Net cash used in operating activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(18,785</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(9,749</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 5.4pt">Net cash used in investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,372</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(13,172</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 5.4pt">Net cash provided by financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">45,691</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,881</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">Our primary use of capital
has been for the continued development and commercialization of the Accelerate ID/AST system. We believe our capital requirements
will continue to be met with our existing cash balance and those provided under grants, exercises of warrants and stock options
and/or, additional issuance of equity or debt securities. Further, if capital requirements vary materially from those currently
planned, we may require additional capital sooner than expected. There can be no assurance that such capital will be available
in sufficient amounts or on terms acceptable to us, if at all. Additional issuances of equity or convertible debt securities will
result in dilution to our current common stockholders.</P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in">Off-Balance Sheet Arrangements</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">We did not have any off-balance
sheet arrangements as of December 31, 2014.</P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in">Recent Accounting Pronouncements</P>

<P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">In August 2014, the Financial
Accounting Standards Board (&ldquo;FASB&rdquo;) issued Accounting Standards Update (&ldquo;ASU&rdquo;) 2014-15, <I>Presentation
of Financial Statements &ndash; Going Concern</I>. The new standard required management of public and private companies to evaluate
whether there is substantial doubt about the entity&rsquo;s ability to continue as a going concern and, if so, disclose that fact.
Management will also be required to evaluate and disclose whether its plans alleviate that doubt. The new standard is effective
for annual periods ending after December 15, 2016, and interim periods within annual periods beginning after December 15, 2016.
Early adoption is permitted. We do not expect the adoption of the ASU to have a significant impact on our consolidated financial
statements.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">In May 2014, the FASB issued
ASU 2014-09 <I>Revenue from Contracts with Customers</I>, which will supersede nearly all existing revenue recognition guidance
under U.S. GAAP. The standard&rsquo;s core principle is that a company will recognize revenue when it transfers promised goods
or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for
those goods or services. We are carefully evaluating our existing revenue recognition practices to determine whether any contracts
in the scope of the guidance will be affected by the new requirements. The effects may include identifying performance obligations
in existing arrangements, determining the transaction price and allocating the transaction price to each separate performance obligation.
We will also establish practices to determine when a performance obligation has been satisfied, and recognize revenue in accordance
with the new requirements. The new standard is effective for us on January 1, 2017. Early adoption is not permitted. The standard
allows for either &ldquo;full retrospective&rdquo; adoption, meaning the standard is applied to all of the periods presented, or
&ldquo;modified retrospective&rdquo; adoption, meaning the standard is applied only to the most current period presented in the
financial statements. We are currently evaluating the transition method that will be elected.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0pt; margin-bottom: 9pt; text-align: center">48</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0pt; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 55 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify"></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">In December 2013, the FASB
issued ASU No. 2013-12, <I>Definition of a Public Business Entity</I>. The purpose of this standard is to clarify which nonpublic
entities potentially qualify for alternative financial accounting and reporting guidance by defining &ldquo;public business entity&rdquo;
for future use in U.S. GAAP. Currently, FASB Accounting Standards Codification (&ldquo;ASC&rdquo;) includes multiple definitions
of &ldquo;public entity&rdquo;. This standard provides a single definition of &ldquo;public business entity&rdquo; for use in future
financial accounting and reporting guidance but does not affect existing requirements. There is no effective date for this standard
but the definition will start to be used in ASU&rsquo;s as FASB feels is appropriate. The standard defines &ldquo;public business
entity&rdquo; as a business entity that meets any one of a number of criteria, one of which is the requirement to file financial
statements with the SEC. We have reviewed the definition and have determined that we will be defined as a &ldquo;public business
entity&rdquo; and there will be no impact on the Company&rsquo;s financial position, results of operations or cash flows.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">In July 2013, the FASB issued
ASU 2013-11,<I> Presentation of an Unrecognized Tax Benefit (UTB) When a Net Operating Loss (NOL) Carryforward, a Similar Tax Loss,
or a Tax Credit Carryforward Exists, </I>which requires a reporting entity to present an unrecognized tax benefit as a liability
in the financial statements separate from deferred tax assets if a net operating loss carryforward, a similar tax loss, or a tax
credit carryforward is not available as of the reporting date to settle taxes that would result from the disallowance of the tax
position or if a reporting entity does not intend to use the deferred tax asset for such purpose. The amendments in ASU 2013-11
are effective for fiscal years, and interim periods within those years, beginning on or after December 15, 2013. The adoption of
ASU 2013-11 did not have a material impact on our financial position, results of operations or cash flows.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">In March 2013, the FASB issued
ASU 2013-04, <I>Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation
is Fixed at the Reporting Date</I>, which provides guidance on the recognition, measurement, and disclosure of obligations resulting
from joint and several liability arrangements for which the total amount of the obligation is fixed at the reporting date. The
update requires an entity to measure obligations resulting from joint and several liability obligations for which the total amount
of the obligation within the scope of the update is fixed at the reporting date, as the sum of the amount the reporting entity
agreed to pay on the basis of its arrangements among its co-obligors and any additional amount the reporting entity expects to
pay on behalf of its co-obligors. The update also requires an entity to disclose the nature and amount of the obligation as well
as other information about those obligations. The amendments in ASU 2013-04 are effective for fiscal years, and interim periods
within those years, beginning on or after December 15, 2013 and must be applied retrospectively. The adoption of ASU 2013-04 in
the first quarter of 2014 did not have a material impact on our financial position, results of operations or cash flows.</P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in">Critical Accounting
Policies and Estimates</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">We consider our
accounting policies related to deferred taxes, inventory and equity-based compensation to be critical accounting policies. A
number of significant estimates, assumptions, and judgments are inherent in our calculations which are based on historical
experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could
differ materially from these estimates.</P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in"><B><I>Deferred
Taxes</I></B></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">We recognize deferred tax
assets and liabilities based on the differences between the financial statement carrying amounts and the tax bases of assets and
liabilities. We regularly review our deferred tax assets for recoverability and establish a valuation allowance based on historical
taxable income, projected future taxable income, and the expected timing of the reversals of existing temporary differences. As
of December 31, 2014 and 2013, we have established a valuation allowance equal to our net deferred tax asset, as we have not been
able to determine that we will generate sufficient future taxable income to allow us to realize the deferred tax asset prior to
their limitations or expirations. See Item 8, Note 12, Income Taxes for additional information.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0pt; margin-bottom: 9pt; text-align: center">49</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0pt; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; text-align: justify; text-indent: 0in; margin-right: 0; margin-bottom: 6pt; margin-left: 0"><B><I>&nbsp;</I></B></P>

<!-- Field: Page; Sequence: 56 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 6pt; margin-left: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 6pt; margin-left: 0"><B><I></I></B></P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in"><B><I>Equity-Based
Compensation</I></B></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">We account for equity-based
compensation in accordance with FASB ASC 718. Equity-based compensation is measured at the grant date based on the estimated fair
value of the award and is recognized over the requisite service period.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">In determining the fair value
of the award, we use the Black-Scholes option pricing model. This model requires the input of subjective assumptions which are
further discussed in Item 8, Note 2, Summary of Significant Accounting Policies and Item 8, Note 11, Employee and Consultant Equity-Based
Compensation. Once estimated, the Black-Scholes assumptions remain fixed throughout the requisite service period for employee grants.
For unvested consultant grants, the assumptions are updated at the end of each reporting period until the grant is vested. Changes
in the inputs can materially affect the estimate of the fair value</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">Employees who terminate employment
prior to the requisite service period forfeit their unvested options and we derecognize the fair value of these shares. In accordance
with FASB ASC 718, we estimate the amount of such forfeitures. Our estimate is based on the forfeiture rate of unvested awards
in the previous twelve-month period. The rate is calculated separately for awards to the board of directors/executives and all
other awards. The rate is adjusted at the end of each period and any change is recognized through a cumulative catch-up adjustment.
Rate changes will also impact the amount of equity-based compensation expense to be recognized in future periods. Due to our relatively
small employee base this estimate is particularly sensitive to termination activity and any change in this assumption can materially
affect the estimate of fair value of equity-based compensation.</P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in">Inventory</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">We currently purchase
and produce inventory prior to U.S. Food and Drug Administration (&ldquo;FDA&rdquo;) or other regulatory agency approval. We
do not believe probable future economic benefit can be asserted prior to the completion of 510(k) clearance or other non-U.S.
regulatory body equivalent. Accordingly, we do not capitalize pre-launch inventory prior to the receipt of 510(k) clearance,
unless regulatory approval has been achieved in other jurisdictions, or the regulatory review process has progressed to a
point that we have objective and persuasive evidence that regulatory approval is probable. Inventory is reported as research
and development costs on the Statements of Operations and Comprehensive Loss.</P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-style: normal"><B>Contractual
Obligations</B></FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">The Company has certain contractual
obligations and commercial commitments as disclosed in Item 8, Note 13, Commitments that do not meet the definition of long term
debt obligations, capital leases, operating leases or purchase obligations. The Company has entered into a Lease Agreement as described
in Item 2, Properties and Item 8, Note 13, Commitments. The operating and capital lease obligations associated with the Lease Agreement
over the next five years are (in thousands):</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="25" STYLE="font: 10pt Arial,sans-serif; text-align: center"><B>Contractual Obligations</B> <BR>(in thousands)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left; text-indent: 0in; padding-left: 5.4pt; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: center; vertical-align: top; border-bottom: Black 1pt solid"><B>Total</B></TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: center; vertical-align: top; padding-bottom: 1pt"><B>&nbsp;</B></TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: center; vertical-align: top; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: center; vertical-align: top; padding-bottom: 1pt"><B>&nbsp;</B></TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: center; vertical-align: top; border-bottom: Black 1pt solid"><B>2015</B></TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: center; vertical-align: top; padding-bottom: 1pt"><B>&nbsp;</B></TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: center; vertical-align: top; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: center; vertical-align: top; padding-bottom: 1pt"><B>&nbsp;</B></TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: center; vertical-align: top; border-bottom: Black 1pt solid"><B>2016</B></TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: center; vertical-align: top; padding-bottom: 1pt"><B>&nbsp;</B></TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: center; vertical-align: top; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: center; vertical-align: top; padding-bottom: 1pt"><B>&nbsp;</B></TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: center; vertical-align: top; border-bottom: Black 1pt solid"><B>2017</B></TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: center; vertical-align: top; padding-bottom: 1pt"><B>&nbsp;</B></TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: center; vertical-align: top; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: center; vertical-align: top; padding-bottom: 1pt"><B>&nbsp;</B></TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: center; vertical-align: top; border-bottom: Black 1pt solid"><B>2018</B></TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: center; vertical-align: top; padding-bottom: 1pt"><B>&nbsp;</B></TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: center; vertical-align: top; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: center; vertical-align: top; padding-bottom: 1pt"><B>&nbsp;</B></TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: center; vertical-align: top; border-bottom: Black 1pt solid"><B>2019</B></TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: center; vertical-align: top; padding-bottom: 1pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left; text-indent: 0in; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; font: 10pt Arial,sans-serif; text-align: left; text-indent: 0in; padding-left: 5.4pt">Operating Lease Obligations</TD><TD STYLE="width: 2%; font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Arial,sans-serif; text-align: left">$</TD><TD STYLE="width: 6%; font: 10pt Arial,sans-serif; text-align: right">693</TD><TD STYLE="width: 1%; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Arial,sans-serif; text-align: left">$</TD><TD STYLE="width: 6%; font: 10pt Arial,sans-serif; text-align: right">633</TD><TD STYLE="width: 1%; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Arial,sans-serif; text-align: left">$</TD><TD STYLE="width: 6%; font: 10pt Arial,sans-serif; text-align: right">60</TD><TD STYLE="width: 1%; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Arial,sans-serif; text-align: left">$</TD><TD STYLE="width: 6%; font: 10pt Arial,sans-serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Arial,sans-serif; text-align: left">$</TD><TD STYLE="width: 6%; font: 10pt Arial,sans-serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Arial,sans-serif; text-align: left">$</TD><TD STYLE="width: 6%; font: 10pt Arial,sans-serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left; padding-bottom: 1pt; text-indent: 0in; padding-left: 5.4pt">Capital Lease Obligations</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">164</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">151</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">13</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left; text-indent: 0in; padding-left: 5.4pt">Total</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">$</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">857</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">$</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">784</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">$</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">73</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">$</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">$</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">$</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 10pt 0 6pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial, Helvetica, Sans-Serif; margin-top: 10pt; margin-bottom: 6pt; text-align: center">50</P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin-top: 10pt; margin-bottom: 6pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 10pt 0 6pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 57 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 10pt 0 6pt; text-align: justify"></P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in">Item 7A. Quantitative
and Qualitative Disclosures About Market Risk</P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify">Interest Rate Risk</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">The Company&rsquo;s interest
income is sensitive to fluctuations in the general level of U.S. interest rates. As such, changes in U.S. interest rates affect
the interest earned on the Company&rsquo;s cash and cash equivalents and investments.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">Our exposure to market risk
is limited to our cash and cash equivalents, all of which have original maturities of less than three months and available-for-sale
investments some of which have maturities under a year and some of which have maturities of more than a year. The goals of our
investment policy are preservation of capital, fulfillment of liquidity needs and fiduciary control of cash and investments. We
also seek to maximize income from our investments without assuming significant risk. To achieve our goals, we maintain a portfolio
of cash equivalents and investments in a variety of securities that management believes to be of high credit quality. We currently
do not hedge interest rate exposure. Further information regarding our investments is included in Item 8, Note 4, Investments.</P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in">Item 8. Financial Statements
and Supplementary Data</P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in"><B><I>Financial
Statements of Accelerate Diagnostics, Inc.</I></B></P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <TD STYLE="width: 100%">
        <P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0; text-align: justify; text-indent: 0in"><font style="font-weight: normal; font-style: normal">Report
        of Independent Registered Public Accounting Firm</font></P>
        <P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0; text-align: justify; text-indent: 0in"><font style="font-weight: normal; font-style: normal">&nbsp;</font></P>
        <P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0; text-align: justify; text-indent: 0in"><font style="font-weight: normal; font-style: normal">Report
        of Independent Registered Public Accounting Firm from Prior Audit Periods</font></P></td>
    <TD STYLE="width: 0%; text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif">&nbsp;</td></tr>
<tr>
    <TD STYLE="text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif">&nbsp;</td>
    <TD STYLE="text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif">&nbsp;</td></tr>
<tr>
    <TD STYLE="text-align: justify; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><font style="font-family: Arial,sans-serif; font-weight: normal; font-style: normal">Balance Sheets as of December 31, 2014 and 2013 </font></td>
    <TD STYLE="text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif">&nbsp;</td></tr>
<tr>
    <TD STYLE="text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif">&nbsp;</td>
    <TD STYLE="text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif">&nbsp;</td></tr>
<tr>
    <TD STYLE="text-align: justify; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><font style="font-family: Arial,sans-serif; font-weight: normal; font-style: normal">Statements of Operations and Comprehensive Loss for the years ended December 31, 2014 and &nbsp;2013, the five-month periods ended December 31, 2012 and 2011 and the fiscal year ended July 31, 2012</font></td>
    <TD STYLE="text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif">&nbsp;</td></tr>
<tr>
    <TD STYLE="text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif">&nbsp;</td>
    <TD STYLE="text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif">&nbsp;</td></tr>
<tr>
    <TD STYLE="text-align: justify; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><font style="font-family: Arial,sans-serif; font-weight: normal; font-style: normal">Statements of Stockholders&rsquo; Equity for the years ended December 31, 2014 and 2013, transition period ended December 31, 2012 and the fiscal year ended July 31, 2012</font></td>
    <TD STYLE="text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif">&nbsp;</td></tr>
<tr>
    <TD STYLE="text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif">&nbsp;</td>
    <TD STYLE="text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif">&nbsp;</td></tr>
<tr>
    <TD STYLE="text-align: justify; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><font style="font-family: Arial,sans-serif; font-weight: normal; font-style: normal">Statements of Cash Flow for the years ended December 31, 2014 and 2013, the five-month periods ended December 31, 2012 and 2011 and the fiscal year ended July 31, 2012</font></td>
    <TD STYLE="text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif">&nbsp;</td></tr>
<tr>
    <TD STYLE="text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif">&nbsp;</td>
    <TD STYLE="text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif">&nbsp;</td></tr>
<tr>
    <TD STYLE="text-align: justify; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><font style="font-family: Arial,sans-serif; font-weight: normal; font-style: normal">Notes to Financial Statements</font></td>
    <TD STYLE="text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif">&nbsp;</td></tr>
</table>



<P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0 0 6pt; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0 0 6pt; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Arial,sans-serif; margin-top: 0; margin-bottom: 6pt; text-align: center">51</P>

<P STYLE="font: 10pt/normal Arial,sans-serif; margin-top: 0; margin-bottom: 6pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0 0 6pt; text-align: center; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 58 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0 0 6pt; text-align: center; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0 0 6pt; text-align: center; text-indent: 0.5in"><B>Report of Independent
Registered Public Accounting Firm </B></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">The Board of Directors and
Stockholders of Accelerate Diagnostics, Inc. and Subsidiaries</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">We have audited the accompanying
consolidated balance sheets of Accelerate Diagnostics, Inc. and subsidiaries as of December&nbsp;31, 2014 and 2013, and the related
consolidated statements of operations and comprehensive loss, stockholders&rsquo; equity, and cash flows for the years ended December&nbsp;31,
2014 and 2013. These financial statements are the responsibility of the Company&rsquo;s management. Our responsibility is to express
an opinion on these financial statements based on our audit.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">We conducted our audits in
accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we
plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.
An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit
also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the
overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">In our opinion, the
financial statements referred to above present fairly, in all material respects, the financial position of Accelerate
Diagnostics, Inc. and subsidiaries at December&nbsp;31, 2014 and 2013 and the results of its operations and its cash flows
for the years ended December&nbsp;31, 2014 and 2013, in conformity with U.S. generally accepted accounting principles.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">We also have audited, in
accordance with the standards of the Public Company Accounting Oversight Board (United States), Accelerate Diagnostics, Inc.&rsquo;s
internal control over financial reporting as of December&nbsp;31, 2014, based on criteria established in Internal Control-Integrated
Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (1992 framework) and our report dated
February 26, 2015, expressed an unqualified opinion thereon.</P>

<P STYLE="font: 10pt/normal Arial,sans-serif; margin-top: 9pt; margin-bottom: 6pt; text-align: center">/s/ Ernst&nbsp;&amp;
Young LLP</P>

<P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Arial,sans-serif; margin: 9pt 0 6pt; text-align: justify; text-indent: 0.5in">Phoenix, Arizona</P>

<P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">February 26, 2015</P>

<P STYLE="font: 12pt/normal Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt/normal Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 6pt; text-align: center">52</P>

<P STYLE="font: 10pt/normal Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 6pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>


<!-- Field: Page; Sequence: 59 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Arial,sans-serif; margin-top: 0; margin-bottom: 6pt; text-align: center"><B>Report of Independent
Registered Public Accounting Firm</B></P>

<P STYLE="font: 10pt/normal Arial,sans-serif; margin-top: 0; margin-bottom: 6pt; text-align: center">The Board of Directors
and Stockholders of Accelerate Diagnostics, Inc. and Subsidiaries</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">We have audited
Accelerate Diagnostics, Inc. and subsidiaries&rsquo; internal control over financial reporting as of December&nbsp;31, 2014,
based on criteria established in Internal Control &mdash; Integrated Framework issued by the Committee of Sponsoring
Organizations of the Treadway Commission (1992 framework) (the COSO criteria). Accelerate Diagnostics, Inc.&rsquo;s
management is responsible for maintaining effective internal control over financial reporting, and for its assessment of the
effectiveness of internal control over financial reporting included in the accompanying Management&rsquo;s Report on Internal
Control Over Financial Reporting. Our responsibility is to express an opinion on the company&rsquo;s internal control over
financial reporting based on our audit.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">We conducted our audit in
accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we
plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was
maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting,
assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control
based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that
our audit provides a reasonable basis for our opinion.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">A company&rsquo;s internal
control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.
A company&rsquo;s internal control over financial reporting includes those policies and procedures that (1)&nbsp;pertain to the
maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets
of the company; (2)&nbsp;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial
statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being
made only in accordance with authorizations of management and directors of the company; and (3)&nbsp;provide reasonable assurance
regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&rsquo;s assets that could
have a material effect on the financial statements.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Because of its inherent limitations,
internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness
to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree
of compliance with the policies or procedures may deteriorate.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">In our opinion, Accelerate
Diagnostics, Inc. and subsidiaries maintained, in all material respects, effective internal control over financial reporting as
of December&nbsp;31, 2014, based on the COSO criteria.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">We also have audited, in
accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheet
of Accelerate Diagnostics, Inc. and subsidiaries as of December&nbsp;31, 2014 and 2013 and the related consolidated statements
of operations and comprehensive loss, stockholders&rsquo; equity, and cash flows for each of the two years in the period ended
December&nbsp;31, 2014 and our report dated February 26, 2015, expressed an unqualified opinion thereon.</P>

<P STYLE="font: 10pt/normal Arial,sans-serif; margin-top: 6pt; margin-bottom: 6pt; text-align: center">/s/&nbsp;&nbsp;&nbsp;&nbsp;Ernst&nbsp;&amp;
Young LLP</P>

<P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0; text-align: justify">Phoenix, Arizona</P>

<P STYLE="margin-top: 0; text-align: left; margin-bottom: 0">February 26, 2015</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">53</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; border-bottom: Black 1pt solid"><BR CLEAR="ALL">
</P>



<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 6pt; text-align: center"><BR CLEAR="ALL">
<B>Report of Independent Registered Public Accounting Firm</B></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">Board of Directors</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">Accelerate Diagnostics, Inc.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">Tucson, Arizona</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">We have audited the accompanying
balance sheets of Accelerate Diagnostics, Inc. (a Delaware corporation) as of December 31, 2012, July 31, 2012 and July 31, 2011
and the related statements of operations and comprehensive loss, stockholders&rsquo; equity and cash flows for the five month period
ended December 31, 2012 and for each of the years ended July 31, 2012 and 2011. These financial statements are the responsibility
of the Company&rsquo;s management. Our responsibility is to express an opinion on these financial statements based on our audits.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">We conducted our audits in
accordance with standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan
and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement.
The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting.
Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are
appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company&rsquo;s
internal control over financial reporting. Accordingly, we express no such opinion. An audit includes examining, on a test basis,
evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles
used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe
that our audits provide a reasonable basis for our opinion.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">In our opinion, the financial
statements referred to above present fairly, in all material respects, the financial position of Accelerate Diagnostics, Inc. as
of December 31, 2012, July 31, 2012 and July 31, 2011 and the results of its operations and changes in its cash flows for the five
month period ended December 31, 2012 and each of the years ended July 31, 2012 and 2011, in conformity with U.S. generally accepted
accounting principles.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0in">Denver, Colorado</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0in">March 19, 2013</P>

<table align="center" cellspacing="3" cellpadding="0" style="font-size: 10pt">
<tr style="vertical-align: bottom">
    <td style="width: 214.4pt; padding: 0.75pt">
        <P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: left; text-indent: 0.5in">/s/ COMISKEY &amp; COMPANY</P>
        <P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: left; text-indent: 0.5in">PROFESSIONAL CORPORATION</P>
        <P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: left; text-indent: 0.5in">&nbsp;</P></td></tr>
</table>




<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">54</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 61 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font: 10pt Arial,sans-serif; text-align: center; text-indent: 0in; padding-left: 5.4pt; vertical-align: top"><B>ACCELERATE DIAGNOSTICS, INC.</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font: 10pt Arial,sans-serif; text-align: center; text-indent: 0in; padding-left: 5.4pt; vertical-align: top"><B>CONSOLIDATED</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font: 10pt Arial,sans-serif; text-align: center; text-indent: 0in; padding-left: 5.4pt; vertical-align: top"><B>BALANCE SHEETS</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font: 10pt Arial,sans-serif; text-align: center; text-indent: 0in; padding-left: 5.4pt; vertical-align: top">(in
    thousands, except share data)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font: 10pt Arial,sans-serif; text-align: center; text-indent: 0in; padding-left: 5.4pt; vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left; text-indent: 0in; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="font: bold 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Arial,sans-serif; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font: bold 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Arial,sans-serif; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font: bold 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left; text-indent: 0in; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="font: bold 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Arial,sans-serif; text-align: center; vertical-align: top"><U>12/31/2014</U></TD><TD STYLE="font: bold 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Arial,sans-serif; text-align: center; vertical-align: top"><U>12/31/2013</U></TD><TD STYLE="font: bold 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="9" STYLE="font: 10pt Arial,sans-serif; text-align: center; text-indent: 0in; padding-left: 5.4pt; vertical-align: top"><B>ASSETS</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left; text-indent: 0in; padding-left: 5.4pt">Current assets:</TD><TD STYLE="font: bold 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 56%; font: 10pt Arial,sans-serif; text-align: left; text-indent: -0.1in; padding-left: 22pt">Cash and cash equivalents</TD><TD STYLE="width: 8%; font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Arial,sans-serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Arial,sans-serif; text-align: right">53,563</TD><TD STYLE="width: 1%; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Arial,sans-serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Arial,sans-serif; text-align: right">30,029</TD><TD STYLE="width: 1%; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left; text-indent: -0.1in; padding-left: 22pt">Investments</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">13,115</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">11,960</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left; text-indent: -0.1in; padding-left: 22pt">Trade accounts receivable</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">78</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">24</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 22pt">Prepaid expenses</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">342</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">130</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left; text-indent: 0in; padding-left: 5.4pt">Total current assets</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">67,098</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">42,143</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Property and equipment, net</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">2,536</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">1,047</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Intellectual property, net</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">167</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">241</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in">Total assets</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Arial,sans-serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Arial,sans-serif; text-align: right">69,801</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Arial,sans-serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Arial,sans-serif; text-align: right">43,431</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: justify; text-indent: 0.5in; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="9" STYLE="font: bold 10pt Arial,sans-serif; text-align: center; text-indent: 0in; padding-left: 5.4pt">LIABILITIES AND STOCKHOLDERS' EQUITY</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: justify; text-indent: 0in; padding-left: 5.4pt">Current liabilities:</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: justify; text-indent: -0.1in; padding-left: 22pt">Accounts payable</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">$</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">2,129</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">$</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">540</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: justify; text-indent: -0.1in; padding-left: 22pt">Accrued liabilities</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">494</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">515</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: justify; text-indent: -0.1in; padding-left: 22pt">Deferred revenue and income</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">13</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">82</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: justify; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 22pt">Capital lease obligations</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">147</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: justify; text-indent: 0in; padding-left: 5.4pt">Total current liabilities</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">2,783</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">1,137</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: justify; text-indent: -0.1in; padding-left: 0.1in">Long-term deferred income</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">1,014</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">777</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: justify; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Long-term capital lease obligation</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">13</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: justify; text-indent: -0.1in; padding-left: 0.1in">Total liabilities</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">3,810</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">1,914</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: justify; text-indent: 0.5in; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: justify; text-indent: 0in; padding-left: 5.4pt">Stockholders' equity:</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left; text-indent: 0; padding-left: 5.4pt">Common stock, $0.001 par value;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left; padding-left: 11pt">55,000,000 common shares authorized <BR>44,639,829 (as of December 31, 2014) and 41,649,521 (as of December 31, 2013) shares issued and outstanding <BR></TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">45</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">42</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left; padding-left: 11pt">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left; text-indent: -0.1in; padding-left: 0.2in">5,000,000 preferred shares authorized and none outstanding as of December 31, 2014 and December 31, 2013</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: justify; text-indent: -0.1in; padding-left: 22pt">Contributed capital</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">131,356</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">75,937</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: justify; text-indent: -0.1in; padding-left: 22pt">Accumulated deficit</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">(65,417</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">)</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">(34,484</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: justify; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 22pt">Accumulated other comprehensive income</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">7</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">22</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: justify; padding-bottom: 1pt; text-indent: 0in; padding-left: 5.4pt">Total stockholders' equity</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">65,991</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">41,517</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: justify; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in">Total liabilities and stockholders' equity</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Arial,sans-serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Arial,sans-serif; text-align: right">69,801</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Arial,sans-serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Arial,sans-serif; text-align: right">43,431</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 11pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: center; text-indent: 0.5in"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 11pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 11pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 11pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 11pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: center; text-indent: 0.5in">See accompanying notes to
financial statements.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: center; text-indent: 0.5in">55</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: center; text-indent: 0.5in; border-bottom: Black 1pt solid">&nbsp;</P>


<!-- Field: Page; Sequence: 62 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->






<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="21" STYLE="font: 10pt Arial,sans-serif; text-align: center; padding-bottom: 1pt"><B>ACCELERATED DIAGNOSTICS,
    INC.</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="21" STYLE="font: 10pt Arial,sans-serif; text-align: center; padding-bottom: 1pt"><B>CONSOLIDATED</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="21" STYLE="font: 10pt Arial,sans-serif; text-align: center; padding-bottom: 1pt"><B>STATEMENTS OF OPERATIONS
    AND COMPREHENSIVE LOSS</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="21" STYLE="font: 10pt Arial,sans-serif; text-align: center; padding-bottom: 1pt">(in thousands, except per share data)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="21" STYLE="font: 10pt Arial,sans-serif; text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">1<B>2
                                         months</B></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><B>12/31/2014</B></P></TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left; padding-bottom: 1pt"><B>&nbsp;</B></TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left; padding-bottom: 1pt"><B>&nbsp;</B></TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"><B>12 months</B></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><B>12/31/2013</B></P></TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left; padding-bottom: 1pt"><B>&nbsp;</B></TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left; padding-bottom: 1pt"><B>&nbsp;</B></TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"><B>5
                                         months 12/31/2012</B></TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left; padding-bottom: 1pt"><B>&nbsp;</B></TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: center; vertical-align: top; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"><B>5
                                         months</B></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><B>12/31/2011</B></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><B>(unaudited)</B></P></TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left; padding-bottom: 1pt"><B>&nbsp;</B></TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left; padding-bottom: 1pt"><B>&nbsp;</B></TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"><B>12
                                         months</B></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><B>7/31/2012</B></P></TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left"><B>Revenues:</B></TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 35%; font: 10pt Arial,sans-serif; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.2in">Licensing and royalty revenues</TD><TD STYLE="width: 1%; font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">122</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">48</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">18</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">202</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">236</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left; text-indent: -0.1in; padding-left: 0.2in">Total revenues</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">122</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">48</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">18</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">202</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">236</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left; text-indent: 0.5in; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Arial,sans-serif; text-align: left; text-indent: -7.55pt; padding-left: 7.55pt">Costs and expenses:</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left; text-indent: -0.1in; padding-left: 0.2in">Research and development</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">20,053</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">10,673</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">1,777</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">163</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">432</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left; text-indent: -0.1in; padding-left: 0.2in">Sales, general and administrative</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">10,695</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">4,312</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">1,267</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">562</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">2,954</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left; text-indent: -0.1in; padding-left: 0.2in">Amortization</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">71</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">77</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">38</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">64</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">203</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left; text-indent: -0.1in; padding-left: 0.2in">Depreciation</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">817</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">286</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">5</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">1</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">2</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left; padding-bottom: 1pt; text-indent: 0in; padding-left: 0.1in">Impairment of intangibles</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">3</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">11</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">333</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">1,997</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.2in">Total costs and expenses</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">31,639</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">15,359</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">3,420</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">790</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">5,588</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left; text-indent: -7.55pt; padding-left: 7.55pt">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left; text-indent: -7.55pt; padding-left: 7.55pt">Loss from operations</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">(31,517</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">)</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">(15,311</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">)</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">(3,402</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">)</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">(588</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">)</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">(5,352</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left; text-indent: -7.55pt; padding-left: 7.55pt">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Interest expense and other</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">(7</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">)</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">1</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">1</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Interest and dividend income</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">64</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">29</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">2</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">4</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">16</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Unrealized holding (loss) gain on investments</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">(4</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">)</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">24</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Total other income</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">57</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">29</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">2</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">1</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">41</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left; text-indent: -7.55pt; padding-left: 7.55pt">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left; text-indent: -7.55pt; padding-left: 7.55pt">Net loss before income taxes</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">(31,460</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">)</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">(15,282</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">)</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">(3,400</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">)</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">(587</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">)</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">(5,311</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left; padding-bottom: 1pt; text-indent: -7.55pt; padding-left: 7.55pt">Benefit from income taxes</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">527</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left; padding-bottom: 2.5pt; text-indent: -7.55pt; padding-left: 7.55pt">Net loss</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Arial,sans-serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Arial,sans-serif; text-align: right">(30,933</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Arial,sans-serif; text-align: left">)</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Arial,sans-serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Arial,sans-serif; text-align: right">(15,282</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Arial,sans-serif; text-align: left">)</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Arial,sans-serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Arial,sans-serif; text-align: right">(3,400</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Arial,sans-serif; text-align: left">)</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Arial,sans-serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Arial,sans-serif; text-align: right">(587</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Arial,sans-serif; text-align: left">)</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Arial,sans-serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Arial,sans-serif; text-align: right">(5,311</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Arial,sans-serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left; text-indent: -7.55pt; padding-left: 7.55pt">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Basic and diluted net loss per share</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">$</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">(0.71</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">)</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">$</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">(0.41</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">)</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">$</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">(0.13</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">)</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">$</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">(0.05</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">)</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">$</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">(0.43</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Weighted average shares outstanding</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">43,626</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">37,599</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">25,354</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">11,132</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">12,462</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left; text-indent: -7.55pt; padding-left: 7.55pt">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Arial,sans-serif; text-align: left; text-indent: -7.55pt; padding-left: 7.55pt">Other comprehensive loss:</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Net loss</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">$</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">(30,933</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">)</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">$</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">(15,282</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">)</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">$</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">(3,400</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">)</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">$</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">(587</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">)</TD><TD STYLE="font: 10pt Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left">$</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: right">(5,311</TD><TD STYLE="font: 10pt Arial,sans-serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Net unrealized (loss) gain on available-for-sale investments</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">(15</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">)</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">22</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Arial,sans-serif; text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in">Comprehensive loss</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Arial,sans-serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Arial,sans-serif; text-align: right">(30,948</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Arial,sans-serif; text-align: left">)</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Arial,sans-serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Arial,sans-serif; text-align: right">(15,260</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Arial,sans-serif; text-align: left">)</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Arial,sans-serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Arial,sans-serif; text-align: right">(3,400</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Arial,sans-serif; text-align: left">)</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Arial,sans-serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Arial,sans-serif; text-align: right">(587</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Arial,sans-serif; text-align: left">)</TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Arial,sans-serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Arial,sans-serif; text-align: right">(5,311</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Arial,sans-serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: center; text-indent: 0.5in">See accompanying notes to
financial statements.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: center; text-indent: 0.5in">56</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: center; text-indent: 0.5in; border-bottom: Black 1pt solid">&nbsp;</P>


<!-- Field: Page; Sequence: 63 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>




<P STYLE="margin: 0"></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>ACCELERATE
DIAGNOSTICS, INC.</B></FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>CONSOLIDATED</B></FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>STATEMENTS
OF STOCKHOLDERS&rsquo; EQUITY</B></FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">(in thousands)</P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><B>Shares</B></FONT></TD><TD STYLE="text-align: center; padding-bottom: 1pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>&nbsp;</B></FONT></TD><TD STYLE="text-align: center; padding-bottom: 1pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>&nbsp;</B></FONT></TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><B>Common</B></FONT></P>
                                                                          <P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><B>Stock</B></FONT></P>
                                                                          <P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><B>Amount</B></FONT></P></TD><TD STYLE="text-align: center; padding-bottom: 1pt"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><B>&nbsp;</B></FONT></TD><TD STYLE="text-align: center; padding-bottom: 1pt"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><B>&nbsp;</B></FONT></TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><B>Contributed</B></FONT></P>
                                                                          <P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><B>Capital</B></FONT></P></TD><TD STYLE="text-align: center; padding-bottom: 1pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>&nbsp;</B></FONT></TD><TD STYLE="text-align: center; padding-bottom: 1pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>&nbsp;</B></FONT></TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><B>Accumulated
                                         Deficit</B></FONT></TD><TD STYLE="text-align: center; padding-bottom: 1pt"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><B>&nbsp;</B></FONT></TD><TD STYLE="text-align: center; padding-bottom: 1pt"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><B>&nbsp;</B></FONT></TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><B>For</B></FONT></P>
                                                                          <P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><B>Employee</B></FONT></P>
                                                                          <P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><B>Benefit</B></FONT></P></TD><TD STYLE="text-align: center; padding-bottom: 1pt"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><B>&nbsp;</B></FONT></TD><TD STYLE="text-align: center; padding-bottom: 1pt"></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><B>&nbsp;</B></FONT></TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><B>Accumulated</B></FONT></P>
                                                                          <P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><B>Other</B></FONT></P>
                                                                          <P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><B>Comprehensive</B></FONT></P>
                                                                          <P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><B>Income</B></FONT></P></TD><TD STYLE="text-align: center; padding-bottom: 1pt"></TD><TD STYLE="text-align: center; padding-bottom: 1pt"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><B>&nbsp;</B></FONT></TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><B>Total</B></FONT></P>
                                                                          <P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><B>Stockholders&rsquo;</B></FONT></P>
                                                                          <P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><B>Equity</B></FONT></P></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 37%; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Balances,
    August 1, 2011</FONT></TD><TD STYLE="width: 2%; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="width: 5%; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">11,103</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">$</FONT></TD><TD STYLE="width: 5%; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">14,333</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">$</FONT></TD><TD STYLE="width: 5%; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">1,247</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">$</FONT></TD><TD STYLE="width: 5%; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(10,491</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD STYLE="width: 2%; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">$</FONT></TD><TD STYLE="width: 5%; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(274</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD STYLE="width: 2%; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">$</FONT></TD><TD STYLE="width: 5%; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">$</FONT></TD><TD STYLE="width: 5%; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">4,815</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Net
    loss</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(5,311</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(5,311</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Issuance
    of common stock and warrants</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">14,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">8,524</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">5,896</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">14,420</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Exercise
    of options and warrants</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">129</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">129</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">129</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Equity-based
    compensation</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">782</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">782</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Balances,
    July 31, 2012</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">25,232</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">22,986</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">7,925</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(15,802</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(274</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">14,835</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Net
    loss</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(3,400</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(3,400</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Issuance
    of common stock and warrants</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Exercise
    of options and warrants</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">100</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">100</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">100</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Transfer
    of Rabbi trust</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(274</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">274</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Establish
    par value stock for DE corp</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(22,961</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">22,961</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Equity-based
    compensation</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">533</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">533</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Balances,
    December 31, 2012</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">25,332</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">25</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">31,245</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(19,202</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"></FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">12,068</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Net
    loss</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(15,282</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(15,282</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Issuance
    of common stock and warrants</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">2,488</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">3</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">19,909</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">19,912</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Exercise
    of options and warrants</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">13,830</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">14</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">20,955</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">20,969</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Unrealized
    gain on available-for-sale securities</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">22</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">22</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Equity-based
    compensation</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">3,828</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">3,828</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Balances,
    December 31, 2013</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">41,650</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">42</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">75,937</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(34,484</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">22</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">41,517</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Net
    loss</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(30,933</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(30,933</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Issuance
    of common stock</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">2,678</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">3</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">44,872</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">44,875</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Exercise
    of options</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">312</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">923</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">923</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Unrealized
    loss on available-for-sale securities</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(15</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(15</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Equity-based
    compensation</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">9,624</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">9,624</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Balances,
    December 31, 2014</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">44,640</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">45</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">131,356</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(65,417</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">7</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">65,991</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: center; text-indent: 0in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: center; text-indent: 0.5in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">See
accompanying notes to financial statements.</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: center; text-indent: 0.5in">57</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: center; text-indent: 0.5in; border-bottom: Black 1pt solid">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: center; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 64 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: center; text-indent: 0.5in"></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="21" STYLE="font: 10pt Arial,sans-serif"><P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>
                                                         <P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>ACCELERATE
                                         DIAGNOSTICS, INC.</B></FONT></P>

<P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>CONSOLIDATED</B></FONT></P>

<P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>STATEMENT
OF CASH FLOWS</B></FONT></P>

<P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(in thousands)</FONT></P>

</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font-family: Arial,sans-serif; font-weight: bold; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>12
    Months<BR>12/31/2014</B></FONT></TD><TD STYLE="font-family: Arial,sans-serif; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="3" STYLE="font-family: Arial,sans-serif; font-weight: bold; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>12
    Months<BR>12/31/2013</B></FONT></TD><TD STYLE="font-family: Arial,sans-serif; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="3" STYLE="font-family: Arial,sans-serif; font-weight: bold; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>5
    months<BR>12/31/2012</B></FONT></TD><TD STYLE="font: bold 9pt Arial,sans-serif; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="3" STYLE="font: bold 9pt Arial,sans-serif; border-bottom: Black 1pt solid"><P STYLE="font: 10pt/normal Arial,sans-serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>5
                                         months<BR>12/31/2011</B></FONT></P> <P STYLE="font: 9pt/normal Arial,sans-serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>(unaudited)</B></FONT></P></TD><TD STYLE="font: bold 9pt Arial,sans-serif; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="3" STYLE="font: bold 9pt Arial,sans-serif; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>12
    months<BR>7/31/2012</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="8" STYLE="font-family: Arial,sans-serif; font-weight: bold; text-align: left; text-indent: 33.3pt; padding-left: 5.4pt"><B>&nbsp;</B></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><B>&nbsp;</B></TD><TD STYLE="font-family: Arial,sans-serif"><B>&nbsp;</B></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><B>&nbsp;</B></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><B>&nbsp;</B></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><B>&nbsp;</B></TD><TD STYLE="font-family: Arial,sans-serif"><B>&nbsp;</B></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><B>&nbsp;</B></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><B>&nbsp;</B></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD STYLE="text-align: left"><B>&nbsp;</B></TD><TD STYLE="text-align: right"><B>&nbsp;</B></TD><TD STYLE="text-align: left"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="8" STYLE="font-family: Arial,sans-serif; font-weight: bold; text-align: left; text-indent: 33.3pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>Cash
    flows from operating activities:</B></FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Arial,sans-serif; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Arial,sans-serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Net
    loss</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">$</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(30,933</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">$</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(15,282</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">$</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(3,400</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">$</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(587</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">$</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(5,311</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Arial,sans-serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Adjustments
    to reconcile net loss to net cash used in operating activities:</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Arial,sans-serif; text-indent: -0.1in; padding-left: 0.2in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Depreciation</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">817</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">286</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">5</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">1</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">2</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Arial,sans-serif; text-align: left; text-indent: -0.1in; padding-left: 0.2in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Amortization
    of intangible assets</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">71</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">77</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">38</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">64</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">203</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Arial,sans-serif; text-align: left; text-indent: -0.1in; padding-left: 0.2in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Amortization
    of investment discount</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">269</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">76</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Arial,sans-serif; text-indent: -0.1in; padding-left: 0.2in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Equity-based
    compensation</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">9,624</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">3,828</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">533</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">273</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">782</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Arial,sans-serif; text-align: left; text-indent: -0.1in; padding-left: 0.2in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Impairment
    loss</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">3</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">11</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">333</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">1,997</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Arial,sans-serif; text-align: left; text-indent: -0.1in; padding-left: 0.2in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Unrealized
    gain on investments</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(24</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Arial,sans-serif; text-align: left; text-indent: -0.1in; padding-left: 0.2in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Realized
    gain on sale of investments, interest and dividends reinvested</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(8</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Arial,sans-serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(Increase)
    decrease in assets:</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Arial,sans-serif; text-align: left; text-indent: -0.1in; padding-left: 0.2in; width: 35%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Accounts
    receivable</FONT></TD><TD STYLE="font-family: Arial,sans-serif; width: 2%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left; width: 1%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right; width: 9%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(54</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left; width: 1%">)<FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; width: 2%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left; width: 1%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right; width: 9%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">739</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left; width: 1%"></TD><TD STYLE="font-family: Arial,sans-serif; width: 2%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left; width: 1%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right; width: 9%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(13</FONT>)</TD><TD STYLE="font-family: Arial,sans-serif; text-align: left; width: 1%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; width: 2%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left; width: 1%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right; width: 9%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">2</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left; width: 1%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"></FONT></TD><TD STYLE="font-family: Arial,sans-serif; width: 2%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left; width: 1%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right; width: 9%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">591</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left; width: 1%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; width: 0%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"></FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: right; width: 0%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Arial,sans-serif; text-indent: -0.1in; padding-left: 0.2in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Inventory</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">10</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">20</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Arial,sans-serif; text-align: left; text-indent: -0.1in; padding-left: 0.2in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Prepaid
    expense and other</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(166</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(114</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">2</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(8</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">3</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Arial,sans-serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Increase
    (decrease) in liabilities:</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Arial,sans-serif; text-align: left; text-indent: -0.1in; padding-left: 0.2in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Accounts
    payable</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">1,336</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">205</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">236</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">41</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">27</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Arial,sans-serif; text-align: left; text-indent: -0.1in; padding-left: 0.2in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Accrued
    liabilities</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">80</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(356</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">127</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">7</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">719</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Arial,sans-serif; text-align: left; text-indent: -0.1in; padding-left: 0.2in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Deferred
    revenue and income</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">168</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">781</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(7</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">95</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">76</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Arial,sans-serif; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.2in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Deferred
    compensation</FONT></TD><TD STYLE="font-family: Arial,sans-serif; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(73</FONT></TD><TD STYLE="padding-bottom: 1pt; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD STYLE="font-family: Arial,sans-serif; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">107</FONT></TD><TD STYLE="padding-bottom: 1pt; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Arial,sans-serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Net
    cash used in operating activities</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(18,785</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(9,749</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(2,136</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(185</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(816</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="8" STYLE="font-family: Arial,sans-serif; font-weight: bold; text-align: left; text-indent: 37.8pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>Cash
    flows from investing activities:</B></FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Arial,sans-serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Purchases
    of equipment and capitalized patents</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(1,933</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(1,158</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(158</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(19</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(96</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Arial,sans-serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Contribution
    to deferred compensation trust</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">16</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(150</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Arial,sans-serif; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Purchase
    of available-for-sale securities</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(7,657</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(12,014</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Arial,sans-serif; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Sales
    of available-for-sale securities</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">861</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Arial,sans-serif; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Maturity
    of available-for-sale securities</FONT></TD><TD STYLE="font-family: Arial,sans-serif; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">5,357</FONT></TD><TD STYLE="padding-bottom: 1pt; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Arial,sans-serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Net
    cash used in investing activities</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(3,372</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(13,172</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(158</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(3</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(246</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Arial,sans-serif; text-indent: 0in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="8" STYLE="font-family: Arial,sans-serif; font-weight: bold; text-align: left; text-indent: 33.3pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>Cash
    flows from financing activities:</B></FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Arial,sans-serif; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Exercise
    of warrants and options</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">923</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">20,969</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">100</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">129</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Arial,sans-serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Issuance
    of common stock and warrants</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">44,875</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">19,912</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">14,420</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Arial,sans-serif; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Payments
    on capital lease obligations</FONT></TD><TD STYLE="font-family: Arial,sans-serif; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(107</FONT></TD><TD STYLE="padding-bottom: 1pt; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD STYLE="font-family: Arial,sans-serif; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Arial,sans-serif; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Net
    cash provided by financing activities</FONT></TD><TD STYLE="font-family: Arial,sans-serif; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">45,691</FONT></TD><TD STYLE="padding-bottom: 1pt; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">40,881</FONT></TD><TD STYLE="padding-bottom: 1pt; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">100</FONT></TD><TD STYLE="padding-bottom: 1pt; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">14,549</FONT></TD><TD STYLE="padding-bottom: 1pt; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Arial,sans-serif; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Arial,sans-serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Increase
    (decrease) in cash and cash equivalents</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">23,534</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">17,960</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(2,194</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(188</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">13,487</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Arial,sans-serif; text-align: left; padding-bottom: 1pt; text-indent: 0in; padding-left: 5.4pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Cash
    and cash equivalents, beginning of period</FONT></TD><TD STYLE="font-family: Arial,sans-serif; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">30,029</FONT></TD><TD STYLE="padding-bottom: 1pt; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">12,069</FONT></TD><TD STYLE="padding-bottom: 1pt; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right"><P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0; text-align: right; text-indent: 0in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P><P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0; text-align: right; text-indent: 0in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">14,263</FONT></P></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">776</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Arial,sans-serif; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">776</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Arial,sans-serif; text-align: left; padding-bottom: 2.5pt; text-indent: 0in; padding-left: 5.4pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Cash
    and cash equivalents, end of period</FONT></TD><TD STYLE="font-family: Arial,sans-serif; padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">53,563</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">30,029</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">12,069</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">588</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">14,263</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: center; text-indent: 0.5in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: center; text-indent: 0.5in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">See
accompanying notes to financial statements.</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: center; text-indent: 0.5in">58</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: center; text-indent: 0.5in; border-bottom: Black 1pt solid">&nbsp;</P>


<!-- Field: Page; Sequence: 65 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: center; text-indent: 0.5in"><B>ACCELERATE DIAGNOSTICS,
INC</B>.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: center; text-indent: 0.5in"><B>NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS</B></P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 10pt 0 9pt; text-align: justify; text-indent: 0in">NOTE 1. ORGANIZATION
AND NATURE OF BUSINESS; BASIS OF PRESENTATION; PRINCIPLES OF CONSOLIDATION</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Accelerate Diagnostics, Inc.
(&ldquo;we&rdquo; or &ldquo;us&rdquo; or &ldquo;our&rdquo; or &ldquo;Accelerate&rdquo; or &ldquo;the Company&rdquo;) is an <I>in
vitro</I> diagnostics company dedicated to providing solutions which improve patient outcomes and lower healthcare costs through
the rapid diagnosis of serious infections. Microbiology laboratories are in need of new tools to address what the U.S. Centers
for Disease Control and Prevention (&ldquo;CDC&rdquo;) calls one of the most serious healthcare threats of our time, antibiotic
resistance. A significant contributor to the rise of resistance is the overuse and misuse of antibiotics, which is exacerbated
by a lack of timely diagnostic results. The delay of these results is often due to the reliance of microbiology laboratories on
traditional culture-based tests that often take two to three days to complete. Our technology platform is built to address these
challenges by delivering significantly faster and accurate testing of infectious pathogens in various patient sample types.</P>



<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; text-align: justify; text-indent: 0in; margin-right: 0; margin-bottom: 9pt; margin-left: 0"><B><I>Basis
of Presentation</I></B></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">The accompanying consolidated
financial statements have been prepared in accordance with U.S. generally accepted accounting principles, (&ldquo;U.S. GAAP&rdquo;),
and applicable rules and regulations of the United States Securities and Exchange Commission (&ldquo;SEC&rdquo;), regarding annual
financial reporting.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">All amounts are rounded to
the nearest thousand dollars unless otherwise indicated.</P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; text-align: justify; text-indent: 0in; margin-right: 0; margin-bottom: 9pt; margin-left: 0"><B><I>Principles
of Consolidation</I></B></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">The consolidated financial
statements include the accounts of the Company and its wholly-owned subsidiaries after elimination of intercompany transactions
and balances. There were no intercompany transactions for the years ending December 31, 2014 and 2013.</P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 10pt 0 9pt; text-align: justify; text-indent: 0in">NOTE 2. SUMMARY OF
SIGNIFICANT ACCOUNTING POLICIES</P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; text-align: justify; text-indent: 0in; margin-right: 0; margin-bottom: 9pt; margin-left: 0">Use
of Estimates</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">The preparation of financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the
reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; text-align: justify; text-indent: 0in; margin-right: 0; margin-bottom: 9pt; margin-left: 0">Concentration
of Credit Risk</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Financial instruments that
potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, short-term investments
and accounts receivable, including receivables from major customers.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">The Company periodically
maintains cash balances at a commercial bank in excess of the Federal Deposit Insurance Corporation insurance limit of $250,000.
At December 31, 2014 and December 31, 2013, the Company&rsquo;s uninsured cash balance was approximately $53.6 million and $30.1
million, respectively.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">The Company grants credit
to domestic and international clients in various industries. Exposure to losses on accounts receivable is principally dependent
on each client's financial position. At December 31, 2014, 98% of the outstanding receivable balance was with Denver Health and
the Department of Defense related to the Defense Medical Research and Development Program. See Note 6, License Agreements and Grants
for more information.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center">59</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; text-align: justify; text-indent: 0in; margin-right: 0; margin-bottom: 9pt; margin-left: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 66 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0"></P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; text-align: justify; text-indent: 0in; margin-right: 0; margin-bottom: 9pt; margin-left: 0">Estimated
Fair Value of Financial Instruments</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">The Company follows <I>ASC
Topic 820, Fair Value Measurements and Disclosures</I> which has defined fair value and requires the Company to establish a framework
for measuring fair value and disclose fair value measurements. The framework requires the valuation of assets and liabilities subject
to fair value measurements using a three tiered approach and fair value measurement be classified and disclosed in one of the following
three categories:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Arial,sans-serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date
for identical, unrestricted assets or liabilities;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Arial,sans-serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets
that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset
or liability;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Arial,sans-serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Level 3: Prices or valuation techniques that require inputs that are both significant to the fair
value measurement and unobservable (i.e. supported by little or no market activity).</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">The carrying amounts of financial
instruments such as cash and cash equivalents, trade accounts receivable, prepaid expenses, accounts payable, accrued liabilities,
and other current liabilities approximate the related fair values due to the short-term maturities of these instruments.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">See Note 3, Fair Value of
Financial Instruments for further information and related disclosures regarding the Company&rsquo;s fair value measurements.</P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; text-align: justify; text-indent: 0in; margin-right: 0; margin-bottom: 9pt; margin-left: 0">Cash
and Cash Equivalents</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">All highly liquid investments
with an original maturity of three months or less at time of purchase are considered to be cash equivalents. Cash and cash equivalents
include overnight repurchase agreement accounts. As part of our cash management process, excess operating cash is invested in overnight
repurchase agreements with our bank. Repurchase agreements are not deposits and are not insured by the U.S. Government, the FDIC
or any other government agency and involve investment risk including possible loss of principal. We believe however, that the market
risk arising from holding these financial instruments is minimal.</P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; text-align: justify; text-indent: 0in; margin-right: 0; margin-bottom: 9pt; margin-left: 0">Investments</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">The Company invests excess
funds in various short-term and long-term investments which are primarily held in the custody of a major financial institution.
Investments consist of debt securities in U.S. government-sponsored entities, corporate debt securities and commercial paper. Management
classifies its investments as available-for-sale investments and records these investments in the Balance Sheets at fair value.
Unrealized gains or losses for available-for-sale securities are included in accumulated other comprehensive income or loss, a
component of stockholders&rsquo; equity. The Company classifies its investments as current based on the nature of the investments
and their availability for use in current operations.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">The Company assesses whether
an other-than-temporary impairment loss has occurred due to declines in fair value or other market conditions when an investment&rsquo;s
fair value remains less than its cost for more than twelve months. This assessment includes a determination of whether the investment
is expected to recover in value and whether the Company as the intent and ability to hold the investment until the anticipated
recovery in value occurs. When an investment is identified as having an other-than-temporary impairment loss, we adjust the cost
basis of the investment down to fair value resulting in a realized loss. The new cost basis is not changed for subsequent recoveries
in fair value and future increases or decreases in fair value are included in other comprehensive income.</P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; text-align: justify; text-indent: 0in; margin-right: 0; margin-bottom: 9pt; margin-left: 0">Property
and Equipment</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Property and equipment are
recorded at cost. Maintenance and repairs are charged to expense as incurred and expenditures for major improvements are capitalized.
Gains and losses from retirement or replacement are included in costs and expenses. Depreciation of property and equipment is computed
using the straight-line method over the estimated useful life of the assets, ranging from one to seven years. Leasehold improvements
are depreciated over the remaining life of the lease or the life of the asset, whichever is less. See Note 5, Property and Equipment
below.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center">60</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; text-align: justify; text-indent: 0in; margin-right: 0; margin-bottom: 9pt; margin-left: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 67 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0"></P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; text-align: justify; text-indent: 0in; margin-right: 0; margin-bottom: 9pt; margin-left: 0">Long-lived
Assets</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Long-lived assets and certain
identifiable intangibles to be held and used by the Company are reviewed for impairment whenever events or changes in circumstances
indicate that the carrying amount of an asset may not be recoverable. The Company continuously evaluates the recoverability of
its long-lived assets based on estimated future cash flows from and the estimated fair value of such long-lived assets, and provides
for impairment if such undiscounted cash flows or the estimated fair value are insufficient to recover the carrying amount of the
long-lived asset.</P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; text-align: justify; text-indent: 0in; margin-right: 0; margin-bottom: 9pt; margin-left: 0">Inventory</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">The Company produces
inventory prior to U.S. Food and Drug Administration (&ldquo;FDA&rdquo;) or other regulatory agency approval. We do not
believe probable future economic benefit can be asserted prior to the completion of 510(k) clearance or other non-U.S.
regulatory body equivalent. Accordingly, the Company does not capitalize pre-launch inventory prior to the receipt of 510(k)
clearance, unless regulatory approval has been achieved in other jurisdictions, or the regulatory review process has
progressed to a point that the Company has objective and persuasive evidence that regulatory approval is probable. Inventory
is reported as research and development costs on the Statement of Operations and Comprehensive Loss.</P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; text-align: justify; text-indent: 0in; margin-right: 0; margin-bottom: 9pt; margin-left: 0">Revenue
Recognition</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">The Company recognizes revenue
in accordance with ASC 605, &ldquo;Revenue Recognition,&rdquo; when persuasive evidence of an arrangement exists, the price is
fixed or determinable, collection is reasonably assured and delivery of products has occurred or services have been rendered.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Additional considerations
include whether the applicable fee arrangement contains future delivery or performance obligations that should be divided into
separate accounting units, whether the arrangement requires the Company to retain risks consistent with a collaborative arrangement,
and/or whether any of the fees are contingent on the achievement of future milestones.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">The Company recognizes income
from royalty and licensing fee agreements based upon information and reports received from licensees and in accordance with the
terms of the agreements underlying such arrangements. &nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Deferred revenue represents
amounts received but not yet earned under existing agreements.</P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; text-align: justify; text-indent: 0in; margin-right: 0; margin-bottom: 9pt; margin-left: 0"><B><I>Accounts
Receivable Allowances</I></B></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Allowances on accounts receivable
are recorded when circumstances indicate collection is doubtful for a particular accounts receivable. Receivables are written off
if reasonable collection efforts prove unsuccessful. The Company provides for allowances on a specific account basis.</P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; text-align: justify; text-indent: 0in; margin-right: 0; margin-bottom: 9pt; margin-left: 0">Leases</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">The Company accounts for
leases in accordance with ASC 840, <I>Leases, </I>which requires leases to be classified as either operating or capital leases.
In general, the Company classifies leases as capital leases when there is either a transfer of ownership at the end of the lease
term, the lease contains a bargain purchase option, the lease term is seventy-five percent or more of the estimated economic life
of the leased property or the minimum lease payments are ninety percent or more of the fair value at lease inception. Other leases
are classified as operating leases.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Operating lease rent is recorded
as an operating expense monthly. For capital leases, both an asset and liability are recorded at the inception of the lease based
on the present value of lease payments. The asset is included with property and equipment on the Balance Sheet and amortization
is recorded on a straight-line basis over the term of the lease with the amortization expense included with depreciation on the
Statements of Operations and Comprehensive Loss. For the liability, the amount due within the next year is recorded as capital
lease obligations and the amount due in more than a year is recorded as long-term capital lease obligation on the Balance Sheet.
Interest expense is recorded based on the implicit or explicit interest rate used in the lease and is included as non-operating
interest expense on the Statements of Operations and Comprehensive Loss.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center">61</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 68 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in">Income
Taxes</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">Deferred
tax assets and liabilities are recorded for the estimated future tax effects of temporary differences between the tax basis of
assets and liabilities and amounts reported in the accompanying balance sheets. The change in deferred tax assets and liabilities
for the period represents the deferred tax provision or benefit for the period. Effects of changes in enacted tax laws in deferred
tax assets and liabilities are reflected as an adjustment to the tax provision or benefit in the period of enactment.</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">The
Company follows the provisions of ASC 740, <I>Income Taxes</I>, to account for any uncertainty in income taxes with respect to
the accounting for all tax positions taken (or expected to be taken) on any income tax return. This guidance applies to all open
tax periods in all tax jurisdictions in which the Company is required to file an income tax return. Under U.S. GAAP, in order to
recognize an uncertain tax benefit the taxpayer must be more likely than not of sustaining the position, and the measurement of
the benefit is calculated as the largest amount that is more than 50% likely to be realized upon resolution of the benefit. Interest
and penalties, if any, would be recorded as tax expense in general and administrative expenses.</FONT></P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in">Earnings
Per Share</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">The Company follows <I>ASC
260, Earnings Per Share</I>, which requires companies to present basic earnings per share and diluted earnings per share. Basic
earnings (loss) per share includes no dilution and is computed by dividing income (loss) available to common stockholders by the
weighted average number of common shares outstanding for the period. Diluted earnings per share are computed similarly to basic
earnings (loss) per share except the denominator includes additional common shares that would have been outstanding if warrants
and share-based payments had been issued. Diluted earnings are not presented when the effect of adding such additional common shares
is antidilutive.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">Earnings per share are restated
when certain transactions or events, including rights offerings determined to have bonus elements have occurred.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">See Note 10, Earnings per
Share for more information.</P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in">Equity-Based
Compensation</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">The Company awards stock
options and other equity-based instruments to its employees, directors and consultants. Compensation cost related to equity-based
awards is based on the fair value of the instrument on the grant date, and is recognized over the requisite service period on a
straight-line basis over the vesting period for each tranche (an accelerated attribution method). For unvested consultant grants,
the assumptions are updated at the end of each reporting period until the grant is vested. The Company estimates the fair value
of stock option awards, including modifications of stock option awards, using the Black-Scholes option pricing model. This model
derives the fair value of stock options based on certain assumptions related to expected stock price volatility, expected option
life, risk-free interest rate and dividend yield.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif">Volatility: The expected volatility is based on the historical
volatility of the Company's stock price over the most recent period commensurate with the expected term of the stock option award.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif">Option life: The estimated expected option life for employee
awards is based on the calculation published by the SEC in SAB110 for use when there is not a sufficient history of employee exercise
patterns. For consultant awards, the estimated expected option life is the same as the life of the award.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif">Risk-free interest rate: The risk-free interest rate
is based on published U.S. Treasury rates for a term commensurate with the expected option life.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif">Dividend yield: The dividend yield is estimated as zero
as the Company has not paid dividends in the past and does not have any plans to pay any dividends in the future. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0pt; margin-bottom: 9pt; text-align: center">62</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0pt; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 69 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">The Company estimates the
forfeiture rate of unvested awards based on the forfeitures in the previous twelve-month period. The rate is calculated separately
for awards to the board of directors/executives and all other awards.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in">See Note 11, Employee and Consultant
Equity-Based Compensation for further information.</P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in">Comprehensive
Income (loss)</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">The Company follows <I>ASC
220, Reporting Comprehensive Income</I>, which establishes standards for reporting and displaying comprehensive income (loss) and
its components (revenues, expenses, gains and losses) in a full set of general-purpose financial statements. The Company holds
investments classified as available-for-sale securities and records the change in fair market value as a component of comprehensive
income (loss).</P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in">Recently
Issued Accounting Pronouncements</P>

<P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">In August 2014, the Financial
Accounting Standards Board (&ldquo;FASB&rdquo;) issued Accounting Standards Update (&ldquo;ASU&rdquo;) 2014-15, <I>Presentation
of Financial Statements &ndash; Going Concern</I>. The new standard required management of public and private companies to evaluate
whether there is substantial doubt about the entity&rsquo;s ability to continue as a going concern and, if so, disclose that fact.
Management will also be required to evaluate and disclose whether its plans alleviate that doubt. The new standard is effective
for annual periods ending after December 15, 2016, and interim periods within annual periods beginning after December 15, 2016.
Early adoption is permitted. We do not expect the adoption of the ASU to have a significant impact on our consolidated financial
statements.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">In May 2014, the FASB issued
ASU 2014-09 <I>Revenue from Contracts with Customers</I>, which will supersede nearly all existing revenue recognition guidance
under U.S. GAAP. The standard&rsquo;s core principle is that a company will recognize revenue when it transfers promised goods
or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for
those goods or services. We are carefully evaluating our existing revenue recognition practices to determine whether any contracts
in the scope of the guidance will be affected by the new requirements. The effects may include identifying performance obligations
in existing arrangements, determining the transaction price and allocating the transaction price to each separate performance obligation.
We will also establish practices to determine when a performance obligation has been satisfied, and recognize revenue in accordance
with the new requirements. The new standard is effective for us on January 1, 2017. Early adoption is not permitted. The standard
allows for either &ldquo;full retrospective&rdquo; adoption, meaning the standard is applied to all of the periods presented, or
&ldquo;modified retrospective&rdquo; adoption, meaning the standard is applied only to the most current period presented in the
financial statements. We are currently evaluating the transition method that will be elected.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">In December 2013, the FASB
issued ASU No. 2013-12, <I>Definition of a Public Business Entity</I>. The purpose of this standard is to clarify which nonpublic
entities potentially qualify for alternative financial accounting and reporting guidance by defining &ldquo;public business entity&rdquo;
for future use in U.S. GAAP. Currently, FASB Accounting Standards Codification (&ldquo;ASC&rdquo;) includes multiple definitions
of &ldquo;public entity&rdquo;. This standard provides a single definition of &ldquo;public business entity&rdquo; for use in future
financial accounting and reporting guidance but does not affect existing requirements. There is no effective date for this standard
but the definition will start to be used in ASU&rsquo;s as FASB feels is appropriate. The standard defines &ldquo;public business
entity&rdquo; as a business entity that meets any one of a number of criteria, one of which is the requirement to file financial
statements with the SEC. We have reviewed the definition and have determined that we will be defined as a &ldquo;public business
entity&rdquo; and there will be no impact on the Company&rsquo;s financial position, results of operations or cash flows.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">In July 2013, the FASB issued
ASU 2013-11,<I> Presentation of an Unrecognized Tax Benefit (UTB) When a Net Operating Loss (NOL) Carryforward, a Similar Tax Loss,
or a Tax Credit Carryforward Exists, </I>which requires a reporting entity to present an unrecognized tax benefit as a liability
in the financial statements separate from deferred tax assets if a net operating loss carryforward, a similar tax loss, or a tax
credit carryforward is not available as of the reporting date to settle taxes that would result from the disallowance of the tax
position or if a reporting entity does not intend to use the deferred tax asset for such purpose. The amendments in ASU 2013-11
are effective for fiscal years, and interim periods within those years, beginning on or after December 15, 2013. The adoption of
ASU 2013-11 did not have a material impact on our financial position, results of operations or cash flows.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0pt; margin-bottom: 9pt; text-align: center">63</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0pt; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 70 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify"></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">In March 2013, the FASB issued
ASU 2013-04, <I>Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation
is Fixed at the Reporting Date</I>, which provides guidance on the recognition, measurement, and disclosure of obligations resulting
from joint and several liability arrangements for which the total amount of the obligation is fixed at the reporting date. The
update requires an entity to measure obligations resulting from joint and several liability obligations for which the total amount
of the obligation within the scope of the update is fixed at the reporting date, as the sum of the amount the reporting entity
agreed to pay on the basis of its arrangements among its co-obligors and any additional amount the reporting entity expects to
pay on behalf of its co-obligors. The update also requires an entity to disclose the nature and amount of the obligation as well
as other information about those obligations. The amendments in ASU 2013-04 are effective for fiscal years, and interim periods
within those years, beginning on or after December 15, 2013 and must be applied retrospectively. The adoption of ASU 2013-04 in
the first quarter of 2014 did not have a material impact on our financial position, results of operations or cash flows.</P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in">NOTE 3. FAIR VALUE
OF FINANCIAL INSTRUMENTS</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">The following tables represent
the financial instruments measured at fair value on a recurring basis on the financial statements of the Company and the valuation
approach applied to each class of financial instruments at December 31, 2014 and 2013 (see Note 2, Summary of Significant Accounting
Policies for further information):</P>




<P STYLE="margin: 0">&nbsp;</P>


<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; font-style: normal; text-align: justify; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="15" STYLE="border-bottom: Black 1pt solid; text-align: center; vertical-align: top; font: 10pt Arial, Helvetica, Sans-Serif"><P STYLE="margin-top: 0; margin-bottom: 0"><B>December
                                         31, 2014</B></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">(in
                                         thousands)</P></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; font-style: normal; text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Quoted Prices <BR>in Active <BR>Markets for <BR>Identical <BR>Assets <BR>(Level 1)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">Significant <BR>Other <BR>Observable Inputs <BR>(Level 2)</P></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Significant <BR>Unobservable <BR>Inputs <BR>(Level 3)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; font-style: normal; text-align: justify; text-indent: 0in">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic">&nbsp;</TD>
    <TD STYLE="font-weight: bold; font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic">&nbsp;</TD>
    <TD STYLE="font-weight: bold; font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic">&nbsp;</TD>
    <TD STYLE="font-weight: bold; font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic">&nbsp;</TD>
    <TD STYLE="font-weight: bold; font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; font-style: normal; text-align: justify; text-indent: 0in">Assets:</TD><TD STYLE="font-weight: bold; font-style: italic">&nbsp;</TD>
    <TD STYLE="font-weight: bold; font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic">&nbsp;</TD>
    <TD STYLE="font-weight: bold; font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic">&nbsp;</TD>
    <TD STYLE="font-weight: bold; font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic">&nbsp;</TD>
    <TD STYLE="font-weight: bold; font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 40%; font-weight: normal; font-style: normal; text-align: left; text-indent: 0in">Money market funds (cash equivalents)</TD><TD STYLE="width: 3%; font-weight: normal; font-style: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left">$</TD><TD STYLE="width: 10%; font-weight: normal; font-style: normal; text-align: right">13,127</TD><TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 3%; font-weight: normal; font-style: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left">$</TD><TD STYLE="width: 10%; font-weight: normal; font-style: normal; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 3%; font-weight: normal; font-style: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: right; vertical-align: top">$</TD><TD STYLE="width: 10%; font-weight: normal; font-style: normal; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 3%; font-weight: normal; font-style: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left">$</TD><TD STYLE="width: 10%; font-weight: normal; font-style: normal; text-align: right">13,127</TD><TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; text-indent: 0in">Corporate notes and bonds</TD><TD STYLE="font-weight: normal; font-style: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right">12,974</TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right">12,974</TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 1pt; text-indent: 0in">Asset-backed securities</TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-align: right">141</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-align: right">141</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 2.5pt; text-indent: 0in">Total assets measured at fair value</TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-align: right">13,127</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-align: right">13,115</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-align: right; vertical-align: top">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-align: right">26,242</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; font-style: italic; text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="15" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: italic bold 10pt/normal Arial,sans-serif; margin: 0; text-align: center; text-indent: 0in"><font style="font-style: normal">December 31, 2013</font></P> <P STYLE="font: italic 10pt/normal Arial,sans-serif; margin: 0; text-align: center; text-indent: 0in"><font style="font-weight: normal; font-style: normal">(in thousands)</font></P></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; font-style: italic; text-align: justify; text-indent: 0in; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"></TD>
    <TD STYLE="font-size: 9pt; font-weight: bold; text-align: left; padding-bottom: 1pt"></TD><TD STYLE="font-size: 9pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; vertical-align: bottom"><B><BR></B><P STYLE="font: bold 9pt/normal Arial,sans-serif; margin-top: 0; margin-bottom: 0; text-align: center"><B></B></P>
                                                                                                                                                                                               <P STYLE="font: bold 9pt/normal Arial,sans-serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>
                                                                                                                                                                                               <P STYLE="font: bold 9pt/normal Arial,sans-serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-style: normal"></FONT></P>
                                                                                                                                          <P STYLE="font: italic bold 9pt/normal Arial,sans-serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-style: normal"></FONT></P> <P STYLE="font: italic bold 9pt/normal Arial,sans-serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-style: normal">
                                         </FONT></P>Quoted Prices <BR>in Active <BR>Markets for <BR>Identical <BR>Assets <BR>(Level 1) &nbsp;</TD><TD STYLE="font-size: 9pt; font-weight: bold; text-align: left; padding-bottom: 1pt"></TD><TD STYLE="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"></TD>
    <TD STYLE="font-size: 9pt; font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 9pt; font-weight: bold; text-align: right; border-bottom: Black 1pt solid"><P STYLE="font: italic bold 9pt/normal Arial,sans-serif; margin: 0; text-align: center; text-indent: 0in"><font style="font-style: normal">Significant Other Observable Inputs </font></P> <P STYLE="font: italic bold 9pt/normal Arial,sans-serif; margin: 0; text-align: center; text-indent: 0in"><font style="font-style: normal; text-underline-style: double">(Level 2)</font></P></TD><TD STYLE="font-size: 9pt; font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 9pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 9pt; font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 9pt; font-weight: bold; text-align: right; border-bottom: Black 1pt solid"><P STYLE="font: italic bold 9pt/normal Arial,sans-serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-style: normal">Significant Unobservable Inputs </font></P> <P STYLE="font: italic bold 9pt/normal Arial,sans-serif; margin: 0; text-align: center; text-indent: 0in"><font style="font-style: normal; text-underline-style: double">(Level 3)</font></P></TD><TD STYLE="font-size: 9pt; font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 9pt; font-weight: bold; font-style: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 9pt; font-weight: bold; font-style: normal; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 9pt; font-weight: bold; font-style: normal; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 9pt; font-style: normal; text-underline-style: double">Total</font></TD><TD STYLE="font-size: 9pt; font-weight: bold; font-style: normal; text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; font-style: normal; text-align: justify; text-indent: 0in">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic">&nbsp;</TD>
    <TD STYLE="font-weight: bold; font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic">&nbsp;</TD>
    <TD STYLE="font-weight: bold; font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic">&nbsp;</TD>
    <TD STYLE="font-weight: bold; font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic">&nbsp;</TD>
    <TD STYLE="font-weight: bold; font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; font-style: normal; text-align: justify; text-indent: 0in">Assets:</TD><TD STYLE="font-weight: bold; font-style: italic">&nbsp;</TD>
    <TD STYLE="font-weight: bold; font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic">&nbsp;</TD>
    <TD STYLE="font-weight: bold; font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic">&nbsp;</TD>
    <TD STYLE="font-weight: bold; font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic">&nbsp;</TD>
    <TD STYLE="font-weight: bold; font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 40%; font-weight: normal; font-style: normal; text-align: left; text-indent: 0in">Money market funds (cash equivalents)</TD><TD STYLE="width: 3%; font-weight: normal; font-style: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left">$</TD><TD STYLE="width: 10%; font-weight: normal; font-style: normal; text-align: right">27,096</TD><TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 3%; font-weight: normal; font-style: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left">$</TD><TD STYLE="width: 10%; font-weight: normal; font-style: normal; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 3%; font-weight: normal; font-style: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left">$</TD><TD STYLE="width: 10%; font-weight: normal; font-style: normal; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 3%; font-weight: normal; font-style: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left">$</TD><TD STYLE="width: 10%; font-weight: normal; font-style: normal; text-align: right">27,096</TD><TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; text-indent: 0in">Corporate notes and bonds</TD><TD STYLE="font-weight: normal; font-style: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right">11,460</TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic">&nbsp;</TD>
    <TD STYLE="font-weight: bold; font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; text-align: right">&mdash; &nbsp; </TD><TD STYLE="font-weight: bold; font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right">11,460</TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 1pt; text-indent: 0in">Asset-backed securities</TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-align: right">500</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-align: right">&mdash; &nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-align: right">500</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 2.5pt; text-indent: 0in">Total assets measured at fair value</TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-align: right">27,096</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-align: right">11,960</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-align: right">39,056</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-right: 0; margin-bottom: 9pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-bottom: 9pt; text-align: center">64</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-right: 0; margin-bottom: 9pt; margin-left: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 71 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-right: 0; margin-bottom: 9pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-right: 0; margin-bottom: 9pt; margin-left: 0; text-align: justify; text-indent: 0.5in">Level 1 assets are priced
using quoted prices in active markets for identical assets which include cash accounts and money market funds as these specific
assets are liquid.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-right: 0; margin-bottom: 9pt; margin-left: 0; text-align: justify; text-indent: 0.5in">Level 2 available-for-sale
securities are priced using quoted market prices for similar instruments or nonbinding market prices that are corroborated by observable
market data. The Company uses inputs such as actual trade data, benchmark yields, broker/dealer quotes, and other similar data,
which are obtained from quoted market prices, independent pricing vendors, or other sources, to determine the ultimate fair value
of these assets and liabilities. The Company uses such pricing data as the primary input to make its assessments and determinations
as to the ultimate valuation of its investment portfolio and has not made, during the periods presented, any material adjustments
to such inputs. There were no transfers between levels during the year ended December 31, 2014.</P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin-right: 0; margin-bottom: 9pt; margin-left: 0; text-align: justify; text-indent: 0in">NOTE 4. INVESTMENTS</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-right: 0; margin-bottom: 9pt; margin-left: 0; text-align: justify; text-indent: 0.5in">The following tables summarize
the Company&rsquo;s available-for-sale investments at December 31, 2014 and 2013 (in thousands):</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="17" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center"><P STYLE="font: italic bold 9pt/normal Arial,sans-serif; margin: 0; text-align: center; text-indent: 0in"><font style="font-style: normal">AVAILABLE-FOR-SALE INVESTMENTS</font></P> <P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0; text-align: center; text-indent: 0in">December 31, 2014</P> <P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0; text-align: center; text-indent: 0in">(in thousands)</P></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: normal; font-style: normal; text-align: justify; text-indent: 0in; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"><B>Amortized</B></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><B>Cost</B></P></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 1pt"><B>&nbsp;</B></TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 1pt"><B>&nbsp;</B></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: center; vertical-align: top; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"><B>Gross</B></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><B>Unrealized</B></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><B>Gains</B></P></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: center; vertical-align: top; padding-bottom: 1pt"><B>&nbsp;</B></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: center; vertical-align: top; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: center; vertical-align: top; padding-bottom: 1pt"><B>&nbsp;</B></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: center; vertical-align: top; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"><B>Gross<BR></B></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><B>Unrealized<BR>
                                         Losses</B></P></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: center; vertical-align: top; padding-bottom: 1pt"><B>&nbsp;</B></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: center; vertical-align: top; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: center; vertical-align: top; padding-bottom: 1pt"><B>&nbsp;</B></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"><B>Fair
                                         Value</B></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: center; vertical-align: top; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: normal; font-style: normal; text-align: justify; text-indent: 0in">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 30%; font-weight: normal; font-style: normal; text-align: justify; text-indent: 0in">Asset-backed securities</TD><TD STYLE="width: 3%; font-weight: normal; font-style: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left">$</TD><TD STYLE="width: 10%; font-weight: normal; font-style: normal; text-align: right">141</TD><TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 3%; font-weight: normal; font-style: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left">$</TD><TD STYLE="width: 10%; font-weight: normal; font-style: normal; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 3%; font-weight: normal; font-style: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left">$</TD><TD STYLE="width: 10%; font-weight: normal; font-style: normal; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 3%; font-weight: normal; font-style: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left">$</TD><TD STYLE="width: 10%; font-weight: normal; font-style: normal; text-align: right">141</TD><TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 1pt; text-indent: 0in">Corporate notes and bonds</TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-align: right">12,967</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-align: right">10</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-align: right">(3</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; font-style: normal; text-align: left">)</TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-align: right">12,974</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 2.5pt; text-indent: 0in">Total</TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-align: right">13,108</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-align: right">10</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-align: right">(3</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: normal; font-style: normal; text-align: left">)</TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-align: right">13,115</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="17" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center"><P STYLE="font: italic bold 9pt/normal Arial,sans-serif; margin: 0; text-align: center; text-indent: 0in"><font style="font-style: normal">AVAILABLE-FOR-SALE INVESTMENTS</font></P> <P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0; text-align: center; text-indent: 0in">December 31, 2013</P> <P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0; text-align: center; text-indent: 0in">(in thousands)</P></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; font-style: italic; text-align: justify; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 9pt; font-weight: bold; font-style: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 9pt; font-weight: bold; font-style: normal; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 9pt; font-style: normal">Amortized <font style="text-underline-style: double">Cost</font></font></TD><TD STYLE="font-size: 9pt; font-weight: bold; font-style: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 9pt; font-weight: bold; font-style: normal; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 9pt; font-style: normal">Gross<BR>Unrealized<BR>Gains</font></TD><TD STYLE="font-size: 9pt; font-weight: bold; font-style: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 9pt; font-weight: bold; font-style: normal; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 9pt; font-style: normal">Gross<BR> Unrealized<BR> Losses</font></TD><TD STYLE="font-size: 9pt; font-weight: bold; font-style: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 9pt; font-weight: bold; font-style: normal; text-align: center; border-bottom: Black 1pt solid">Fair Value</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: normal; font-style: normal; text-align: justify; text-indent: 0in">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 30%; font-weight: normal; font-style: normal; text-align: justify; text-indent: 0in">Asset-backed securities</TD><TD STYLE="width: 3%; font-weight: normal; font-style: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left">$</TD><TD STYLE="width: 10%; font-weight: normal; font-style: normal; text-align: right">500</TD><TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 3%; font-weight: normal; font-style: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left">$</TD><TD STYLE="width: 10%; font-weight: normal; font-style: normal; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 3%; font-weight: normal; font-style: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left">$</TD><TD STYLE="width: 10%; font-weight: normal; font-style: normal; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 3%; font-weight: normal; font-style: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left">$</TD><TD STYLE="width: 10%; font-weight: normal; font-style: normal; text-align: right">500</TD><TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 1pt; text-indent: 0in">Corporate notes and bonds</TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-align: right">11,438</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-align: right">23</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-align: right">(1</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; font-style: normal; text-align: left">)</TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-align: right">11,460</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 2.5pt; text-indent: 0in">Total</TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-align: right">11,938</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-align: right">23</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-align: right">(1</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: normal; font-style: normal; text-align: left">)</TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-align: right">11,960</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">The following table summarizes
the maturities of the Company&rsquo;s available-for-sale securities at December 31, 2014 and 2013 (in thousands):</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="17" STYLE="text-align: center"><P STYLE="font: italic bold 9pt/normal Arial,sans-serif; margin: 0; text-align: center; text-indent: 0in"><font style="font-style: normal">AVAILABLE-FOR-SALE INVESTMENT MATURITIES</font></P> <P STYLE="font: italic 10pt/normal Arial,sans-serif; margin: 0; text-align: center; text-indent: 0.5in"><font style="font-weight: normal; font-style: normal">(in thousands)</font></P></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; font-style: italic; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 9pt; font-weight: bold; font-style: normal">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-size: 9pt; font-weight: bold; font-style: normal; text-align: center">At December 31, 2014</TD><TD STYLE="font-size: 9pt; font-weight: bold; font-style: normal">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-size: 9pt; font-weight: bold; font-style: normal; text-align: center">At December 31, 2013</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; font-style: italic; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 9pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 9pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: italic bold 9pt/normal Arial,sans-serif; margin: 0; text-align: center; text-indent: 0in"><font style="font-style: normal">Amortized </font></P> <P STYLE="font: italic bold 9pt/normal Arial,sans-serif; margin: 0; text-align: center; text-indent: 0in"><font style="font-style: normal">Cost</font></P></TD><TD STYLE="font-size: 9pt; font-weight: bold; font-style: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 9pt; font-weight: bold; font-style: normal; text-align: center; border-bottom: Black 1pt solid">Fair Value</TD><TD STYLE="font-size: 9pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 9pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: italic bold 9pt/normal Arial,sans-serif; margin: 0; text-align: center; text-indent: 0in"><font style="font-style: normal">Amortized </font></P> <P STYLE="font: italic bold 9pt/normal Arial,sans-serif; margin: 0; text-align: center; text-indent: 0in"><font style="font-style: normal">Cost</font></P></TD><TD STYLE="font-size: 9pt; font-weight: bold; font-style: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 9pt; font-weight: bold; font-style: normal; text-align: center; border-bottom: Black 1pt solid">Fair Value</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: normal; font-style: normal; text-align: justify; text-indent: 0in">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 30%; font-weight: normal; font-style: normal; text-align: justify; text-indent: 0in">Due in less than 1 year</TD><TD STYLE="width: 3%; font-weight: normal; font-style: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left">$</TD><TD STYLE="width: 10%; font-weight: normal; font-style: normal; text-align: right">10,586</TD><TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 3%; font-weight: normal; font-style: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left">$</TD><TD STYLE="width: 10%; font-weight: normal; font-style: normal; text-align: right">10,585</TD><TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 3%; font-weight: normal; font-style: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left">$</TD><TD STYLE="width: 10%; font-weight: normal; font-style: normal; text-align: right">4,999</TD><TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 3%; font-weight: normal; font-style: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left">$</TD><TD STYLE="width: 10%; font-weight: normal; font-style: normal; text-align: right">5,002</TD><TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 1pt; text-indent: 0in">Due in 1-3 years</TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-align: right">2,522</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-align: right">2,530</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-align: right">6,939</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-align: right">6,958</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 2.5pt; text-indent: 0in">Total</TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-align: right">13,108</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-align: right">13,115</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-align: right">11,938</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-align: right">11,960</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">For the year ended December
31, 2014, $861,000 in proceeds from sales of marketable securities (including principle paydowns) were collected while no proceeds
were received for the year ended December 31, 2013. The Company determines gains and losses of marketable securities based on specific
identification of the securities sold. There were no gross realized gains and losses from sales of marketable securities for the
years ended December 31, 2013 and 2014.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center">65</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 72 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">No other-than-temporary impairments
are recorded as no investments had a fair value that remained less than its cost for more than twelve months as of December 31,
2014 and 2013. The Company does not intend to sell investments and it is more likely than not that we will not be required to sell
investments before recovering the amortized cost. <FONT STYLE="line-height: 115%"> </FONT></P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 10pt 0 9pt; text-align: justify; text-indent: 0in">NOTE 5. PROPERTY AND
EQUIPMENT</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Property and equipment are
recorded at cost and consisted of the following at December 31, 2014 and 2013 (in thousands).</P>


<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 84%; font: 10pt Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="text-align: center; text-indent: 0in; padding-left: 5.4pt; vertical-align: top"><B>PROPERTY AND EQUIPMENT</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="text-align: center; text-indent: 0in; padding-left: 5.4pt; vertical-align: top">(in thousands)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; text-indent: 0in; padding-left: 5.4pt; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: top; border-bottom: Black 1pt solid"><B>12/31/2014</B></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt"><B>&nbsp;</B></TD><TD STYLE="text-align: center; vertical-align: top; border-bottom: Black 1pt solid"><B>12/31/2013</B></TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; text-indent: 0in; padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: 0in; padding-left: 5.4pt; width: 40%">Computer equipment</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">$</TD><TD STYLE="text-align: right; width: 12%">1,020</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">$</TD><TD STYLE="text-align: right; width: 12%">567</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: 0in; padding-left: 5.4pt">Laboratory and scientific equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,435</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">791</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: 0in; padding-left: 5.4pt">Furniture and fixtures</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">212</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: 0in; padding-left: 5.4pt">Leasehold improvements</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">630</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">279</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: 0in; padding-left: 5.4pt">Manufacturing equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">190</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 5.4pt">Capital lease &ndash; leasehold improvements</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">266</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0in; padding-left: 5.4pt">Capital projects in progress</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">227</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: 0in; padding-left: 5.4pt">Total property and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,980</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,674</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: 0in; padding-left: 5.4pt">Accumulated amortization &ndash; capital lease</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(133</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1pt; text-indent: 0in; padding-left: 5.4pt">Accumulated depreciation - other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,311</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(627</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt; text-indent: 0in; padding-left: 5.4pt">Net property and equipment</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,536</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,047</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Depreciation expense (which
includes amortization of capital lease assets) for the for the years ended December 31, 2014 and 2013, five months ended December
31, 2012 and 2011, and twelve months ended July 31, 2012 was $817,000, $286,000, $5,000, $1,000, and $2,000, respectively.</P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 10pt 0 9pt; text-align: justify; text-indent: 0in">NOTE 6. LICENSE AGREEMENTS
AND GRANTS</P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; text-align: justify; text-indent: 0in; margin-right: 0; margin-bottom: 9pt; margin-left: 0"><B><I>Schott
Janaer Glas GmbH</I></B></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">The Company signed a licensing
agreement for microarraying slides using OptiChem coatings with Schott Jenaer Glas GmbH (&ldquo;SCHOTT&rdquo;) in November 2004.
Since this time, SCHOTT and the Company have extended this license. In August 2011, SCHOTT renewed and expanded its licenses for
OptiChem microarray slide products, designated as Schott Nexterion Slide H and Slide HS. The terms remain substantially the same
as in previous agreements, with the expansion to include microarray slide products intended for use in medical diagnostic devices.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&#9;The August 2011, agreement
extended the non-exclusive license through November 2014. SCHOTT paid the Company $150,000 comprised of a one-time license fee
($50,000) and non-refundable prepaid royalties ($100,000). Royalties consist of 5% of SCHOTT&rsquo;s net product sales. The prepaid
royalty was recognized as deferred revenue, and was recognized as SCHOTT&rsquo;s net product sales were reported to the Company.
Upon expiration of the amendment in 2014, the remaining royalty fees totaling $60,000 were recognized as revenue.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">In November 2014 the agreement
was amended and extended with an expiration date that coincides with the expiration of the underlying patents. The terms remain
substantially the same with royalties continuing to be 5% of SCHOTT&rsquo;s net product sales. SCHOTT is not required to pay a
one-time license fee or non-refundable prepaid royalty as part of the new agreement. Revenue will be recognized as SCHOTT&rsquo;s
net product sales are reported to the Company.</P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in"><B><I>NanoString
Technologies</I></B></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">In October 2007, the Company
entered into an exclusive seven-year license with NanoString Technologies, Inc. (&ldquo;NanoString&rdquo;). The license grants
NanoString the right to apply OptiChem coatings to NanoString&rsquo;s proprietary molecular detection products.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0pt; margin-bottom: 9pt; text-align: center">66</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0pt; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<!-- Field: Page; Sequence: 73 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in"><B><I>Nanosphere,
Inc.</I></B></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">In July 2010, the Company
entered into a non-exclusive license to Nanosphere, Inc. (&ldquo;Nanosphere&rdquo;). The license grants to Nanosphere the right
to apply OptiChem coatings to Nanosphere&rsquo;s proprietary analytical products. The products may also include FDA-regulated diagnostics
devices. Pursuant to the license agreement, Nanosphere paid the Company a non-refundable first-year fee of $150,000 plus a $15,000
technology transfer fee. On each anniversary of the agreement date, the license called for Nanosphere to pay to the Company the
amounts of $350,000 in 2011; $600,000 in 2012, and $750,000 in 2013 in order to complete the payments for rights under the remaining
patent life. The final installment of this arrangement for $750,000 was received in full in July 2013. A<FONT STYLE="line-height: 115%">ll
of the amounts due from </FONT>Nanosphere were recognized as revenue during the fiscal year ended July 31, 2010.</P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in"><B><I>Defense
Medical Research and Development Program</I></B></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">In May 2012, the Company
and Denver Health were notified that the Defense Medical Research and Development Program (&ldquo;DMRDP&rdquo;) recommended $2.0
million of funding for a proposed 35-month project of which the Company estimates it will receive direct monies for internal research
and development of $650,000. The joint proposal became the sole recipient under the Military Infectious Diseases Applied Research
Award program for rapid detection of serious antibiotic-resistant infections. &nbsp;The project will apply the Accelerate ID/AST
system to wound infections and other serious infections secondary to trauma. The Company has invoiced a cumulative total of $379,000
under this grant which is recorded as an offset to research and development expenses. The amount invoiced for the years ended December
31, 2014 and 2013, five months ended December 31, 2012 and 2011, and twelve months ended July 31, 2012 amounting to $221,000, $143,000,
$15,000, $0, and $0, respectively.</P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in"><B><I>Arizona
Commerce Authority</I></B></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">In August 2012, the Company
entered into a Grant Agreement (the &ldquo;Grant Agreement&rdquo;) with the Arizona Commerce Authority, an agency of the State
of Arizona (the &ldquo;Authority&rdquo;), pursuant to which the Authority provided certain state and county sponsored incentives
for the Company to relocate its corporate headquarters to, and expand its business within, the State of Arizona (the &ldquo;Project&rdquo;).
Pursuant to the Grant Agreement, the Authority agreed to provide a total grant in the amount of $1,000,000 (the &ldquo;Grant&rdquo;)
for the use by the Company in the advancement of the Project. The Grant is payable out of an escrow account in four installments,
upon the achievement of the following milestones:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt/115% Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif">Milestone 1 &ndash; Relocation of Company&rsquo;s operations
and corporate headquarters to Arizona and creation of 15 Qualified Jobs (as defined below).</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt/115% Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif">Milestone 2 &ndash; Creation of 30 Qualified Jobs (including
Qualified Jobs under Milestone 1).</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt/115% Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif">Milestone 3 &ndash; Creation of 40 Qualified Jobs (including
Qualified Jobs under Milestones 1 and 2).</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt/115% Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif">Milestone 4 &ndash; Creation of 65 Qualified Jobs (including
Qualified Jobs under Milestones 1, 2 and 3) and capital investment of at least $4,520,000.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">For purposes of the Grant
Agreement, a &ldquo;Qualified Job&rdquo; is a job that is permanent, full-time, new to Arizona, and for which the Company pays
average (across all Qualified Jobs identified by the Company in its discretion) annual wages of at least $63,000 and offers health
insurance benefits and pays at least 65% of the premiums associated with such benefits. The amount of each installment payment
will be determined in accordance with a formula specified in the Grant Agreement. The Grant Agreement also contains other customary
provisions, including representations, warranties and covenants of both parties. As of December 31, 2014, the Company has collected
all of the $1,000,000 in milestones. The full amount is recorded in long-term deferred income until the economic development provisions
of the grant have been satisfied in full, as there are &ldquo;claw-back&rdquo; provisions which would require repayment of certain
amounts received if employment levels are not sustained during the term of the arrangement. Once the &ldquo;claw-back&rdquo; provisions
expire in January 2018, we will recognize the grant as other non-operating income. Further details are included in Note 7, Deferred
Revenue and Income.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0pt; margin-bottom: 9pt; text-align: center">67</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0pt; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 74 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify"></P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in">NOTE 7. DEFERRED REVENUE
AND INCOME</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">Deferred revenue consists
of amounts received for products or services not yet delivered or earned. Deferred income consists of amounts received for commitments
not yet fulfilled. If we anticipate that the revenue or income will not be earned within the following twelve months, the amount
is reported as long-term deferred income. A summary of the balances as of December 31, 2014 and 2013 follows (in thousands):</P>


<P STYLE="margin: 0">&nbsp;</P><TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 84%">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font-family: Arial,sans-serif; text-align: center; text-indent: 0in; padding-left: 5.4pt; vertical-align: top"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>Deferred
    Revenue and Income</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font-family: Arial,sans-serif; text-align: center; text-indent: 0in; padding-left: 5.4pt; vertical-align: top"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(in thousands)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Arial,sans-serif; text-align: left; text-indent: 0in; padding-left: 5.4pt; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: center; vertical-align: top; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">12/31/2014</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: center; vertical-align: top; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">12/31/2013</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Arial,sans-serif; text-align: left; text-indent: 0in; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="font-family: Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Arial,sans-serif; text-align: right">&nbsp;</TD><TD STYLE="font-family: Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Arial,sans-serif">&nbsp;</TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Arial,sans-serif; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; font-family: Arial,sans-serif; text-align: left; text-indent: 0in; padding-left: 5.4pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Prepaid
    royalties</FONT></TD><TD STYLE="width: 8%; font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">$</FONT></TD><TD STYLE="width: 12%; font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">0</FONT></TD><TD STYLE="width: 1%; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="width: 8%; font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">$</FONT></TD><TD STYLE="width: 12%; font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">69</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Arial,sans-serif; text-align: left; padding-bottom: 1pt; text-indent: 0in; padding-left: 5.4pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Fisher
    agreement</FONT></TD><TD STYLE="font-family: Arial,sans-serif; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">13</FONT></TD><TD STYLE="padding-bottom: 1pt; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">13</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Arial,sans-serif; text-align: left; padding-bottom: 2.5pt; text-indent: 0in; padding-left: 5.4pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Total
    current deferred revenue and income</FONT></TD><TD STYLE="font-family: Arial,sans-serif; padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">13</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">82</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Arial,sans-serif; text-indent: 0in; padding-left: 5.4pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Arial,sans-serif; text-align: left; text-indent: 0in; padding-left: 5.4pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Arizona
    Commerce Authority grant</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">$</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">1,000</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">$</FONT></TD><TD STYLE="font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">750</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Arial,sans-serif; text-align: left; padding-bottom: 1pt; text-indent: 0in; padding-left: 5.4pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Fisher
    agreement</FONT></TD><TD STYLE="font-family: Arial,sans-serif; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">14</FONT></TD><TD STYLE="padding-bottom: 1pt; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">27</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Arial,sans-serif; text-align: left; padding-bottom: 2.5pt; text-indent: 0in; padding-left: 5.4pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Total
    long-term deferred income</FONT></TD><TD STYLE="font-family: Arial,sans-serif; padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">1,014</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Arial,sans-serif; padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Arial,sans-serif; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Arial,sans-serif; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">777</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Deferred revenue recognized
was approximately $69,000, $10,000, $7,000, $5,000, and $24,000 during the years ended December 31, 2014 and 2013, five-month periods
ended December 31, 2012 and 2011, and the fiscal year ended July 31, 2012, respectively. Deferred revenue consists of prepaid royalty
fees from Nanostring and SCHOTT. During the year ended July 31, 2012 an additional $100,000 was received from SCHOTT as prepaid
royalties of which $69,000, $4,000, $7,000, $0, and $20,000 was recognized during the years ended December 31, 2014 and 2013, five-month
period ended December 31, 2012 and 2011, and the fiscal year ended July 31, 2012, respectively and are reflected as licensing and
royalty revenues. Further information regarding the SCHOTT agreement is included in Note 6, License Agreements and Grants.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Deferred income includes
a $40,000 payment received from Fisher Scientific in July 2013, of which $13,000 has been recognized as an offset against research
and development expenses in the year ended December 31, 2014. We anticipate earning $13,000 of the remaining amount in the next
twelve months and the final $14,000 in future years.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Through December 31, 2014,
$1,000,000 in milestone payments from the Arizona Commerce Authority were received of which none has been recognized in income
and we do not anticipate earning any of it in the next fiscal year. Further details regarding the Arizona Commerce Authority agreement
are included in Note 6, License Agreements and Grants.</P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: left; text-indent: 0in">NOTE
8. STOCK PURCHASE</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&#9;In April 2012, we entered
into a Securities Purchase Agreement with Abeja Ventures, LLC (&ldquo;Abeja&rdquo;), pursuant to which the Company agreed to sell
and issue to Abeja at a purchase price of $1.03 per share for an aggregate purchase price of $14,420,000; (i) 14,000,000 shares
of the Company&rsquo;s common stock (&ldquo;Common Stock&rdquo;); (ii) a warrant to purchase 7,000,000 shares of Common Stock at
an exercise price of $1.03 per share (the &ldquo;$1.03 Warrant&rdquo;); and (iii) another warrant to purchase 7,000,000 shares
of Common Stock at an exercise price of $2.00 per share (the &ldquo;$2.00 Warrant&rdquo;), with each warrant exercisable prior
to the fifth anniversary of the closing of the transactions contemplated by the Securities Purchase Agreement (collectively, the
&ldquo;Investment&rdquo;). The purchase of Common Stock and warrants pursuant to the Investment, which was consummated in June,
2012, qualified for equity treatment under U.S. GAAP. The respective values of the warrants and Common Stock were calculated using
their relative fair values and both are classified under Contributed Capital. The value therefore recorded for the warrants was
$5,896,000 and for the Common Stock was $8,524,000.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center">68</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 75 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Both warrants were exercisable
until June 26, 2017, which was the fifth anniversary of the date on which the warrants were issued. Other significant terms and
conditions of the warrants are as follows:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt/115% Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif">the warrants provide for partial exercises, but they
do not provide for a &ldquo;cashless&rdquo; exercise feature (i.e., they may only be exercised for cash);</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt/115% Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif">the warrants do not contain anti-dilution provisions
that would trigger exercise price or other adjustments as a result of subsequent issuances of the Company&rsquo;s equity securities,
but they do contain customary provisions for equitable adjustments in connection with stock dividends, stock splits or reclassifications
of Common Stock;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt/115% Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif">following certain types of fundamental transactions involving
the Company (e.g., a transaction resulting in a change in control of the Company), the holder of the warrants would continue to
be entitled to exercise the warrants in exchange for the equity securities or alternate consideration receivable by a holder of
Common Stock as a result of the fundamental transaction; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt/115% Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif">the holder of the warrants is entitled to certain demand
and piggy-back registration rights, including for shelf registrations, with respect to the shares of Common Stock issuable upon
its exercise of the warrants.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&#9;In March 2013, Abeja
exercised in full its warrant to purchase 7,000,000 shares of Common Stock at an exercise price of $1.03 per share. On the same
date, Abeja also exercised the 92% of its warrant to purchase an additional 7,000,000 shares of Common Stock at an exercise price
of $2.00 per share (Abeja exercised such warrant for 6,428,840 shares, leaving 571,160 shares unexercised). The Company received
aggregate funds of $20,068,000 in connection with such exercises. Shares issued by the Company in connection with the warrant exercises
were issued directly to the members of Abeja on a pro rata basis in accordance with their membership interests and written exercise
instructions provided to the Company by Abeja. Immediately after giving effect to the warrant exercises, Abeja also distributed
in kind to its members (on a pro rata basis in accordance with their membership interests) the remaining shares of Common Stock
held by that entity.</P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 10pt 0 9pt; text-align: justify; text-indent: 0in">NOTE 9. RIGHTS OFFERING</P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; text-align: justify; text-indent: 0in; margin-right: 0; margin-bottom: 9pt; margin-left: 0"><B><I>April
2014 Offering</I></B></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">On April 7, 2014, the Company
commenced a rights offering to raise $45.0 million to fund continued operations, clinical trials, and product commercialization
efforts. Under the terms of the rights offering, the Company distributed, at no charge to the holders of its Common Stock as of
5:00&nbsp;p.m., New York City time, on March 14, 2014, which was established as the record date for the rights offering, 0.063921
non-transferable subscription rights for each share of Common Stock owned on the record date. Each whole subscription right allowed
the holder to subscribe to purchase one share of Common Stock at a subscription price of $16.80 per share which was lower than
the market price of $17.64 per share on the date of the rights offering commencement and the $17.54 per share on the date the rights
offering period expired. In the aggregate, the Company intended to issue 2,678,571 shares of Common Stock in connection with the
rights offering. The purpose of the rights offering was to raise equity capital in a cost-effective manner that gives all of the
Company&rsquo;s existing stockholders the opportunity to participate on a pro rata basis.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">In connection with the rights
offering, the Company received standby commitments from the Jack W. Schuler Living Trust and the Schuler Family Foundation. The
standby purchasers agreed to purchase any and all shares of Common Stock that were not subscribed for by stockholders in connection
with the rights offering. On May 1, 2014, the Company entered into an Assignment and Assumption Agreement with the standby purchasers,
Oracle Institutional Partners, L.P. and Oracle Partners, L.P., pursuant to which each standby purchaser assigned and transferred
its respective rights, responsibilities, liabilities and obligations under the Standby Purchase Agreement to purchase 297,619 shares
of Common Stock not subscribed for by the Company&rsquo;s stockholders in connection with the rights offering to (i) Oracle Institutional
Partners, L.P., with respect to 119,047 shares of such Common Stock, and (ii) Oracle Partners, L.P., with respect to the remaining
178,572 shares of such Common Stock.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center">69</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 76 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">The rights offering period
expired at 5:00 p.m., New York City time, on April 28, 2014, and the transactions contemplated by the rights offering and the Standby
Purchase Agreement described above (including the Company&rsquo;s issuance of an aggregate of 2,678,571 shares of its Common Stock
to the rights offering participants and standby purchasers) were completed on May 19, 2014. The Company received gross proceeds
of $45,000,000 before costs associated with the transactions which totaled $125,000 and are treated as a reduction of contributed
capital in the Stockholders&rsquo; Equity section of the Balance Sheets.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Because the exercise price
of the rights offering of $16.80 was less than the fair value of the Company&rsquo;s shares of Common Stock at the expiration of
the offering, there is a bonus element that is treated similar to a stock dividend. The weighted average shares outstanding, as
well as the basic and diluted loss per share for the year ended December 2013, five-month periods ended December 31, 2012 and 2011,
and fiscal year ended July 31, 2012 have been revised for those effects.</P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in"><B><I>July
2013 Offering</I></B></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">On July 12, 2013, the Company
publicly announced the final terms of a rights offering. Rights offering materials were subsequently distributed to the Company&rsquo;s
stockholders on July 18, 2013, at which time the rights offering period commenced. Pursuant to the terms of the rights offering,
the Company distributed, at no charge to the holders of its Common Stock as of 5:00&nbsp;p.m., New York City time, on July 8, 2013,
which was established as the record date for the rights offering, 0.064038 non-transferable subscription rights for each share
of Common Stock owned on the record date. Each whole subscription right allowed the holder to subscribe to purchase one share of
Common Stock at a subscription price of $8.04 per share. In addition, any holder of subscription rights exercising his, her or
its basic subscription privilege in full was eligible to subscribe to purchase additional shares of Common Stock at the same subscription
price per share, subject to the conditions and limitations described further in the prospectus.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">In connection with the rights
offering, the Company received a standby commitment from Abeja to purchase, at $8.04 per share, any and all shares of Common Stock
that were not subscribed for by stockholders in connection with the rights offering.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">The rights offering period
expired at 5:00 p.m., New York City time, on August 7, 2013, and the transactions contemplated by the rights offering and the Standby
Purchase Agreement described above (including the Company&rsquo;s issuance of an aggregate of 2,487,562 shares of its Common Stock
to the rights offering participants and standby purchaser) were completed on August 8, 2013. The Company received gross proceeds
of $20,000,000 before costs associated with the transactions, which totaled $88,000 and are treated as a reduction of contributed
capital in the Stockholders&rsquo; Equity section of the Balance Sheets.</P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in">NOTE 10. EARNINGS PER
SHARE</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">The financial statements
show basic earnings (loss) per share.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">The Company&rsquo;s net loss
for the periods presented caused the inclusion of all outstanding warrants and options to purchase our Common Stock to be antidilutive.
As of December 31, 2014 and December 31, 2013, there were Common Stock options and warrants exercisable for 6,174,886 (571,160
warrants and 5,603,726 options) and 5,731,246 (571,160 warrants and 5,160,086 options) shares of Common Stock, respectively, which
were not included in diluted loss per share as the effect was antidilutive.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">Weighted average shares outstanding
for the year ended December 2013, five-month periods ended December 31, 2012 and 2011, and fiscal year ended July 31, 2012 have
been revised for the effects of the rights offering (See Note 9, Rights Offering).</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0pt; margin-bottom: 9pt; text-align: center">70</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0pt; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-style: normal"><B>&nbsp;</B></FONT></P>

<!-- Field: Page; Sequence: 77 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify"></P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-style: normal"><B></B></FONT></P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in">NOTE
11. EMPLOYEE and CONSULTANT EQUITY-BASED COMPENSATION</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">The Company has four equity-based
compensation plans, which are discussed below:</P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in"><B><I>Qualified
Stock Option Plan</I></B></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">The Qualified Stock Option
Plan (the &ldquo;Qualified Plan&rdquo;) was a stockholder-approved plan that provided for stock option grants to employees, including
executive officers. The exercise price of each option, which has a maximum ten-year life, was established by the Company's Compensation
Committee on the date of grant.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">As of December 31, 2014,
there were 527,500 options exercised under the Qualified Plan and none that remain outstanding. The Qualified Plan has been replaced
by the 2012 Omnibus Equity Incentive Plan, so no further options are available for grant.</P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in"><B><I>Non-Qualified
Stock Option Plan</I></B></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">The Non-Qualified Stock Option
Plan (the &ldquo;Non-Qualified Plan&rdquo;) was a stockholder-approved plan that provided for stock option grants to independent
contractors, technical advisors and directors of the Company. The exercise price of each option, which has a maximum ten-year life,
was established by the Company's Compensation Committee on the date of grant.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">As of December 31, 2014,
there were 245,000 options exercised under the Non-Qualified Plan and 10,000 that remain outstanding. The Non-Qualified Plan has
been replaced by the 2012 Omnibus Equity Incentive Plan, so no further options are available for grant.</P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in">2004
Omnibus Stock Option Plan</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">In December 2004, the Company&rsquo;s
stockholders approved the Omnibus Stock Option Plan and reserved 500,000 shares of its authorized but unissued Common Stock for
stock options to be granted to employees, independent contractors, technical advisors and directors of the Company. The authorized
shares in this plan were increased by 5,000,000 shares to an aggregate amount of 5,500,000 upon stockholder approval during the
fiscal year ended July 31, 2012.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">As of December 31, 2014,
there were 371,737 options exercised under the 2004 Omnibus Stock Option Plan and 3,568,263 that remain outstanding. The 2004 Omnibus
Stock Option Plan has been replaced by the 2012 Omnibus Equity Incentive Plan, so no further options are available for grant.</P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in">2012
Omnibus Equity Incentive Plan</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">In December 2012, the Company&rsquo;s
stockholders approved the Company&rsquo;s 2012 Omnibus Equity Incentive Plan to replace the Qualified Stock Option Plan, Non-Qualified
Stock Option Plan and 2004 Omnibus Stock Option Plan (&ldquo;Prior Plans&rdquo;). The Prior Plans remain in effect until all awards
granted under those plans have been exercised, forfeited, canceled, expired or otherwise terminated.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">In connection with the approval
of such plan, all stock options, totaling 1,677,500 formerly available for new awards under the Prior Plans were transferred to
the 2012 Omnibus Equity Incentive Plan.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">At the Company&rsquo;s 2014
Annual Meeting of Stockholders held in May 2014, stockholders approved an amendment to the Company&rsquo;s 2012 Omnibus Equity
Incentive Plan increasing the number of stock options of Common Stock reserved and available for grant by 4,000,000 to 5,677,500
shares.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">Stock options granted under
this plan typically vest either (i) one year after grant date, (ii) monthly over a one year period, or (iii) 40% two years after
grant date and the remaining 60% monthly over the next three years. The maximum term is ten years.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">As of December 31, 2014,
there were 3,000 options exercised under the 2012 Omnibus Equity Incentive Plan and 2,025,463 that remain outstanding, leaving
3,649,037<FONT STYLE="line-height: 115%"> </FONT>available for grant.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0pt; margin-bottom: 9pt; text-align: center">71</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0pt; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 78 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify"></P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in">Combined
Plans</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">The following table summarizes
option activity under all plans during the years ending December 31, 2014 and December 31, 2013 and shows the exercisable shares
as of December 31, 2014:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 89%; font: 10pt Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font-weight: bold; text-align: center">Stock Option Activity</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; text-indent: 0in; padding-left: 5.4pt; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif"><P STYLE="margin-top: 0; margin-bottom: 0"><B>Number<BR></B></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><B>of&nbsp;Shares</B></P></TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center; vertical-align: top; border-bottom: Black 1pt solid">Weighted Average Exercise Price per Share</TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify; text-indent: 0in; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 45%; font-weight: bold; text-align: justify; text-indent: 0in; padding-left: 5.4pt">Options outstanding January 1, 2013</TD><TD STYLE="width: 8%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font-weight: bold; text-align: right">4,360,500</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 12%; font-weight: bold; text-align: right">2.14</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: 0in; padding-left: 5.4pt">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,308,086</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.56</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: 0in; padding-left: 5.4pt">Forfeited</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(58,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.47</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: 0in; padding-left: 5.4pt">Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(328,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.54</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1pt; text-indent: 0in; padding-left: 5.4pt">Expired</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(122,500</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1.78</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify; text-indent: 0in; padding-left: 5.4pt">Options Outstanding December 31, 2013</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">5,160,086</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">3.45</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: 0in; padding-left: 5.4pt">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">769,055</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16.22</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: 0in; padding-left: 5.4pt">Forfeited</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(13,678</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13.06</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: 0in; padding-left: 5.4pt">Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(311,737</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.96</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1pt; text-indent: 0in; padding-left: 5.4pt">Expired</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(0</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify; text-indent: 0in; padding-left: 5.4pt">Options Outstanding December 31, 2014</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">5,603,726</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">5.21</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: 0in; padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: 0in; padding-left: 5.4pt">Exercisable December 31, 2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,354,678</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.75</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">The cash received from the
exercise of options during the year ending December 31, 2014 was $923,000 and the tax benefit realized was $0 for the same period.
Upon exercise, shares are issued from shares authorized and held in reserve. The intrinsic value of options exercised was $3,846,000
and $2,583,000 for the years ending December 31, 2014 and 2013, respectively. No options were exercised for the five-months ending
December 31, 2012 and 2011 and fiscal year ending July 31, 2012.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">The total fair value of shares
vesting during the period was $3,786,000, $600,000, and $89,000 for the years ending December 31, 2014 and 2013, and five-months
ending December 31, 2012, respectively.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">As discussed in Note 2, Summary
of Significant Accounting Policies, the Company accounts for all option grants using the Black-Scholes option pricing model in
accordance with ASC 718 for options granted or extended. Note 2 also describes the significant assumptions utilized for estimating
the various inputs required this pricing model. The table below summarizes the resulting weighted average inputs used to calculate
the estimated fair value of options awarded for during the periods shown below:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 96%; font: 10pt Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="17" STYLE="font-weight: bold; text-align: center">Black-Scholes Assumptions for Option Granted</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; text-indent: 0in; padding-left: 5.4pt; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid"><P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0; text-align: center; text-indent: 0in"><b>12 months</b></P> <P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0; text-align: center; text-indent: 0in"><b>12/31/2014</b></P></TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid"><P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0; text-align: center; text-indent: 0in"><b>12 months</b></P> <P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0; text-align: center; text-indent: 0in"><b>12/31/2013</b></P></TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid"><P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0; text-align: center; text-indent: 0in"><b>5 months</b></P> <P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0; text-align: center; text-indent: 0in"><b>12/31/2012</b></P></TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right; border-bottom: Black 1pt solid"><P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0; text-align: center; text-indent: 0in"><b>12 months</b></P> <P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0; text-align: center; text-indent: 0in"><b>7/31/2012</b></P></TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; text-indent: 0in; padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; text-align: justify; text-indent: 0in; padding-left: 5.4pt">Expected term (in years)</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">6.25</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">6.28</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">6.53</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">2.86</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: 0in; padding-left: 5.4pt">Volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">96</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">97</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">98</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">109</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: 0in; padding-left: 5.4pt">Expected dividends</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: 0in; padding-left: 5.4pt">Risk free interest rates</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.9</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.5</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.0</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.5</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: 0in; padding-left: 5.4pt">Estimated forfeitures</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.4</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: 0in; padding-left: 5.4pt">Weighted average fair value</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">12.63</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6.05</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.92</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.65</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">In general, option awards
have a requisite service period and unvested options are forfeited upon employee or consultant termination. The Company estimates
a forfeiture rate which is applied to outstanding options to determine options expected to be forfeited with the remaining outstanding
options being those expected to vest. Further information regarding the forfeiture rate calculation is included in Note 2, Summary
of Significant Accounting Policies. The following table shows summary information for outstanding options, options that are exercisable
(vested) and outstanding options that are either vested or expected to vest as of December 31, 2014:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="13" STYLE="font-weight: bold; text-align: center">Stock Option Supplemental Information</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; text-indent: 0in; padding-left: 5.4pt; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid">Options<BR>Outstanding</TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid">Options<BR>Exercisable</TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center; vertical-align: top; border-bottom: Black 1pt solid">Options Vested and Expected to Vest</TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; text-indent: 0in; padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; text-align: justify; text-indent: 0in; padding-left: 5.4pt">Number of options</TD><TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">5,603,726</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">2,354,678</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">5,595,747</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: 0in; padding-left: 5.4pt">Weighted average remaining contractual term (in years)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.92</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.55</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.92</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: 0in; padding-left: 5.4pt">Weighted average exercise price</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5.21</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5.20</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: 0in; padding-left: 5.4pt">Weighted average fair value</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.01</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.97</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: 0in; padding-left: 5.4pt">Aggregate intrinsic value (in thousands)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">76,494</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">38,056</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">76,423</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center">72</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 79 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">The aggregate intrinsic value
in the table above represents the total pretax intrinsic value that would have been received by the option holders had all option
holders exercised their options on that date. It is calculated as the difference between the Company&rsquo;s closing stock price
of $19.19 on the last trading day of 2014 and the exercise price multiplied by the number of shares for options where the exercise
price is below the closing stock price. This amount changes based on the fair market value of the Company&rsquo;s stock.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">The expense and tax benefits
recognized on Company&rsquo;s Statements of Operations and Comprehensive Loss related to options is summarized below (in thousands):</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="21" STYLE="text-align: center"><B>Equity-Based Compensation Expense and Tax Benefit</B> <BR>(in
    thousands)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">12 months <BR>12/31/2014</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">12 months <BR>12/31/2013</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">5 months <BR>12/31/2012</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">5 months <BR>12/31/2011 <BR>(unaudited)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">12 months <BR>7/31/2012</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; text-align: left; text-indent: 0in; padding-left: 5.4pt">Equity-based compensation expense</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">9,624</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">3,828</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">533</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">273</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">782</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 5.4pt">Recognized tax benefit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">As of December 31, 2014,
unrecognized equity-based compensation cost related to unvested stock options was $8,176,000. This is expected to be recognized
over the years 2015 through 2019.</P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 10pt 0 9pt; text-align: justify; text-indent: 0in">NOTE 12. INCOME TAXES</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">At December 31, 2014, the
provision for income taxes was ($527,000), which resulted in an overall effective tax rate of (1.7%). The tax rate was favorably
affected by refundable state income tax credits which were realized in January of 2014. This compares with a tax provision of
$0 for the tax year ended December 31, 2013, with an effective tax rate of 0.0% for that year.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Deferred income taxes reflect
the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes
and the amounts used for income tax purposes. Significant components of the Company&rsquo;s net deferred income taxes for the years
ending December 31, 2014 and 2013, are as follows (in thousands):</P>


<P STYLE="margin: 0"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P><TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-indent: 0in; padding-left: 5.4pt; text-align: center; vertical-align: top"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>Deferred
    Income Tax Components</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-indent: 0in; padding-left: 5.4pt; text-align: center; vertical-align: top"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;(in thousands)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-indent: 0in; padding-left: 5.4pt; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: center; vertical-align: top; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>12/31/2014&nbsp;</B></FONT></TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>&nbsp;</B></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>&nbsp;</B></FONT></TD><TD STYLE="font-weight: bold; text-align: center; vertical-align: top; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>12/31/2013&nbsp;</B></FONT></TD><TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: 0in; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: 0in; padding-left: 5.4pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><b>Deferred
    tax assets:</B></FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 40%; text-align: left; text-indent: 0in; padding-left: 5.4pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Property
    &amp; equipment</FONT></TD><TD STYLE="width: 8%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">$</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">77</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="width: 4%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">$</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">21</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 5.4pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Intangible
    assets, definite-lived</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">421</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">478</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 5.4pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Deferred
    revenue</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">380</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">313</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 5.4pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Stock
    options</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">3,644</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">1,319</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 5.4pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Inventory</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">620</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 5.4pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Charitable
    contribution</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">13</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">11</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 5.4pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">General
    business credit</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">885</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">637</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 5.4pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Net
    operating loss carryforward</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">15,492</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">8,313</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 5.4pt; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Valuation
    allowance</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(21,532</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(11,092</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 5.4pt; padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Deferred
    tax assets</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">As of December 31, 2014,
the Company has generated regular tax net operating losses of approximately $49,200,000. The Company&rsquo;s ability to realize
tax benefit from the net operating loss is subject to annual limitation under Internal Revenue Code Section 382. Due to the change
in control which occurred as a result of Abeja Ventures, LLC&rsquo;s investment in the Company on June 26, 2012, the Company estimates
that the annual Section 382 limitation on utilization of net operating losses will be $420,000. As such, the Company will never
get the benefit of approximately $4,200,000 of the net operating losses generated prior to June 26, 2012. The deferred tax asset
has been adjusted to reflect the Section 382 limitation. Section 382 also applies to built-in losses at the time of the transaction.
The amounts of any unrealized built-in losses or gains were not calculated at the date of the transaction. The gross net operating
losses available for future use are approximately $45,000,000. For federal purposes, net operating losses can be carried forward
for up to 20 years. The Company&rsquo;s net operating losses will begin to expire in 2023.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center">73</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 80 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify"></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">Additionally, the Company
has relocated its headquarters to Arizona. They began filing in Arizona starting with the year ending December 31, 2013. To date,
the Company has generated Arizona-source net operating losses of approximately $33,700,000. The Company's Arizona net operating
losses will begin to expire in 2033.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">The net deferred tax asset
valuation allowance is $21,532,000 as of December 31, 2014 compared to $11,092,000 as of December 31, 2013. The prior year deferred
taxes and effective tax rate reconciliation have been adjusted to correct for temporary items that were not originally reflected.
Offsetting changes in the valuation allowance to reflect the additional deferred tax assets at the value that is more-likely-than-not
to be realized resulted in no effect on the Company's balance sheet as of December 31, 2013 or results of operations for the year
then ended. The valuation allowance is based on management&rsquo;s assessment that it is more likely than not that the Company
will not have taxable income in the foreseeable future.</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">The difference between the
U.S. federal statutory income tax rate and the Company&rsquo;s effective tax rate for years ending December 31, 2013 and 2014 is
as follows:</P>


<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="text-align: center; text-indent: 0in; padding-left: 5.4pt; vertical-align: top"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>Effective
    Tax Rate</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; text-indent: 0in; padding-left: 5.4pt; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>12/31/2014</B></FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>&nbsp;</B></FONT></TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>12/31/2013</B></FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; text-indent: 0in; padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%; text-align: justify; text-indent: 0in; padding-left: 5.4pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">U.S.
    Federal statutory income tax rate</FONT></TD><TD STYLE="width: 8%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(34.00</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)%</FONT></TD><TD STYLE="width: 4%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(34.00</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; text-indent: 0in; padding-left: 5.4pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">State
    taxes, net of federal tax benefit</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(3.20</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(3.80</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; text-indent: 0in; padding-left: 5.4pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Non-deductible
    equity and other compensation</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">3.70</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">1.20</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; text-indent: 0in; padding-left: 5.4pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">State
    income tax credit</FONT>s, net of Federal effects</TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(1.00</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; text-indent: 0in; padding-left: 5.4pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Limitation
    on net operating losses due to &sect;382</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">0.50</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">1.00</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; text-indent: 0in; padding-left: 5.4pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Credit
    for increased research activities</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(0.80</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(3.20</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; padding-bottom: 1pt; text-indent: 0in; padding-left: 5.4pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Change
    in valuation allowance</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">33.10</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">38.80</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; text-indent: 0in; padding-left: 5.4pt; padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(1.7</FONT>0</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)%</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">0.00</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">%</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">At December 31, 2014, the
Company had uncertain tax positions of $161,000, determined as follows:</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 64%; font: 10pt Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="5" STYLE="text-align: center; vertical-align: top"><B>Uncertain Tax Positions</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="5" STYLE="text-align: center; vertical-align: top">(in thousands)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Balance December 31, 2013</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&mdash;&nbsp;&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 40%; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Increases for prior positions</FONT></TD><TD STYLE="width: 10%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">78</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Increases for current year positions</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">83</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Balance December 31, 2014</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">161</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">These
uncertain positions are not expected to change within the next twelve months. At December 31, 2014, the Company has not recorded
any expenses related to these uncertain tax positions. Rather, the item is a reduction of the Company's deferred tax assets.</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Company has incurred federal net operating losses (NOLs) dating to the tax year ended July 31, 2004. As such, all loss carryovers
are subject to adjustment under IRS and state examination, depending on the jurisdiction in which they were incurred.</FONT></P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">NOTE
13. COMMITMENTS</FONT></P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">Leases</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">As
of December 31, 2012, the Company was a party to a lease for office and laboratory space located in Denver, Colorado that subsequently
expired on February 1, 2013. Total rent expense including common area charges was approximately $0, $11,000, $40,000, $35,000,
and $74,000 during the years ended December 31, 2014 and 2013, five-month periods ended December 31, 2012 and 2011, and the fiscal
year ended July 31, 2012, respectively.</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0pt; margin-bottom: 9pt; text-align: center">74</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0pt; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 81 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">In
August 2012, the Company entered into a Lease Agreement (&ldquo;Lease&rdquo;) with Pima County, a political subdivision of the
State of Arizona (&ldquo;Landlord&rdquo;), pursuant to which the Company leased approximately 15,096 square feet of office space
located in Tucson, Arizona for a period of three years (the &ldquo;Initial Term&rdquo;), which may be extended by the Company
for up to three additional one-year periods (each a &ldquo;Renewal Term&rdquo;). The Lease also provides that the Company has
the option, with six months prior notice to Landlord, to lease either or both of two additional areas with an aggregate size of
approximately 7,920 square feet.</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Pursuant
to the Lease, the Company agreed to: (i) pay rent equal to $9.25 per usable square foot per year (approximately $140,000 per year)
during the Initial Term and $19.80 per usable square foot per year (approximately $299,000 per year) during any Renewal Term;
(ii) relocate its corporate offices to the Tucson area and begin operations within 30 days of the date that the tenant improvements
are substantially completed (the &ldquo;Commencement Date&rdquo;); and (iii) within 18 months of the Commencement Date, employ
at least 30 individuals with a median salary of at least $70,000, which median salary must be maintained throughout the term of
the Lease. For any month that the Company fails to satisfy the condition described in clause (iii) of the preceding sentence,
the rental rate under the Lease will be increased for that month by a percentage that is twice the percentage by which the Company&rsquo;s
annual payroll has fallen short of the specified goal (subject to a cap equal to $19.80 per usable square foot per year). The
Lease also provides that Landlord will pay for tenant improvements (up to a cap of $1,400,000) as well as certain repairs, utilities
and insurance. In January 2013, we relocated our headquarters into the above described leased space in Tucson, Arizona and are
otherwise in compliance with the lease terms as of December 31, 2014 and 2013, thus no increased rental rates were paid.</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">In
October 2013, the Company executed the First Amendment to the Lease with Pima County to exercise its option and to expand its
lease premises by 4,551 square feet whereby Pima County provided tenant improvements. After the completion of tenant improvements,
the Company occupied this additional space in January 2014. Pursuant to the First Amendment, the Company agreed to (i) pay rent
equal to $9.25 per square foot per year (approximately $42,000 per year) and (ii) repay tenant improvements over the remaining
lease term. These tenant improvements are treated as a capital lease whereby both an asset and a liability have been recorded
and periodic interest based on an annual rate of 4% and depreciation are recorded to amortize the value of this asset and the
liability over the remaining lease term. The Company incurred interest cost of $7,000 in the year ended December 31, 2014 and
no interest costs in prior years as a result of this capital lease. Further details regarding this capital lease are included
in Note 5, Property and Equipment.</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
future minimum lease payments under the capital lease together with the present value of the net minimum lease payments as of
December 31, 2014 are as follows:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 67%; font: 10pt Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center">Capital Lease Obligations <BR>(in thousands)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="3" STYLE="text-align: right">Year ending December 31:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 43%; text-align: right">2015</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">151</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2016</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2017</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;</TD><TD STYLE="text-align: left"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2018</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">2019</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;<U></U></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">Total minimum lease payments</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">164</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">Less amount representing interest</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">Present value minimum lease payments</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">160</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in"><BR CLEAR="ALL"></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">In
April 2014 and June 2014, the Company entered into a Second Amendment and Third Amendment, respectively, to the Lease with Pima
County pursuant to which the Company exercised its option to build-out and occupy 3,594 square feet and an additional 4,163 square
feet not contemplated in the Lease for manufacturing and other operational requirements. Pursuant to these Amendments, the Company
also agreed to: (i) pay rent equal to $9.25 per usable square foot per year for the 3,594 option space and $17.63 per usable square
foot per year for the additional 4,163 square feet during the Initial Term; (ii) pay rent of $19.80 per usable square foot per
year for the 3,594 option space and $17.63 per usable square foot per year for the additional 4,163 square feet during any Renewal
Term; (iii) restore the 3,594 option space and the 4,163 additional space to a reasonable office typical tenant space at the end
of the Lease; and (iv) adhere to all other terms of the Lease. The Company estimates that the costs for restoration at the end
of the Lease as described in (ii) of these Amendments are immaterial and, therefore, no accrual has been recorded. As part of
these Amendments, the Company was granted first refusal rights to possible future space that might become available.</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center">75</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 82 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">In
November 2014, the Company entered into a Fourth Amendment to the Lease with Pima County exercising the first refusal rights for
an additional 18,481 square feet of space that became available. Pursuant to this Amendment, the Company agreed to: (i) pay rent
equal to $17.63 per usable square foot per year during the Initial Term; (ii) pay rent of $19.80 per square foot per year for
any Renewal Term, (iii) restore the 18,481 square foot space to a reasonable office typical tenant space at the end of the Lease
(iv) pay utilities of $8,000 per month (v) adhere to all other terms of the Lease. The Company estimates that the costs for restoration
at the end of the Lease as described in (iii) of this Amendment is immaterial and, therefore, no accrual has been recorded.</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Total
rent expense for the Tucson facility, including common area charges was $293,000 and $168,000 for the years ended December 31,
2014 and 2013, respectively with no amounts in previous periods. Future minimum lease payments under this agreement are as follows
(in thousands):</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 67%; font: 10pt Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="7" STYLE="text-align: center"><B>Operating Lease Obligations</B> <BR>(in thousands)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="3" STYLE="text-align: right">Year ending December 31:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 43%; text-align: right">2015</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">633</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2016</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">60</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2017</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2018</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">2019</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&mdash;&nbsp;&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: right; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Thereafter</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&mdash;&nbsp;&nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-size: 10pt">    Total operating lease obligations</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">693</TD></TR>
</TABLE>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; text-align: justify; text-indent: 0in; margin-right: 0; margin-bottom: 9pt; margin-left: 0"><FONT STYLE="font-size: 10pt">Purchase
and License Agreements</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Company periodically enters into agreements to license patents whereby royalty payments and/or payments are made based on sales.
In years ending December 31, 2014 and 2013 there were $50,000 and $0 royalty payments made which are included in research and
development expenses. No amounts have been incurred or recorded for payments based on sales.</FONT></P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; text-align: justify; text-indent: 0in; margin-right: 0; margin-bottom: 9pt; margin-left: 0"><FONT STYLE="font-size: 10pt">Clinical
Trial Agreements</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Company has entered into master agreements with clinical trial sites in which we typically pay a set amount for start-up costs
and then pay for work performed. No amounts have been incurred for these arrangements through December 31, 2014.</FONT></P>

<P STYLE="font: italic bold 10pt/normal Arial,sans-serif; text-align: justify; text-indent: 0in; margin-right: 0; margin-bottom: 9pt; margin-left: 0"><FONT STYLE="font-size: 10pt">Employment
Agreement and Consulting Agreement</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">In
December, 2007, we entered into an Employment Agreement with Mr. Geimer. The agreement provided for an annual base salary of $165,000
with annual deferred compensation of $75,000 and was to have expired on December 31, 2012. In June, 2012, Thomas V. Geimer resigned
as the Company&rsquo;s Chief Executive Officer, Chief Financial Officer and Secretary. In connection with his resignation, Mr.
Geimer entered into an Amendment to Employment Agreement with the Company, as well as a new Consulting Agreement. Pursuant to
the Amendment to Employment Agreement, Mr. Geimer and the Company agreed to stagger certain payments due to him such that $650,000
was paid to Mr. Geimer upon the closing of the Investment and $700,000 payable to him on July 1, 2013. Any payments due to Mr.
Geimer under his Employment Agreement (as amended) but not timely paid by the Company bear interest at a rate of 18% per annum.
In addition, the $75,000 deferred compensation payment for the Company&rsquo;s fiscal year ending July 31, 2012 was contributed
prior to the closing of the Investment. Pursuant to the Consulting Agreement, Mr. Geimer agreed to provide certain transition
and other services to the Company. In exchange, during the remainder of 2012, the Company paid Mr. Geimer an amount equal to $24,000
per month. From January 1, 2013 through December 31, 2013, Mr. Geimer&rsquo;s aggregate consulting fee was $96,000 ($8,000 per
month). As of December 31, 2013, no additional amounts are due under the Consulting Agreement and no further amounts were incurred
during the year ending December 31, 2014.</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center"><FONT STYLE="font-size: 10pt">76</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 10pt 0 9pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt; line-height: 115%">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 83 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 10pt 0 9pt; text-align: justify"></P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 10pt 0 9pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt; line-height: 115%">NOTE
14. </FONT><FONT STYLE="font-size: 10pt">SEGMENTS</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Company operates as one operating segment. Operating segments are defined as components of an enterprise for which separate financial
information is evaluated regularly by the chief operating decision maker, who is the chief executive officer, in deciding how
to allocate resources and assessing performance. The Company&rsquo;s business operates in one operating segment because the Company&rsquo;s
chief operating decision maker evaluates the Company&rsquo;s financial information and resources and assesses the performance
of these resources on a consolidated basis. Since the Company operates in one operating segment, all required financial segment
information can be found in the consolidated financial statements.</FONT></P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 10pt 0 9pt; text-align: justify"><FONT STYLE="line-height: 115%">NOTE
15. </FONT>SUBSEQUENT EVENTS</P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: justify; margin-right: 0; margin-bottom: 9pt; margin-left: 0">Arizona
Department of Revenue</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">In January 2015, we were
notified by the Arizona Commerce Authority (&ldquo;Authority&rdquo;) that we meet the program requirements to receive a &ldquo;Certificate
of Qualification&rdquo; and, therefore, are eligible for a partial refund of research and development investments amounting to
a maximum of $647,000. The &ldquo;Certificate of Qualification&rdquo; does not obligate the Arizona Department of Revenue to issue
the refund. Furthermore, the calculation of the actual refund due will be based on actual qualifying expenses and income tax liability
for the 2014 tax year and if qualifying expenses decrease or income tax liability increases, the refund amount may be less than
the $647,000. If the amount received for this tax credit is later determined to be incorrect or invalid, the excess may be treated
as a tax deficiency.</P>

<P STYLE="font: italic bold 10pt Arial,sans-serif; text-align: left; margin-right: 0; margin-bottom: 9pt; margin-left: 0">National
Institute of Health</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">In February 2015, we were
notified that the National Institute of Health awarded a five year, $5 million grant to Denver Health Medical Center and ourselves
to develop a fast and reliable identification and categorical susceptibility test carbepenem-resistant Enterobacteriaceae directly
from whole blood. We are still working out the final contractual agreement with Denver Health Medical Center and anticipate that
our portion of the award will be approximately $1.8 million over the next five years.</P>



<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 10pt 0 9pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center">77</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 84 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in"></P>









<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"><B>NOTE 16. SUPPLEMENTAL DATA QUARTERLY FINANCIAL INFORMATION (UNAUDITED)</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Arial, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="33" STYLE="text-align: center; padding-left: 5.4pt; padding-bottom: 1pt"><B>QUARTERLY FINANCIAL INFORMATION</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="33" STYLE="text-align: center; padding-left: 5.4pt; padding-bottom: 1pt">(in thousands, except
    per share data)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="33" STYLE="text-align: center; padding-left: 5.4pt; padding-bottom: 1pt">Unaudited</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="33" STYLE="text-align: center; padding-left: 5.4pt; padding-bottom: 1pt">For the quarters ending:</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="33" STYLE="text-align: left; text-indent: 0in; padding-left: 5.4pt; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 5.4pt; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: top; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: top; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: top; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: top; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: top; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: top; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: top; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: top; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 5.4pt; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: top; padding-bottom: 1pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 8pt"><B>12/31/2014</B></FONT></P>
                                                                          <P STYLE="margin-top: 0; margin-bottom: 0; border-bottom: Black 1pt solid"></P></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt"><B>&nbsp;</B></TD><TD STYLE="text-align: center; vertical-align: top; padding-bottom: 1pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 8pt"><B>9/30/2014</B></FONT></P>
                                                                          <P STYLE="margin-top: 0; margin-bottom: 0; border-bottom: Black 1pt solid"></P></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="text-align: center; vertical-align: top; padding-bottom: 1pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 8pt"><B>6/30/2014</B></FONT></P>
                                                                          <P STYLE="margin-top: 0; margin-bottom: 0; border-bottom: Black 1pt solid"></P></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="text-align: center; vertical-align: top; padding-bottom: 1pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 8pt"><B>3/31/2014</B></FONT></P>
                                                                          <P STYLE="margin-top: 0; margin-bottom: 0; border-bottom: Black 1pt solid"></P></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="text-align: center; vertical-align: top; padding-bottom: 1pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 8pt"><B>12/31/2013</B></FONT></P>
                                                                          <P STYLE="margin-top: 0; margin-bottom: 0; border-bottom: Black 1pt solid"></P></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="text-align: center; vertical-align: top; padding-bottom: 1pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 8pt"><B>9/30/2013</B></FONT></P>
                                                                          <P STYLE="margin-top: 0; margin-bottom: 0; border-bottom: Black 1pt solid"></P></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="text-align: center; vertical-align: top; padding-bottom: 1pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 8pt"><B>6/30/2013</B></FONT></P>
                                                                          <P STYLE="margin-top: 0; margin-bottom: 0; border-bottom: Black 1pt solid"></P></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="text-align: center; vertical-align: top; padding-bottom: 1pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 8pt"><B>3/31/2013</B></FONT></P>
                                                                          <P STYLE="margin-top: 0; margin-bottom: 0; border-bottom: Black 1pt solid"><B></B></P></TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 5.4pt; width: 28%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Revenue</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; width: 1%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">$</FONT></TD><TD STYLE="text-align: right; width: 5%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">79</FONT></TD><TD STYLE="text-align: left; width: 1%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; width: 1%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">$</FONT></TD><TD STYLE="text-align: right; width: 5%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">16</FONT></TD><TD STYLE="text-align: left; width: 1%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; width: 1%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">$</FONT></TD><TD STYLE="text-align: right; width: 5%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">13</FONT></TD><TD STYLE="text-align: left; width: 1%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; width: 1%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">$</FONT></TD><TD STYLE="text-align: right; width: 5%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">14</FONT></TD><TD STYLE="text-align: left; width: 1%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; width: 1%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">$</FONT></TD><TD STYLE="text-align: right; width: 5%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">12</FONT></TD><TD STYLE="text-align: left; width: 1%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; width: 1%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">$</FONT></TD><TD STYLE="text-align: right; width: 5%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">13</FONT></TD><TD STYLE="text-align: left; width: 1%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; width: 1%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">$</FONT></TD><TD STYLE="text-align: right; width: 5%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">7</FONT></TD><TD STYLE="text-align: left; width: 1%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; width: 1%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT>$</TD><TD STYLE="text-align: right; width: 5%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">16</FONT></TD><TD STYLE="text-align: left; width: 1%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 5.4pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Net
    loss</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(8,765</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(8,814</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(8,152</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(5,202</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(5,159</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(3,797</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(3,777</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(2,549</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 5.4pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Basic
    and diluted net loss per share (1)</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(0.20</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(0.20</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(0.19</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(0.12</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(0.12</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(0.10</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(0.10</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(0.09</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 5.4pt"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="33" STYLE="text-align: left"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">(1)&nbsp;&nbsp;Loss per share
    has been adjusted for the effects of the rights offering (see Item 8, Note 9, Rights Offering).</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 6pt; text-align: center">78</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 6pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 85 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in"></P>




<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">Item
9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">None.</FONT></P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">Item
9A. Controls and Procedures</FONT></P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">Evaluation
of Disclosure Controls and Procedures</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;&#9;Based
on an evaluation under the supervision and with the participation of the Company&rsquo;s management, the Company&rsquo;s Principal
Executive Officer and Principal Financial Officer have concluded that the Company&rsquo;s disclosure controls and procedures as
defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act were effective as of December 31, 2014 to ensure that information
required to be disclosed by the Company in reports that it files or submits under the Exchange Act is (i)&nbsp;recorded, processed,
summarized and reported within the time periods specified in the Securities and Exchange Commission&rsquo;s rules and forms and
(ii)&nbsp;accumulated and communicated to the Company&rsquo;s management, including its Principal Executive Officer and Principal
Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</FONT></P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 10pt 0 9pt; text-align: justify"><FONT STYLE="font-size: 10pt">Management&rsquo;s
Report on Internal Control over Financial Reporting</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;&#9;Management
is responsible for establishing and maintaining adequate internal control over financial reporting. The Company&rsquo;s internal
control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements for external purposes in accordance with GAAP. The Company&rsquo;s internal control
over financial reporting includes those policies and procedures that:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt/normal Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif">pertain
                                         to the maintenance of records that in reasonable detail accurately and fairly reflect
                                         the transactions and dispositions of our assets;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt/normal Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif">provide
                                         reasonable assurance that transactions are recorded as necessary to permit preparation
                                         of financial statements in accordance with U.S. GAAP, and that our receipts and expenditures
                                         are being made only in accordance with authorizations of our management and our directors;
                                         and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt/normal Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Arial,sans-serif">provide
                                         reasonable assurance regarding prevention or timely detection of unauthorized acquisition,
                                         use or disposition of our assets that could have a material effect on the financial statements.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&#9;Management,
including the Company&rsquo;s Chief Executive Officer and Chief Financial Officer, does not expect that the Company&rsquo;s internal
controls will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide
only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system
must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs.
Because of the inherent limitations in all control systems, no evaluation of internal controls can provide absolute assurance
that all control issues and instances of fraud, if any, have been detected. Also, any evaluation of the effectiveness of controls
in future periods are subject to the risk that those internal controls may become inadequate because of changes in business conditions,
or that the degree of compliance with the policies or procedures may deteriorate.</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&#9;Management
assessed the effectiveness of our internal control over financial reporting as of December 31, 2014. In making this assessment,
we used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO)&nbsp;in <I>Internal
Control - Integrated Framework</I> (1992 Framework). Based on that assessment, management concluded that, during the period covered
by this report, such internal controls and procedures were effective as of December 31, 2014.</FONT></P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">Attestation
Report of Independent Registered Public Accounting Firm</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
attestation report required under this Item 9A is contained in Item 8 of Part II of this Annual Report on Form 10-K under the
heading &ldquo;Report of Independent Registered Public Accounting Firm&rdquo;.</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0pt; margin-bottom: 9pt; text-align: center"><FONT STYLE="font-size: 10pt">79</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0pt; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 86 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">Changes
in Internal Control Over Financial Reporting</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;&#9;There
was no change in the Company&rsquo;s internal control over financial reporting during the period ended December 31, 2014 that
materially affected, or is reasonably likely to materially affect, the Company&rsquo;s internal control over financial reporting.</FONT></P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">Item
9B. Other Information</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Not
Applicable.</FONT></P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: center; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">PART&nbsp;III</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Certain
information required by Part III is omitted from this Annual Report on Form 10-K because the required information will be incorporated
by reference to our definitive proxy statement for our 2015 Annual Meeting of Stockholders, to be filed with the SEC pursuant
to Regulation 14A of the Exchange Act (the &ldquo;Proxy Statement&rdquo;) not later than 120 days after the end of the fiscal
year covered by this Annual Report on Form 10-K.</FONT></P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">Item
10. Directors, Executive Officers and Corporate Governance</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
information required by this Item will be disclosed in the Proxy Statement and is incorporated by reference to the Proxy Statement.</FONT></P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">Item
11. Executive Compensation</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
information required by this Item will be disclosed in the Proxy Statement and is incorporated by reference to the Proxy Statement.</FONT></P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">Item
12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
information required by this Item will be disclosed in the Proxy Statement and is incorporated by reference to the Proxy Statement.</FONT></P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">Item
13. Certain Relationships and Related Transactions, and Director Independence</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
information required by this Item will be disclosed in the Proxy Statement and is incorporated by reference to the Proxy Statement.</FONT></P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">Item
14. Principal Accounting Fees and Services</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
information required by this Item will be disclosed in the Proxy Statement and is incorporated by reference to the Proxy Statement.</FONT></P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">Item
15. Exhibits, Financial Statement Schedules</FONT></P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 0pt 0 9pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Arial,sans-serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 8%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>a)</B></FONT></TD>
    <TD STYLE="width: 92%"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B>Documents filed as part of this report</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B><I>1)</I></B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"><B><I>All financial statements</I></B></FONT></TD></TR>
</TABLE>








<P STYLE="font: 6pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td colspan="2" style="padding-bottom: 6pt; text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="vertical-align: bottom; padding-top: 0.1pt; padding-bottom: 0.1pt; padding-left: 0.5in; text-align: left; text-indent: -0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: top; padding-top: 0.1pt; padding-bottom: 0.1pt; padding-left: 0.5in; text-decoration: underline; text-align: center; text-indent: -0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt"><B><U>Page</U></B></FONT></td></tr>
<tr>
    <td colspan="2" style="padding-bottom: 6pt; text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="vertical-align: bottom; padding-top: 0.1pt; padding-bottom: 0.1pt; padding-left: 0.5in; text-align: left; text-indent: -0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Report
    of Independent Registered Public Accounting Firm</FONT></td>
    <TD STYLE="vertical-align: top; padding-top: 0.1pt; padding-bottom: 0.1pt; padding-left: 0.5in; text-align: center; text-indent: -0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">52</FONT></td></tr>
<tr>
    <td colspan="2" style="padding-bottom: 6pt; text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="vertical-align: bottom; padding-top: 0.1pt; padding-bottom: 0.1pt; padding-left: 0.5in; text-align: left; text-indent: -0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Report
    of Independent Registered Public Accounting Firm for Prior Audit Periods</FONT></td>
    <TD STYLE="vertical-align: top; padding-top: 0.1pt; padding-bottom: 0.1pt; padding-left: 0.5in; text-align: center; text-indent: -0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">54</FONT></td></tr>
<tr>
    <td colspan="2" style="padding-bottom: 6pt; text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="vertical-align: bottom; padding-top: 0.1pt; padding-bottom: 0.1pt; padding-left: 0.5in; text-align: left; text-indent: -0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Balance
    Sheets as of December 31, 2014 and 2013</FONT></td>
    <TD STYLE="vertical-align: top; padding-top: 0.1pt; padding-bottom: 0.1pt; padding-left: 0.5in; text-align: center; text-indent: -0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">55</FONT></td></tr>
<tr>
    <td colspan="2" style="padding-bottom: 6pt; text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="vertical-align: bottom; padding-top: 0.1pt; padding-bottom: 0.1pt; padding-left: 0.5in; text-align: left; text-indent: -0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Statements
    of Operations and Comprehensive Loss for the years ended December 31, 2014 and 2013, five months ended December 31, 2012 and
    2011, and fiscal year ended July 31, 2012</FONT></td>
    <TD STYLE="vertical-align: top; padding-top: 0.1pt; padding-bottom: 0.1pt; padding-left: 0.5in; text-align: center; text-indent: -0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">56</FONT></td></tr>
<tr>
    <td colspan="2" style="padding-bottom: 6pt; text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="vertical-align: bottom; padding-top: 0.1pt; padding-bottom: 0.1pt; padding-left: 0.5in; text-align: left; text-indent: -0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Statements
    of Stockholders&rsquo; Equity for the years ended December 31, 2014 and 2013, five months ended December 31, 2012 and fiscal
    year ended July 31, 2012</FONT></td>
    <TD STYLE="vertical-align: top; padding-top: 0.1pt; padding-bottom: 0.1pt; padding-left: 0.5in; text-align: center; text-indent: -0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">57</FONT></td></tr>
<tr>
    <td colspan="2" style="padding-bottom: 6pt; text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="vertical-align: bottom; padding-top: 0.1pt; padding-bottom: 0.1pt; padding-left: 0.5in; text-align: left; text-indent: -0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Statements
    of Cash Flow for the years ended December 31, 2014 and 2013, five months ended December 31, 2012 and 2011, and&nbsp;&nbsp;fiscal
    year ended July 31, 2012</FONT></td>
    <TD STYLE="vertical-align: top; padding-top: 0.1pt; padding-bottom: 0.1pt; padding-left: 0.5in; text-align: center; text-indent: -0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">58</FONT></td></tr>
<TR>
    <TD COLSPAN="2" STYLE="padding-bottom: 6pt; text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.1pt; padding-bottom: 0.1pt; padding-left: 0.5in; text-align: left; text-indent: -0.5in; line-height: 115%; font-family: Arial,sans-serif">Notes
    to Financial Statements</TD>
    <TD STYLE="vertical-align: top; padding-top: 0.1pt; padding-bottom: 0.1pt; padding-left: 0.5in; text-align: center; text-indent: -0.5in; line-height: 115%; font-family: Arial,sans-serif">59</TD></TR>
<tr>
    <td style="width: 4%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="width: 79.76%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="width: 4.74%; text-align: center; vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
</table>
<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify"><B>2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial
Statement of Schedules</B></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">All
financial statement schedules have been omitted, since the required information is not applicable or because the information required
is included in the financial statements and notes thereto.</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify"><B>b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibits
required by Item 601 of Registration S-K</B></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
information required by this Item is set forth on the exhibit index that follows the signature page of this report.</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 6pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT>80</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 24.5pt; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 24.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 87 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 24pt 0 6pt; text-align: center; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">SIGNATURES</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Report
to be signed on its behalf by the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="padding-right: 0.8pt; padding-bottom: 6pt; text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td colspan="2" style="padding-right: 1.8pt; padding-bottom: 6pt; text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">ACCELERATE
    DIAGNOSTICS, INC.</FONT></td></tr>
<tr style="vertical-align: top">
    <td style="width: 49.92%; padding-right: 0.8pt; padding-bottom: 6pt; text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="width: 4.14%; padding-right: 0.8pt; padding-bottom: 6pt; text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="width: 45.92%; padding-right: 0.8pt; padding-bottom: 6pt; text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 0.8pt; padding-bottom: 6pt; text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">February
    26, 2015</FONT></td>
    <td style="padding-right: 0.8pt; padding-bottom: 6pt; text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"></td>
    <td style="padding-right: 0.8pt; padding-bottom: 6pt; text-decoration: underline; text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt"><U>By:&nbsp;&nbsp;/s/
    Lawrence Mehren&#9;&#9;</U></FONT></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 0.8pt; padding-bottom: 6pt; text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="padding-right: 0.8pt; padding-bottom: 6pt; text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td><P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0.8pt 6pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Lawrence
        Mehren</FONT></P>
        <P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0.8pt 6pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">President
        and Chief Executive Officer</FONT></P></td></tr>
</table>
<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: center; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>Power
of Attorney </B></FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">KNOW
ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Lawrence Mehren, as his
attorney-in-fact, with the power of substitution, for him in any and all capacities, to sign any amendments to this Annual Report
on Form&nbsp;10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities
and Exchange Commission, hereby ratifying and confirming all that said attorney-in-fact, or his substitute or substitutes, may
do or cause to be done by virtue hereof.</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 9pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf
of the registrant and in the capacities and on the date indicated.</FONT></P>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 28.16%; border-bottom: black 1.5pt solid; padding-right: 0.8pt; padding-bottom: 6pt; text-align: center; text-indent: 22.5pt; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Signature</FONT></td>
    <td style="width: 1.76%; padding-right: 0.8pt; padding-bottom: 6pt; text-align: center; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="width: 43.14%; border-bottom: black 1.5pt solid; padding-right: 0.8pt; padding-bottom: 6pt; text-align: center; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Title</FONT></td>
    <td style="width: 1.76%; padding-right: 0.8pt; padding-bottom: 6pt; text-align: center; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="width: 25.18%; border-bottom: black 1.5pt solid; padding-right: 0.8pt; padding-bottom: 6pt; text-align: center; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Date</FONT></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 0.8pt; padding-bottom: 6pt; text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="padding-right: 0.8pt; padding-bottom: 6pt; text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="padding-right: 0.8pt; padding-bottom: 6pt; text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="padding-right: 0.8pt; padding-bottom: 6pt; text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="padding-right: 0.8pt; padding-bottom: 6pt; text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
<tr>
    <td style="vertical-align: bottom"><P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">/s/
                                       Lawrence Mehren&#9;&#9;</FONT></P>
        <P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">Lawrence
        Mehren</FONT></P></td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="vertical-align: top; text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">President,
    Chief Executive Officer and Director</FONT></td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">February
    26, 2015</FONT></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="text-align: left; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <td><P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">/s/
        Steve Reichling&#9;&#9;</FONT></P>
        <P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">Steve
        Reichling</FONT></P></td>
    <td style="text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Corporate
    Secretary, Chief Financial Officer and Chief Accounting Officer</FONT></td>
    <td style="text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">February
    26, 2015</FONT></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="text-align: left; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <td><P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">/s/
        John Patience&#9;&#9;</FONT></P>
        <P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">John
        Patience</FONT></P></td>
    <td style="text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Chairman
    of the Board of Directors</FONT></td>
    <td style="text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">February
    26, 2015</FONT></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="text-align: left; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
<tr>
    <td style="vertical-align: bottom"><P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">/s/
                                       Jack Schuler&#9;&#9;</FONT></P>
        <P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">Jack
        Schuler</FONT></P></td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="vertical-align: top; text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Director</FONT></td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="vertical-align: top; text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">February
    26, 2015</FONT></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="text-align: left; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <td><P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">/s/
        Matthew W. Strobeck&#9; Ph.D.</FONT></P>
        <P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">Matthew
        W. Strobeck, Ph.D.</FONT></P></td>
    <td style="text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Director</FONT></td>
    <td style="text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">February
    26, 2015</FONT></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="text-align: left; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <td><P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">/s/
        Frank ten Brink</FONT></P>
        <P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">Frank
        ten Brink</FONT></P></td>
    <td style="text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Director</FONT></td>
    <td style="text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">February
    26, 2015</FONT></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="text-align: left; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <td><P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">/s/
        Mark Miller&#9;</FONT></P>
        <P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">Mark
        Miller</FONT></P>
        <P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></td>
    <td style="text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Director</FONT></td>
    <td style="text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <td style="text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">February
    26, 2015</FONT></td></tr>
</table>
<P STYLE="font: 8pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;&#9;&#9;</FONT></P>




<P STYLE="font: 8pt/normal Arial,sans-serif; margin: 0; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 8pt/normal Arial,sans-serif; margin: 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 8pt/normal Arial,sans-serif; margin: 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 8pt/normal Arial,sans-serif; margin: 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt/normal Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; text-align: center">81</P>

<P STYLE="font: 10pt/normal Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; text-align: center; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 24pt 0 6pt; text-align: center; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 88 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt/115% Arial,sans-serif; margin: 24pt 0 6pt; text-align: center; text-indent: 0.5in">&nbsp;<FONT STYLE="font-size: 10pt">EXHIBIT
INDEX</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <TD STYLE="width: 10.56%; padding-right: 0.8pt; padding-bottom: 6pt; text-decoration: underline; text-align: justify; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt"><B><U>Exhibit
    No.</U></B></FONT></td>
    <TD STYLE="width: 50.18%; padding-right: 0.8pt; padding-bottom: 6pt; text-decoration: underline; text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt"><B><U>Description</U></B></FONT></td>
    <TD STYLE="width: 0.88%; padding-right: 0.8pt; padding-bottom: 6pt; padding-left: 12.6pt; text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></td>
    <TD STYLE="width: 38.38%; padding-right: 0.8pt; padding-bottom: 6pt; padding-left: 12.6pt; text-decoration: underline; text-align: justify; text-indent: 0.5in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt"><B><U>Filing
    Information</U></B></FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">3.1</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Certificate
    of Incorporation of Registrant</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Incorporated
    by reference to Appendix B of the Registrant&rsquo;s Definitive Proxy Statement on Schedule 14A filed on November 13, 2012</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">3.1.1</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Certificate
    of Amendment to Certificate of Incorporation of Registrant</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Incorporated
    by reference to Exhibit A to the Registrant&rsquo;s Definitive Information Statement on Schedule 14C filed on July 12, 2013</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">3.2</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Bylaws
    of Registrant</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Incorporated
    by reference to Exhibit 3.2 filed with the Registrant&rsquo;s Annual Report on Form 10-K for the fiscal year ended July 31,
    2012.</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">4.1</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Warrant
    No. 2 issued by Registrant to Abeja Ventures, LLC on June 26, 2012</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Incorporated
    by reference to Exhibit 4.2 filed with the Registrant&rsquo;s Annual Report on Form 10-K for the fiscal year ended July 31,
    2012&nbsp;&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">4.2</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Subscription
    and Information Agent Agreement, dated March 10, 2014, by and between the Registrant and Broadridge Corporate Issuer Solutions,
    Inc.</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Incorporated
    by reference to Exhibit 4.2 to the Form S-3 Registration Statement (No. 333-194474) filed by the Registrant on March 10, 2014</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">4.3</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Form
    of Non-Transferable Subscription Rights Certificate</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Incorporated
    by reference to Exhibit 4.1 to the Registration Statement on Form S-3/A (Amendment No. 1) (File No. 333-194474) filed by the
    Registrant on April 7, 2014</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">4.4</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&#9;Form
    of Senior Indenture</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Incorporated
    by reference to Exhibit 4.2 of the Registrant&rsquo;s Form S-3 Registration Statement (No. 333-192321), Amendment No. 1, filed
    on December 2, 2013</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">4.5</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Form
    of Subordinated Indenture</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Incorporated
    by reference to Exhibit 4.2 of the Registrant&rsquo;s Form S-3 Registration Statement (No. 333-192321), Amendment No. 1, filed
    on December 2, 2013</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">10.1</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Registrant&rsquo;s
    2004 Omnibus Stock Option Plan*</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Incorporated
    by reference to Appendix A of the Registrant&rsquo;s Definitive Proxy Statement on Schedule 14A filed on November 15, 2004</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">10.2</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Amendment
    to Registrant&rsquo;s 2004 Omnibus Stock Option Plan*</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Incorporated
    by reference to Annex C of the Registrant&rsquo;s Definitive Proxy Statement on Schedule 14A filed on May 17, 2012</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">10.3</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Form
    of Stock Option Award Agreement under Registrant&rsquo;s 2004 Omnibus Stock Option Plan*</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Incorporated
    by reference to Exhibit 4.4 filed with the Registrant&rsquo;s Form S-8 Registration Statement (No. 333-182930) on July 30,
    2012</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">10.4</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Securities
    Purchase Agreement between Registrant and Abeja Ventures, LLC, dated as of April 20, 2012</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Incorporated
    by reference to Exhibit 10.1 filed with the Registrant&rsquo;s Form 10-Q/A for the quarterly period ended April 30, 2012</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">10.5</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Registration
    Rights Agreement between Registrant and Abeja Ventures, LLC, dated as of June 26, 2012</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Incorporated
    by reference to Exhibit 10.5 filed with the Registrant&rsquo;s Annual Report on Form 10-K for the fiscal year ended July 31,
    2012</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">10.6</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Offer
    Letter between Registrant and Lawrence Mehren, dated as of June 24, 2012*</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Incorporated
    by reference to Exhibit 10.9 filed with the Registrant&rsquo;s Annual Report on Form 10-K for the fiscal year ended July 31,
    2012</FONT></td></tr>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">82</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; border-bottom: Black 1pt solid">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 89 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif; width: 10.56%"><FONT STYLE="font-size: 10pt">10.7</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif; width: 50.18%"><FONT STYLE="font-size: 10pt">CFO
    Offer Letter between Registrant and Steve Reichling, dated as of August 8, 2012*</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif; width: 0.88%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif; width: 38.38%"><FONT STYLE="font-size: 10pt">Incorporated
    by reference to Exhibit 10.10 filed with the Registrant&rsquo;s Annual Report on Form 10-K for the fiscal year ended July
    31, 2012</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">10.8</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Lease
    Agreement between Registrant and Pima County, dated as of August 20, 2012</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Incorporated
    by reference to Exhibit 10.11 filed with the Registrant&rsquo;s Annual Report on Form 10-K for the fiscal year ended July
    31, 2012</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">10.9</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Grant
    Agreement between Registrant and the Arizona Commerce Authority, dated as of August 22, 2012</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Incorporated
    by reference to Exhibit 10.12 filed with the Registrant&rsquo;s Annual Report on Form 10-K for the fiscal year ended July
    31, 2012</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">10.10</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Registrant&rsquo;s
    2012 Omnibus Equity Incentive Plan*</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Incorporated
    by reference to Appendix C of the Registrant&rsquo;s Definitive Proxy Statement on Schedule 14A filed on November 13, 2012</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">10.10.1</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">First
    Amendment to Registrant&rsquo;s 2012 Omnibus Equity Incentive Plan*</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Incorporated
    by reference to Exhibit 99.2 to the Form S-8 Registration Statement (No. 333-187439) filed by the Registrant on March 22,
    2013</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">10.10.2</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Form
    of Nonqualified Stock Option Award Agreement under Registrant&rsquo;s 2012 Omnibus Equity Incentive Plan*</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Incorporated
    by reference to Exhibit 99.3 to the Form S-8 Registration Statement (No. 333-187439) filed by the Registrant on March 22,
    2013</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">10.10.3</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Form
    of Incentive Stock Option Award Agreement under Registrant&rsquo;s 2012 Omnibus Equity Incentive Plan*</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Incorporated
    by reference to Exhibit 99.4 to the Form S-8 Registration Statement (No. 333-187439) filed by the Registrant on March 22,
    2013</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">10.10.4</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Second
    Amendment to Registrant&rsquo;s 2012 Omnibus Equity Incentive Plan*</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Incorporated
    by reference to Appendix A of the Registrant&rsquo;s Definitive Proxy Statement on Schedule 14A filed on April 15, 2014</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">10.11</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Standby
    Purchase Agreement, dated March 10, 2014, among the Registrant and the Jack W. Schuler Living Trust and the Schuler Family
    Foundation</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Incorporated
    by reference to Exhibit 10.1 to the Form S-3 Registration Statement (No. 333-194474) filed by the Registrant on March 10,
    2014</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">10.12</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Assignment
    and Assumption Agreement, dated as of May 1, 2014, by and among Schuler Family Foundation, Jack Schuler, Trustee of the Jack
    W. Schuler Living Trust, Oracle Institutional Partners, L.P., Oracle Partners, L.P. and the Registrant</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Incorporated
    by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by the Registrant on May 2, 2014</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">21</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">List
    of Subsidiaries</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Filed
    herewith</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">23.1</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Consent
    of Independent Registered Public Accounting Firm (Ernst &amp; Young LLP)</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Filed
    herewith&nbsp;&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">23.2</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Consent
    of Independent Registered Public Accounting Firm (Comiskey &amp; Company, P.C.)</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Filed
    herewith</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">31.1</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Certification
    of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Filed
    herewith</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">31.2</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Certification
    of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Filed
    herewith</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">32</FONT></td>
    <TD><P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">Certificate
        of Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</FONT></P>
        <P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">Filed
    herewith</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">101**</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">XBRL
    Instance Document</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">101**</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">XBRL
    Taxonomy Extension Schema Document</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">101**</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">XBRL
    Taxonomy Calculation Linkbase Document</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">101**</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">XBRL
    Taxonomy Extension Definition Linkbase Document</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">101**</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">XBRL
    Taxonomy Label Linkbase Document</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">101**</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">XBRL
    Taxonomy Presentation Linkbase Document</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: left; text-indent: 0in; line-height: 115%; font-family: Arial,sans-serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
</table>
<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;83</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin-top: 0; margin-bottom: 9pt; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 8pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="font: 8pt/normal Arial,sans-serif; margin: 0; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 8pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0 0 6pt; text-align: right; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt/normal Arial,sans-serif; margin: 0; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/115% Arial,sans-serif; margin: 0; text-align: right; text-indent: 0.5in"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
